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Abstract 
Serosurveillance is a powerful tool fundamental to understanding infectious 
disease dynamics. The presence of virus neutralising antibody (VNAb) in sera is 
considered the best evidence of infection, or indeed vaccination, and the gold 
standard serological assay for their detection is the virus neutralisation test 
(VNT). However, VNTs are labour intensive, costly and time consuming. In 
addition, VNTs for the detection of antibodies to highly pathogenic viruses 
require the use of high containment facilities, restricting the application of 
these assays to the few laboratories with adequate facilities. As a result, robust 
serological data on such viruses are limited. In this thesis I develop novel VNTs 
for the detection of VNAb to two important, highly pathogenic, zoonotic viruses; 
rabies and Rift Valley fever virus (RVFV).  
The pseudotype-based neutralisation test developed in this study allows for the 
detection of rabies VNAb without the requirement for high containment 
facilities. This assay was utilised to investigate the presence of rabies VNAb in 
animals from a variety of ecological settings. In this thesis I present evidence of 
natural rabies infection in both domestic dogs and lions from rabies endemic 
settings. The assay was further used to investigate the kinetics of VNAb response 
to rabies vaccination in a cohort of free-roaming dogs.  
The RVFV neutralisation assay developed herein utilises a recombinant luciferase 
expressing RVFV, which allows for rapid, high-throughput serosurveillance of this 
important neglected pathogen. In this thesis I present evidence of RVFV 
infection in a variety of domestic and wildlife species from Northern Tanzania, 
in addition to the detection of low-level transmission of RVFV during inter-
epidemic periods. Additionally, the investigation of a longitudinal cohort of 
domestic livestock also provided evidence of rapid waning of RVF VNAb following 
natural infection.     
Collectively, the serological data presented in this thesis are consistent with 
existing data in the literature generated using the gold standard VNTs. 
Increasing the availability of serological assays will allow the generation of 
robust serological data, which are imperative to enhancing our understanding of 
the complex, multi-host ecology of these two viruses.  
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 Chapter 1. Introduction 
 
1.1 Serological diagnosis  
1.1.1 Serology 
At one time serology was the backbone of viral diagnosis, however, for many 
infectious diseases it is gradually being replaced by molecular techniques such as 
real-time polymerase chain reaction (PCR) and next generation sequencing. 
During the acute phase of infection, a diagnosis can only be achieved using 
serological methods if virus specific immunoglobulin (Ig) M is detected in serum, 
or if a four-fold rise in antibody titre is observed between acute and 
convalescent sera, in which case diagnosis is retrospective. Additionally, the 
immunological response to many acute viral infections occurs after the 
development of clinical symptoms which limits the use of serology in clinical 
management of cases in the early stage of infection. Nonetheless, serology 
remains a core component of the routine diagnostic virology laboratory. 
Serological tests can provide important information such as a) diagnosing acute 
infection by detecting IgM antibodies; b) detecting antibodies which always 
indicate current infection (for example in HIV); c) the identification of patients 
with past exposure who may be at risk of recurrent infection; d) determining the 
immune status following vaccination or natural exposure and e) identifying risk 
factors of infection through retrospective analysis.  
Serology also remains a powerful tool for investigating virus ecology and 
infection dynamics. Antibodies often last considerably longer than viral nucleic 
acid and are therefore a more sensitive indicator of infection prevalence in a 
population compared to molecular techniques. Serosurveillance remains a 
critical component in control and elimination strategies of many important viral 
animal diseases, as shown by the successful eradication of rinderpest (OIE, 2011) 
and current campaigns to control peste de petits ruminants in Africa (OIE and 
FAO, 2015). The serum biobanks that exist across Africa have great potential for 
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serological investigations of other diseases, but have rarely been used for 
secondary analyses. In wildlife, where opportunities for sample collection are 
more limited than for human or domestic animals, serology is often the only 
available tool for inference and modelling of infectious disease dynamics 
(Gilbert et al., 2013). However, data produced by serological assays with poor 
sensitivity or specificity, or those affected by cross-reactivity or unclear cut-off 
thresholds complicate the interpretation of serological data (Viana et al., 2016). 
Thus sensitive, specific and robust serological assays are required to produce 
informative data regarding the prevalence and transmission dynamics of viruses. 
In addition to the innate immune system which is activated upon infection, 
specific acquired immunity occurs in response to viral antigens. The acquired 
immune response refers to the production of antibodies specific to the inducing 
antigen. Antibody secreting plasma cells are capable of secreting five classes of 
immunoglobulins; IgA, IgM, IgG, IgD and IgE. Three of these isotypes, IgA, IgM 
and IgG, are capable of virus neutralisation (Klimpel, 1996), which allows 
antibodies to block viral infection. Enveloped viruses can be neutralised by 
preventing the attachment of virus to cell surface receptors, by blocking 
penetration of the virus into the cell after attachment or by preventing 
uncoating of the virus within the cell. Virus neutralising antibodies (VNAb) are 
raised to viral glycoproteins and for many viral infections the presence of VNAb 
is one of the best correlates of protection from infection (Klasse, 2014).      
1.1.2 Serological assays  
Several assays are available for detecting virus specific antibodies, including the 
complement fixation test (CFT), indirect fluorescent antibody test (IFA), enzyme 
linked immunosorbent assay (ELISA) and the virus neutralisation test (VNT). In 
the CFT antibodies are detected based on the reaction of complement with 
antigen-antibody complexes. Briefly, test sera are heat treated and mixed with a 
fixed concentration of complement, antigen is then added and the test is 
incubated. The serum-antigen complex is then added to sensitised red blood 
cells, which lyse in the absence of antibody and remain intact if antibody is 
present in the test serum. To detect antibodies using the IFA test, antigen is 
coated onto a microscope slide and test sera are added. A fluorescently labelled 
secondary antibody, specific to the host species being tested, is then added to 
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the slide, if antibody is present fluorescence is observed under a fluorescence 
microscope. The ELISA employs a similar principle to the IFA, however a 96-well 
format is most commonly used and the secondary antibodies are coupled to an 
enzyme instead of a fluorophore, allowing a colour change to be determined by 
measuring the optical density. Depending on the ELISA platform used, either the 
presence or absence of colour indicates the presence of antibodies. In both the 
IFA and ELISA, IgM or IgG can be detected using isotype-specific secondary 
antibodies.  
The antibodies detected by the CFT, IFA and ELISA may be either neutralising or 
non-neutralising and the tests cannot differentiate between the two. The VNT is 
the only assay available to measure the presence of VNAb and is generally 
considered the gold standard assay for antibody detection (Monath et al., 2012). 
The test protocol involves mixing dilutions of test sera with a fixed amount of 
virus and incubating to allow VNAb to neutralise the virus. The serum/virus mix 
is then added to a monolayer of permissive cells and incubated for a period 
sufficient for the virus to infect cells and produce a cytopathic effect (CPE). 
Cells are then viewed under the microscope, the presence of VNAb is 
determined by the absence of CPE, as VNAb in the serum have successfully 
neutralised the virus. For viruses which do not produce CPE, labelled antibodies 
directed against the virus can be used to detect virus in the cell culture.  
Although the VNT is considered the gold standard for antibody detection, the 
assay requires the use of cell culture, live virus and involves incubation for a 
number of days before a result is available. Additionally, the test is laborious 
and few samples can be investigated simultaneously, as each serum dilution 
requires testing in individual wells, and tests are often performed in 6 or 12 well 
plates (Mather et al., 2013). Interpretation of the VNT is also subjective, as 
wells are scored for the presence or absence of CPE (or plaques) and results can 
differ from operator to operator. Furthermore, although the VNT is considered 
the gold standard, false positives and false negatives still occur, as is the case in 
all serological assays. False positive results in the VNT may be due to the 
presence of non-specific inhibitors in serum, the detection of cross-neutralising 
antibodies or components in the serum causing cytotoxicity. False negative 
results may occur in the VNT if low levels of antibody are present in the serum. 
A major limitation of the VNT is the use of live virus, if the virus requires high 
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containment facilities the VNT must be performed in such facilities. The 
majority of viruses which require handling at high containment circulate in 
regions of the world where such facilities are seldom available and this can 
hamper serosurveillance efforts for such viruses.   
1.1.3 Viral pseudotypes 
More recently VNTs have been described in which live virus is substituted with 
viral pseudotypes. A pseudotyped virus is a hybrid virus particle consisting of the 
nucleocapsid core of one virus and the glycoprotein of a heterologous virus 
(Temperton et al., 2015). Pseudotypes are used widely for gene transfer, where 
genes of interest are delivered into cells by utilising the glycoprotein of a virus 
with a broad cell tropism such as vesicular stomatitis virus (VSV). Among the 
most commonly used viral pseudotypes for gene therapy are those based on 
retroviruses (Sanders, 2002). The use of pseudotypes as surrogate viruses in VNTs 
is also becoming increasingly popular (Bentley et al., 2015), in such cases the 
‘gene of interest’ is a reporter gene, such as green fluorescent protein (GFP) or 
luciferase, with reporter gene expression indicating cellular entry. Retroviral 
pseudotypes are produced by transfecting plasmids into producer cells (often 
293T). Transfected plasmids include 1) a packaging plasmid 2) a transfer vector 
containing the reporter gene and 3) a plasmid encoding the glycoprotein gene 
(Figure 1.1). The packaging plasmid contains gag and pol genes which produce 
the core viral proteins. The transfer plasmid contains the modified retroviral 
genome encoding the reporter gene which is flanked by the viral long terminal 
repeats, the intact packaging signal allows incorporation of the retroviral 
genome into the pseudotype. The glycoprotein expression plasmid allows the 
viral glycoprotein to be expressed within the producer cells. Transfected genes 
are transcribed and translated within the producer cells and the glycoprotein is 
expressed on the cell surface. The retroviral genome carrying the reporter gene 
is incorporated into the pseudotype via the packaging signal, and the 
nucleocapsid core is targeted to the plasma membrane where the pseudotype 
buds (Temperton et al., 2015). Pseudotyped viruses are released into the 
supernatant of the producer cells and are then able to be used for transduction 
of target cells, where they can be used for applications such as investigating 
cellular tropism, identifying antiviral compounds or used in neutralisation assays.  
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The glycoproteins of the pseudotype mediate cellular attachment via cell 
surface receptors on target cells. The pseudotype is internalised and the 
retroviral construct bearing the reporter gene is integrated into the host cell 
DNA and expressed. Therefore, the level of reporter gene expression correlates 
with the level of transduction of pseudotype particles (Temperton et al., 2015). 
As the defective retroviral genome packaged into the pseudotype carries only 
the reporter gene, but no viral genes, no viral proteins are expressed in the 
target cells.  Hence the pseudotypes are infectious but replication defective, 
which is their greatest advantage when we consider their use in neutralisation 
tests. The glycoproteins of highly pathogenic viruses such as rabies, Ebola, 
Japanese encephalitis virus and highly pathogenic strains of influenza A have 
been used to pseudotype retroviruses (Wright et al., 2008, Wool-Lewis and 
Bates, 1998, Lee et al., 2014, Temperton et al., 2007) resulting in pseudotypes 
that can be used to study these highly pathogenic viruses at biosafety level (BSL) 
2.       
In addition to retroviral pseudotypes, rhabdoviral pseudotypes can also be 
produced using a modified VSV in which the glycoprotein has been deleted and 
replaced with a reporter gene. Due to the mechanism of VSV budding, which 
allows budding to occur in the absence of glycoprotein, this recombinant VSV 
can therefore be used to produce pseudotypes using the glycoprotein of 
heterologous viruses (Whitt, 2010).  
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Figure 1.1 Schematic representation of retroviral pseudotype production. 
Schematic diagram of a three-plasmid transfection system for producing 
retroviral pseudotypes. Transfected plasmids comprise of a retroviral packaging 
plasmid containing the viral gag-pol, a plasmid encoding the glycoprotein of 
interest and a transfer vector expressing the reporter gene containing the 
packaging signal and flanked by long terminal repeats (LTR). The three plasmids 
are simultaneously transfected into producer cells (usually 293T cells) and 48 h 
later supernatants containing retroviral pseudotypes are harvested. 
PRO=promoter. Figure adapted from Temperton et al. (2015). 
 
 
1.1.4 Pseudotype-based neutralisation tests 
As neutralising antibodies are elicited to viral glycoproteins, pseudotypes can be 
used to replace live virus in the VNT. The pseudotype neutralisation test (pNT) 
follows the same protocol as previously described for the VNT, however serum is 
mixed with pseudotypes in place of virus and instead of observing CPE, reporter 
gene expression is detected (Figure 1.2). Neutralisation is measured by an 
absence (or decrease) in reporter gene expression in the target cell line, as the 
Ψ 
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pseudotypes have been neutralised by VNAb in the sera before they have 
entered the cells and hence no (or less) reporter gene is expressed in the cells.   
The main advantage of the pNT over the conventional VNT is that pseudotypes of 
highly pathogenic viruses can be used in BSL-2, hence neutralisation assays for 
such viruses can be performed outside of high containment, vastly increasing the 
number of laboratories capable of performing such assays. Further advantages of 
the pNT include the use of the reporter gene to detect pseudotype transduction. 
Using reporters such as luciferase removes the subjective nature of assessing 
whether cells are displaying CPE, as luciferase expression is measured as an 
absolute number. Although luciferase reporter genes have been termed the gold 
standard for pNTs (Mather et al., 2013), high costs hamper their use in resource 
limited laboratories. The flexibility of pseudotype production allows for various 
reporter genes to be included, based on the preference of individual 
laboratories. Pseudotypes bearing the lacZ reporter gene may be most suitable 
for use in the pNT in resource limited settings as this reporter system is 30 times 
less expensive than the luciferase equivalent (Wright et al., 2009). In addition, 
the use of reporter genes in pseudotypes lends itself to the development of high-
throughput platforms for VNAb detection.      
A further advantage of the pNT is that significantly smaller volumes of sera are 
required in comparison to the conventional VNT, typically requiring a 5-25 fold 
reduction in serum volume (Temperton et al., 2015). Wright et al. (2010) have 
also described a multiplex pNT in which different reporters are utilised for 
pseudotypes of different viruses and both are simultaneously detected in the 
same well. This demonstrates the potential to detect VNAb to multiple viruses 
using an already decreased serum volume, a strategy which would be 
particularly beneficial when screening for VNAb in wildlife species in which often 
little serum is available.  
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Figure 1.2 Schematic representation of the pseudotype neutralisation 
test. In the pseudotype neutralisation test, test sera is mixed with a fixed 
concentration of viral pseudotype. The serum/pseudotype mix is incubated for 1 
h after which it is plated onto target cells and further incubated. If virus 
neutralising antibodies (VNAb) are present in the test sera, antibodies neutralise 
the pseudotypes and no reporter gene expression is observed in the target cells. 
In the absence of VNAb, pseudotypes transduce the target cells and expression 
of the reporter gene is observed.  
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Numerous studies have utilised pNTs for the detection of VNAb to a wide variety 
of viruses (Table 1.1). Previous studies have demonstrated that pNTs are as 
sensitive as their conventional VNT counterparts, and some have even 
demonstrated increased sensitivities compared to VNT (Temperton et al., 2007, 
Logan et al., 2016, Wright et al., 2008, Fukushi et al., 2006). The specificities of 
the pNTs described in the literature are also high, as the glycoprotein is the only 
protein present on the pseudotype membrane it can be inferred that any 
neutralisation demonstrated in the pNT is specifically due to interactions with 
the viral glycoprotein.  
In this thesis I aim to utilise pseudotyped viruses to develop pNTs to two high 
containment viruses, rabies and Rift Valley fever virus (RVFV). Improving the 
availability of these assays will allow further data generation to advance our 
understanding of the ecology of these two important zoonotic viruses. However, 
RVFV pseudotypes were not produced to a high enough titre to allow for large 
scale screening of sera therefore other novel alternatives to the conventional 
neutralisation test were developed.  
  
 
2
9
 
Viral species pseudotyped 
Core vector 
system 
Reporter gene Reference 
Rabies virus, Lagos bat virus, Mokola virus, 
Duvenhage virus, European bat lyssavirus 
types 1 and 2 
HIV Firefly luciferase (Wright et al., 2008, Wright et al., 2009) 
Influenza A virus HIV/MLV Firefly luciferase/GFP (Temperton et al., 2007, Labrosse et al., 
2010) 
SARS coronavirus MLV/VSV GFP (Temperton et al., 2005, Fukushi et al., 
2006) 
Feline immunodeficiency virus HIV Firefly luciferase (Samman et al., 2010) 
Canine distemper virus  VSV Firefly luciferase (Logan et al., 2016) 
Nipah virus VSV GFP (Kaku et al., 2009) 
Severe fever with thrombocytopenia  virus VSV Firefly luciferase (Hofmann et al., 2013) 
 
 
      30
 
Ebola virus HIV Firefly luciferase (Shedlock et al., 2010) 
Japanese encephalitis virus MLV β-galactosidase (Lee et al., 2014) 
Rift Valley fever virus VSV Firefly luciferase (Bukbuk et al., 2014) 
Hantaan virus VSV Renilla luciferase/GFP (Higa et al., 2012, Ogino et al., 2003) 
Puumala virus VSV Renilla luciferase (Higa et al., 2012) 
Seoul virus VSV GFP (Ogino et al., 2003) 
Hepatitis C virus HIV/MLV Firefly luciferase/GFP (Logvinoff et al., 2004, Bartosch et al., 2003) 
Human immunodeficiency virus type 1 HIV Firefly luciferase (Simek et al., 2009) 
Chikungunya virus HIV Firefly luciferase (Kishishita et al., 2013) 
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Table 1.1 Neutralisation tests in which viral pseudotypes have been 
utilised as surrogates for live virus. Examples of viral pseudotypes which have 
been utilised in pNTs for the detection of virus specific VNAb. 
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1.2 Rabies virus  
1.2.1 Rabies virus genome  
Rabies is one of the oldest and most feared zoonotic diseases (Muller et al., 
2014), and unsurprisingly as the disease proves fatal in very almost every case 
once symptoms occur. Rabies virus is the prototype of the Lyssavirus genus, 
family Rhabdoviridae (King et al., 2012). The virus has a single stranded, 
negative sense, unsegmented RNA genome which is approximately 12 kb in size 
and encodes five structural proteins; the nucleoprotein (N), phosphoprotein (P), 
matrix protein (M), glycoprotein (G) and the viral RNA-dependent RNA 
polymerase (RdRP) (L) (Jackson and Wunner, 2007) (Figure 1.3). Each gene is 
separated by non-coding intergenic sequences.The intergenic sequence between 
the G and L genes is unusually long (~423 bp) and is unique to members of the 
Lyssavirus genus (Tordo et al., 1986). Cellular entry is mediated by the viral 
glycoprotein, and although several putative rabies receptors have been 
identified, the definitive rabies receptor(s) have yet to be fully elucidated 
(Lafon, 2005).  
 
Figure 1.3 Schematic diagrams of rabies virus virion and the viral genome. 
Schematic representation of a) the rabies virus virion and b) the viral genome 
which encodes the nucleoprotein (N), phosphoprotein (P), matrix protein (M), 
glycoprotein (G) and the viral RNA-dependent RNA polymerase (L).    
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1.2.2 Host species 
All mammals are susceptible to rabies virus infection, however only a limited 
number of host species act as reservoirs of the virus. Rabies virus demonstrates 
distinct phylogeographical patterns, with particular reservoir hosts associated 
with particular regions and viral strains. Domestic dogs are the principal host 
reservoir for rabies in Asia and Africa (Cleaveland et al., 2006). In much of 
Western Europe canine rabies has been eliminated, yet rabies still persists in 
East and South-East Europe where it is maintained in wildlife reservoirs (Freuling 
et al., 2012). Bats maintain rabies virus across the Americas with canine rabies 
co-circulating in Latin America and wildlife rabies maintained in North America 
by mesocarnivores. Throughout the world, distinct lineages of rabies virus are 
maintained in various carnivore reservoirs, which include raccoon dogs, skunks, 
coyotes, mongooses, raccoons and grey, red and arctic foxes (Müller et al., 
2015). Interestingly, whilst rabies in carnivores is maintained globally, rabies 
virus is only observed in bats in the Americas and it appears Old World bats are 
not infected with rabies virus. Tthey are however reservoir hosts of other 
lyssavirus species.  
Although canine rabies has been eliminated in most developed countries, it is 
still the cause of around 59,000 human deaths globally each year (Hampson et 
al., 2015). Domestic dog vaccination campaigns are key to controlling canine 
rabies in endemic settings.  Dog vaccination schedules suggest a single dose of 
vaccine followed by boosters every 1-3 years, depending on the duration of 
immunity specified by the vaccine manufacturer (Day et al., 2010). Attempts to 
control rabies in wildlife (excluding bats) rely upon oral vaccination programmes 
utilising vaccine-laden baits, which have resulted in elimination of rabies in 
many countries in Western Europe (Rupprecht et al., 2004). 
1.2.3 Rabies virus infection  
Rabies virus can be transmitted from reservoir host species to dead end hosts 
and such spillover infections occur in both humans and animals. The vast 
majority of human rabies infections occur via the bite of a rabid animal, as the 
virus is present in large quantities in the saliva (Fekadu et al., 1982). However, 
direct contact of infected bodily fluids with mucous membranes, such as by licks 
or scratches, are an additional route of natural infection. Rare cases of rabies 
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transmission through solid organ (Srinivasan et al., 2005) and corneal transplant 
(Gode and Bhide, 1988) have also been reported. Airborne transmission of rabies 
virus, due to exposure to bats in caves and also through laboratory associated 
infections, have been reported in humans (Johnson et al., 2006).    
Initial clinical symptoms in humans in the prodromal phase may include fever, 
loss of appetite and pain at the site of infection. Two clinical forms of rabies can 
occur in humans; encephalitic or paralytic (Fooks et al., 2014), however overlap 
of clinical symptoms is often observed (Deitzgen and Kuzmin, 2012). The 
encephalitic form often presents with agitation, insomnia and hallucinations in 
addition to the less commonly observed features of hydrophobia, aerophobia and 
photophobia. In paralytic rabies muscle weakness occurs early and agitation and 
anxiety are mild or absent. In both forms of rabies, patients become comatose 
and die, due to respiratory failure or cardiac arrest, typically within 1-10 days 
post symptoms (Deitzgen and Kuzmin, 2012).   
1.2.4 Treatment and vaccination  
Although rabies is almost always fatal once clinical symptoms present, the 
disease is entirely preventable through vaccination in both humans and animals. 
Vaccination in humans is recommended for anyone at risk of infection, namely 
veterinarians, bat handlers, laboratory workers and those travelling to rabies 
endemic areas. Due to the serious consequences of infection and the possibility 
of waning antibody titres, a course of post-exposure vaccination is also 
recommended after a potential exposure, even for patients who have previously 
been vaccinated.  Patients who receive a high risk rabies exposure and have not 
been prophylactically vaccinated, additionally receive human rabies 
immunoglobulin (HRIG) which is administered at the exposure site as soon as 
possible (PHE, 2013). The use of HRIG aims to neutralise the virus at the 
inoculation site, reducing the viral load and allowing time for the host’s adaptive 
immune response to develop (Wilde et al., 2002).  
Neutralising antibodies, raised against the viral glycoprotein, play a prominent 
role in the immune defence against rabies virus and the presence of VNAb confer 
protection against infection (Jackson and Wunner, 2007). During infection 
antibodies are also raised against the viral nucleoprotein, these antibodies are 
not neutralising but they have been shown to protect experimentally infected 
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mice in the absence of VNAb (Lodmell et al., 1993), however the exact 
mechanisms that infer such protection remain unclear.      
1.2.5 Rabies diagnosis 
Clinical symptoms and a history of potential rabies exposure are often sufficient 
for a clinical diagnosis of rabies infection, however in paralytic rabies clinical 
symptoms are often indistinguishable from those of other neurological conditions 
(Mani and Madhusudana, 2013). Furthermore, potential rabies exposures are 
often lacking from a patient’s clinical history (Despond et al., 2002).  The gold 
standard diagnostic assay for rabies infection is the fluorescent antibody test 
which detects viral antigen in tissue samples using immunofluorescence (OIE, 
2012a). Other diagnostic tests include rabies virus isolation, antigen detection by 
ELISA and detection of viral RNA by molecular techniques.    
Serology is rarely used for rabies diagnosis as seroconversion occurs late in 
disease and the negative predictive value of rabies antibody detection is low, as 
VNAb are often undetectable even in the terminal stages of disease (Mani et al., 
2014). Additionally, if patients have received rabies vaccination or HRIG, 
antibody detection cannot be used diagnostically. However, serological testing is 
useful for demonstrating seroconversion following vaccination and for rabies 
epidemiological studies. The gold standard measure of seroconversion is the 
detection of rabies-specific VNAb by VNT. The World Organisation for Animal 
Health (OIE) prescribed VNTs are the rapid fluorescent focus inhibition test 
(RFFIT) and the fluorescent antibody virus neutralisation (FAVN) test. 
The RFFIT is performed by mixing dilutions of test sera and the challenge virus 
standard-11 (CVS-11) strain of rabies virus in tissue culture chamber slides which 
are then incubated at 35°C in a humid incubator for 90 min. Mouse 
neuroblastoma cells or baby hamster kidney cells (BHK-21) are then added to the 
wells and incubated for a further 20 h. Media is removed and cells are washed in 
PBS, fixed in acetone and dried, after which FITC-conjugated anti-rabies serum 
is added to the slide and incubated for 30 min. Wells are then observed under 
fluorescence microscopy and the number of fluorescent cells are manually 
counted (Smith et al., 1973). The FAVN is a modified version of the RFFIT which 
retains a similar protocol, although requires 48 h incubation. The advantage of 
the FAVN over the RFFIT is that the read out of the FAVN is absolute, simply the 
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presence or absence of fluorescence, and is therefore considered less subjective 
than the RFFIT (Cliquet et al., 1998). Results of the RFFIT and FAVN can be 
expressed either as a serum dilution titre or in International Units (IU). For 
expression of titres in IU an international standard reference serum of known 
concentration is tested in parallel with test sera and antibody titres are derived 
from comparison with the reference standard. 
Both the RFFIT and the FAVN utilise live virus and therefore must be performed 
within high containment facilities. Rabies virus is considered a Group 4 pathogen 
under the Specified Animals Pathogens Order (SAPO) and requires enhanced 
containment conditions for handling virus (DEFRA, 2015). These assays are time 
consuming and require highly trained individuals to perform and interpret. As a 
result, very few laboratories are able to perform these assays and their use is 
particularly hampered in developing countries, those that are most often rabies 
endemic. Although it is the gold standard, the RFFIT has been shown to be 
sensitive to cytotoxicity when poor quality sera are tested (Ma et al., 2012) and 
false positives can occur due to nonspecific inhibitors in sera (Mani and 
Madhusudana, 2013). Furthermore, interpretation of both the RFFIT and FAVN 
are subjective. 
ELISAs are a simple, cheap, rapid and safe alternative to the VNT, no high 
containment facilities are required and this platform is much better suited to 
high-throughput testing. However, some studies have demonstrated poor 
correlation between the ELISA and VNT, especially when samples contain low 
concentrations of rabies antibody (Welch et al., 2009, Cliquet et al., 2004). It 
should also be noted that ELISAs are not functional assays, measuring antibody 
binding, not neutralisation, and therefore cannot be used to determine 
protection.  
1.2.6 Alternatives to conventional virus neutralisation tests 
Wright et al. (2008) described a rabies VNT utilising retroviral pseudotypes in 
place of live rabies virus. In this study they successfully produced pseudotypes 
using an HIV (lentivirus) core pseudotyped with rabies virus glycoprotein which 
expressed a luciferase reporter gene and an MLV (gammaretrovirus) rabies 
pseudotype expressing GFP. The lentiviral pseudotypes were used to measure 
rabies VNAb in human, canine and feline sera and the pNT titres were highly 
Chapter 1. Introduction                                                                                                          37 
 
      30
 
correlated with VNAb titres obtained using the gold standard FAVN. These 
replication incompetent particles allow VNAb measurement outwith the high 
containment facilities required to handle live rabies virus, greatly improving the 
availability and utility of this assay. In addition, the study reported 100% 
specificity and was as sensitive at detecting VNAb positive samples as the FAVN. 
Additional alternative assays for measuring rabies VNAb have also been 
described. Latex agglutination tests (LAT) use antigen coated latex beads 
incubated with serum to detect antibodies to rabies virus, in which agglutination 
signifies the presence of antibodies. Original tests used whole virus to coat the 
latex beads (Perrin et al., 1988), however to detect only glycoprotein-specific 
antibodies, methods utilising beads coated with only the viral glycoprotein have 
since been described (Jemima et al., 2014). The test is very simple and cheap to 
perform therefore large scale serosurveillance can be performed easily. 
Although these tests appear to be specific, the sensitivity is poor when low titres 
of antibody are present in test sera (Madhusudana and Saraswati, 2003, Jemima 
et al., 2014). This assay measures antibodies to the glycoprotein, which in 
addition to VNAb may also include non-neutralising antibodies, therefore the 
results of this assay cannot be used to infer protection. Additionally, 
measurements from LATs are only qualitative and cannot be used to determine 
specific titres of rabies VNAb in sera. 
Rabies VNTs that utilise recombinant rabies virus expressing GFP, produced by 
reverse genetics techniques, have also been described (Khawplod et al., 2005, 
Xue et al., 2014, Tang et al., 2015). These tests demonstrate high sensitivity and 
specificity when compared with the RFFIT or FAVN. These tests are easier to 
interpret than conventional VNTs as GFP fluorescence is easily identified and 
post-assay processing is reduced as antibody staining is not required. However, 
these recombinant viruses are still infectious and replication competent, 
therefore still require handling in the high containment facilities associated with 
the RFFIT and FAVN.  
The majority of rabies VNTs are used to determine whether or not a sufficient 
immune response has been mounted post vaccination and only a minority of 
testing occurs diagnostically to provide evidence of infection. VNTs are also 
performed for serosurveillance of lyssavirus antibodies in bats and rabies VNTs 
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are also used, although rarely, for rabies serosurveillance in terrestrial 
mammals. Non-fatal rabies infection is an accepted outcome of rabies infection 
in bats but such infection in other species challenges the theory that rabies 
infection is always fatal. There have been documented cases of recovery from 
rabies infection in animals during clinical trials and there have also been reports 
of rabies antibodies in healthy animals, suggesting non-fatal rabies infections in 
nature (Table 1.2). Potential explanations for such non-fatal infections include 
receiving a low infectious dose, spontaneous viral clearance or the presence of 
defective interfering (DI) particles. The presence of DI rabies virus particles have 
been demonstrated in vivo and in vitro, such particles are produced alongside 
functional virions during viral replication but are themselves non-infectious 
(Baer, 1991). The presence of DI particles can interfere with replication of non-
defective rabies virions and such a phenomenon has been shown to actually 
protect experimentally infected animals from disease (Wiktor et al., 1977). The 
role of DI rabies virus particles in natural infection has not been studied but is a 
theoretical explanation for the presence of rabies VNAb in unvaccinated animals.      
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Exposure 
Testing 
method 
Species Comments Reference 
Experimental 
infection 
RFFIT Ferret One ferret recovered from rabies virus infection, 
demonstrating VNAb in serum and CNS 
(Hamir et al., 2011) 
Experimental 
infection 
FAVN Dog An unvaccinated control dog survived rabies challenge, 
demonstrating VNAb at a titre of 0.22 IU/ml in serum 
(Darkaoui et al., 2016) 
Natural 
infection 
RFFIT Cattle 42/350 unvaccinated cattle from Guatemala  had 
rabies VNAb titres of ≥0.1 IU/ml 
(Gilbert et al., 2015) 
Natural 
infection 
RFFIT/IFA Humans  6/63 humans from bat exposed communities had 
rabies VNAb with no history of previous vaccination  
(Gilbert et al., 2012) 
Natural  
infection 
RFFIT Humans High VNAb titre in a fox trapper in Alaska with no 
previous history of rabies vaccination 
(Follmann et al., 1994) 
Natural 
infection 
RFFIT Dogs 115/233 unvaccinated dogs from a rabies endemic area 
of Tanzania demonstrated rabies VNAb 
(Cleaveland et al., 1999) 
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Natural 
infection 
FAVN Dogs 24/123 unvaccinated dogs from a rabies endemic area 
of Tanzania demonstrated rabies VNAb 
(McNabb, 2008) 
Natural 
infection 
FAVN Dogs VNAb in unvaccinated dogs from rabies endemic areas 
of South Africa and Indonesia (n=20) 
(Morters et al., 2014a) 
Natural 
infection 
RFFIT Mongooses 502/1675 of mongooses tested had rabies VNAb at 
serum dilutions of ≥1:5  
(Everard et al., 1981) 
Natural 
infection 
RFFIT Jackal 3/16 unvaccinated animals had rabies VNAb titres at 
serum dilutions of ≥1:50  
(Mebatsion et al., 1992) 
Natural 
infection 
RFFIT African wild 
dogs 
3/12 unvaccinated animals had rabies VNAb titres (Gascoyne et al., 1993) 
 
Table 1.2 Studies in which rabies virus neutralising antibodies have been demonstrated in the absence of clinical disease or 
after recovery from rabies infection. Examples of studies demonstrating rabies VNAb in humans and animals in the absence of, or 
recovery from, clinical disease. Titres of VNAb recorded in the studies were ≥0.5 IU/ml unless otherwise stated. RFFIT=rapid fluorescent 
focus inhibition test, FAVN=fluorescent antibody virus neutralisation test, IFA=indirect fluorescent antibody test. 
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1.3 Non-rabies lyssaviruses 
Rabies virus is the prototype virus of the Lyssavirus genus, of which 14 distinct 
species are recognised (King et al., 2012), with a further potential species 
(Lleida bat lyssavirus (LLEBV)) reported in 2013 (Aréchiga Ceballos et al., 2013) 
(Table 1.3). The majority of these lyssaviruses have been reported in bats; 
however Mokola virus (MOKV) and Ikoma lyssavirus (IKOV) have only been 
isolated from terrestrial mammals. Mokola virus was first identified in shrews 
(Shope et al., 1970) and has been further isolated from cats, dogs and a mouse 
(Sabeta et al., 2007). Ikoma lyssavirus has been identified only in one African 
civet from within the Serengeti National Park (Marston et al., 2012), and 
although this is likely to signify a spillover infection from a bat reservoir host, no 
evidence of IKOV infection in bats has been detected to date (Horton et al., 
2014). All lyssaviruses have the same genomic structure as rabies virus (Delmas 
et al., 2008) and it has been proposed that lyssaviruses evolved in bats long 
before spilling over into terrestrial mammals (Badrane et al., 2001, Streicker et 
al., 2010). As with rabies virus the phylogeography of lyssaviruses is distinct, 
with specific lyssaviruses circulating in particular regions (Table 1.3). To date, 
spillover infections of non-rabies lyssaviruses caused by MOKV, Duvenhage virus 
(DUVV), European bat lyssavirus (EBLV) types 1 and 2, Australian bat lyssavirus 
(ABLV) and Irkut virus (IRKV) have been reported in humans (Evans et al., 2012). 
Transmission routes are identical to rabies virus and the clinical picture is 
indistinguishable from that of rabies virus infection. Human cases of non-rabies 
lyssavirus infection however are incredibly rare, only around 12 cases have been 
documented (Evans et al., 2012), and these were invariably fatal.  
Genetically, lyssavirus species can be separated into distinct phylogroups (Table 
1.3 and Figure 1.4).  Badrane et al. (2001) described two distinct phylogroups 
which separated rabies virus, DUVV, EBLV-1, EBLV-2 and ABLV into phylogroup 1 
and MOKV and Lagos bat virus (LBV) into phylogroup 2 based on both genetic 
relationships and serological studies. A further putative phylogroup has been 
proposed (Kuzmin et al., 2005) which includes West Caucasian bat virus (WCBV), 
IKOV and LLBEV. Testing for VNAb against lyssavirus species is conducted using 
the same assays as for rabies virus, the RFFIT or FAVN, by simply substituting the 
test virus used in the assay. These VNTs are useful for measuring the antibody 
response if the lyssavirus responsible for infection is known, for example in 
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laboratory experiments or when the infecting virus has been identified by 
molecular techniques. However, cross-neutralising antibodies to lyssaviruses can 
obscure results in VNTs if the infecting lyssavirus is unknown and also during 
sero-epidemiological studies.  
Antibodies raised against rabies virus cross-neutralise other phylogroup 1 
lyssaviruses to varying degrees, but do not readily neutralise viruses from 
phylogroup 2 (Lafon et al., 1988, Brookes et al., 2005b, Hanlon et al., 2005, 
Wright et al., 2008, Badrane et al., 2001). The degree of neutralisation has been 
shown to correlate with the amino acid similarity of lyssaviruses (Badrane et al., 
2001). Hanlon et al. (2005) demonstrated cross-neutralisation between two 
phylogroup 2 lyssavirus, LBV and MOKV, however no cross-neutralisation was 
observed to WCBV, a member of the putative third phylogroup. The cross-
neutralising ability of rabies-specific VNAb across the phylogroup 1 viruses 
provides encouragement that rabies vaccination should protect against these 
viruses and therefore vaccination should be offered to those at risk of infection 
with phylogroup 1 lyssaviruses, such as laboratory workers and bat handlers. 
However, rabies vaccination would elicit little, if any, protection against 
phylogroup 2 viruses or those from the third phylogroup.  
These cross-neutralisation patterns must be considered when interpreting 
serology from regions where lyssaviruses of the same phylogroup circulate, and 
indeed consideration must also be given to those as yet unidentified lyssaviruses 
that are undoubtedly circulating across the globe. Although VNAbs may cross-
neutralise a number of lyssaviruses, it has been documented that the highest 
VNAb titres are observed against the particular lyssavirus to which the initial 
immune response was elicited (Wright et al., 2008, Wright et al., 2010).  
Pseudotype neutralisation tests have been described for LBV, MOKV, EBLV-1 and 
EBLV-2 (Wright et al., 2008, Wright et al., 2009). Serological assays that can be 
performed safely without the use of live virus are even more important for non-
rabies lyssaviruses, as no specific vaccines are available for prophylaxis or post 
exposure treatment. An additional advantage of the pNT is that only the 
sequence for the glycoprotein is required, as opposed to a culture of live virus. 
Therefore, if a new lyssavirus is discovered the glycoprotein could be cloned 
directly from sequenced material, or even synthesised, negating the need to 
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culture large quantities of virus, which is time consuming and not always 
successful.       
 
 
Figure 1.4 Phylogenetic tree of species of the Lyssavirus genus. 
Phylogenetic reconstruction based on the nucleoprotein gene of lyssaviruses, 
scale bar represents number of substitutions per site. Figure reproduced from 
Aréchiga Ceballos et al. (2013).     
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 Lyssavirus Year 
identified 
Country 
identified 
Geographical 
distribution 
Host species Reference 
Phylogroup 
1 
Duvenhage virus (DUVV) 1970 South 
Africa 
Africa Insectivorous bats (Meredith et al., 1971) 
European bat lyssavirus 
type -1 (EBLV-1) 
1977 Russia Europe Insectivorous bats (Banyard et al., 2014) 
European bat lyssavirus 
type -2 (EBLV-2) 
1985 Finland Europe Insectivorous bats (Lumio et al., 1986) 
Australian bat lyssavirus 
(ABLV) 
1996 Australia Australia Frugivorous bats (Fraser et al., 1996) 
Aravan virus (ARAV) 1991 Kyrgyzstan Eurasia Insectivorous bats (Kuz'min et al., 1992) 
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Khujand virus (KHUV) 2001 Tajikistan Eurasia Insectivorous bats (Kuzmin et al., 2003) 
Irkut virus (IRKV) 2002 Russia Eurasia Insectivorous bats (Botvinkin et al., 2003) 
Bokeloh bat virus 
(BBLV) 
2010 Germany Europe Insectivorous bats (Freuling et al., 2011) 
Phylogroup 
2 
Lagos bat virus (LBV) 1956 Nigeria Africa Frugivorous bats (Boulger and Porterfield, 
1958) 
Mokola virus (MOKV) 1968 Nigeria Africa Terrestrial mammals (Shope et al., 1970) 
Shimoni bat virus 
(SHIBV) 
2009 Kenya Africa Insectivorous bats (Kuzmin et al., 2010) 
Putative 
3rd 
West Caucasian bat 
virus (WCBV) 
2002 Russia Eurasia Insectivorous bats (Botvinkin et al., 2003) 
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phylogroup 
Ikoma lyssavirus (IKOV) 2009 Tanzania Africa African civet* (Marston et al., 2012) 
Lleida bat lyssavirus 
(LLEBV) 
2011 Spain Europe Insectivorous bats (Aréchiga Ceballos et al., 
2013) 
 
Table 1.3 Geographical location and species associations of the non-rabies lyssaviruses. The date and place of virus identification, 
phylogroup, host species and geographical range of the 13 species (and the additional putative species, LLEBV) of non-rabies lyssaviruses. 
*IKOV has only been isolated from one animal to date.    
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1.4 Rift Valley fever virus  
1.4.1 Rift Valley fever virus genome 
Rift Valley fever virus was first described  in Kenya in 1930, when a previously 
undescribed disease was affecting sheep farms: high mortality rates were 
observed in new born lambs and the majority of pregnant ewes aborted 
(Daubney et al., 1931). The cause of the disease was identified as RVFV, a 
member of the Bunyaviridae family and the Phlebovirus genus (King et al., 
2012). The RVFV genome is around 12 kb in size and comprises three single 
stranded RNA segments; large (L), medium (M) and small (S). The L and M 
segments are negative sense whereas the S segment is of ambisense polarity. 
The L segment encodes for the viral RdRP, the M segment encodes for the 
glycoprotein precursor and the S segment encodes for the nucleoprotein and the 
non-structural NSs protein (Pepin et al., 2010) (Figure 1.5). The polyprotein 
precursor produced from the M segment is co-translationally cleaved into two 
glycoproteins, Gn and Gc, and two non-structural proteins (NSm1 and NSm2) 
(Gerrard and Nichol, 2007). The glycoproteins mediate virus entry into cells, 
however the specific receptors of RVFV remain to be identified (Harmon et al., 
2012). 
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Figure 1.5 Schematic diagram of Rift Valley fever virus virion and the 
segmented genome. Schematic representation of a) the RVFV virion and b) the 
tripartite segmented genome. Figure adapted from Pepin et al. (2010).  
 
 
1.4.2 Host species  
The primary maintenance and transmission vectors of RVFV are mosquitoes of 
the Aedes genus, with mosquitoes of the Culex genus being implicated in 
transmission during outbreaks (Crabtree et al., 2012). However over 30 species 
of mosquito have been reported as being naturally infected with RVFV (Chevalier 
et al., 2010). Transmission cycles are complex, and differ between epidemics 
and through inter-epidemic periods (IEP). The leading hypothesis regarding viral 
maintenance between outbreaks involves the persistence of RVFV in diapause 
mosquito eggs which survive in shallow wetlands during IEP, although often 
quoted as ‘months’ there is very little natural or experimental data regarding 
the duration of such egg viability. Major outbreaks of RVFV tend to occur after 
heavy rainfall (Anyamba et al., 2009). It is hypothesised that following flooding 
of these wetlands, diapause eggs hatch releasing RVFV infected mosquitoes into 
the environment. Infected mosquitoes then transmit the virus to ruminants, who 
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act as amplifying hosts, and an explosive epidemic ensues. Mosquitoes transmit 
the virus to ruminants and humans, direct transmission from infected ruminants 
to other animals and humans is another major route of transmission during 
outbreaks and vertical transmission of RVFV has also been demonstrated in 
animals (Antonis et al., 2013). The role of wildlife hosts, both during outbreaks 
and IEP, is yet to be fully elucidated (Olive et al., 2012) (Figure 1.6). Rift Valley 
fever virus is predominantly considered a disease of domestic ruminants and 
humans, however clinical disease has also been documented in a variety of even-
toed ungulate species such as camels (El Mamy et al., 2011), buffalo and 
waterbuck (Beechler et al., 2015).  Rift Valley fever virus was confined to 
continental Africa until it was detected in Madagascar in 1979 (Carroll et al., 
2011) and subsequently the virus has spread further, being detected in the 
Arabian Peninsula in 2000 (Balkhy and Memish, 2003).   
Little is known about maintenance of the virus during IEP, and although RVFV 
has been shown to persist in mosquito eggs during such periods, there have been 
many studies suggesting that RVFV does in fact circulate at a low-levels between 
outbreaks in livestock, humans and wildlife (Sumaye et al., 2013, Gray et al., 
2015, LaBeaud et al., 2008, Beechler et al., 2015, Wensman et al., 2015). Hence 
further sero-epidemiological studies are required to understand inter-epidemic 
transmission and maintenance of RVFV, to better advise on preparedness and 
management of RVFV.  
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Figure 1.6 Proposed transmission cycle of Rift Valley fever virus. 
Transmission of RVFV between mosquito vectors, ruminant and human hosts. The 
role of wildlife in maintenance and transmission remains unclear.  
 
 
1.4.3 Rift Valley fever virus infection 
Sheep, and to a lesser extent cattle, are the principle hosts of RVFV in sub-
Saharan Africa (Davies, 2010). Outbreaks of the disease are characterised by 
‘abortion storms’ in domestic livestock and high mortality rates are observed in 
animals of less than one week of age. Clinical symptoms include pyrexia, 
mucopurulent nasal discharge, haemorrhagic diarrhoea, vomiting and jaundice.  
Onset of disease is sudden and death occurs within 12-24 h of developing 
symptoms. During outbreaks the mortality rate in animals of less than 10 days of 
age is 100% and 70% for lambs and calves respectively. Goats suffer the same 
clinical picture as sheep however present with less severe clinical symptoms and 
a lower mortality rate is observed (Davies and Martin, 2006). 
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In humans most RVFV infection causes a self-limiting febrile illness which lasts 3-
4 days, however long term sequelae are observed in a minority of patients and 
can result in neurological manifestations and loss of vision (Ikegami and Makino, 
2011). In rare cases RVFV infection involves haemorrhagic manifestations, 
patients present with fever, rigor, headaches, maculopapular rash, bleeding 
gums and bloody diarrhoea, death occurs 3-6 days after the onset of symptoms 
(Ikegami and Makino, 2011). No treatment is available for either the self-limiting 
or haemorrhagic forms of RVFV infection. Overall case fatality rates have 
historically been reported as around 1% (Spickler, 2010), however higher fatality 
rates of up to 47% have been recorded in more recent outbreaks (Mohamed et 
al., 2010). Human infection is increased in regions where consumption of milk 
and meat from sick animals is still practiced (Sindato et al., 2011). 
During outbreaks the economic burden of RVFV is immense, the most affected 
communities tend to be the poorest, mainly farmers who rely on milk and meat 
production as both income and sustenance. These communities often live in 
remote areas with poor communication facilities, which means they are often 
unable to report RVFV outbreaks to the authorities (Fyumagwa et al., 2011). In 
addition to the immediate economic loss due to livestock deaths, bans on 
livestock trade during outbreaks also impact on livelihoods.  
1.4.4 Vaccination  
The development of effective and safe RVFV vaccines is required to protect 
humans and livestock during outbreaks. However, little progress in vaccine 
development has been made since the discovery of the virus and there is at 
present no licensed vaccine for use in humans (Ikegami and Makino, 2009). The 
first vaccine, produced in 1949 (Smithburn, 1949), is still in use in livestock 
today. This is a live-attenuated vaccine, which is inexpensive and provides long 
lasting immunity but has been reported to cause abortions and foetal 
abnormalities in pregnant animals (Botros et al., 2006). Inactivated whole-virus 
vaccines are also available and have a much higher safety rating than the live-
attenuated vaccine, however these are expensive to produce and booster doses 
are required for optimal protection (Barnard, 1979).   
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1.4.5 Rift Valley fever diagnosis 
Laboratory diagnosis of RVFV infection can be made by genome detection using 
real-time or gel based RT-PCR, however viraemia lasts only 3-4 days (Mansfield 
et al., 2015) hence the window for detection is limited. Therefore delays in 
hospitalisation or testing would result in the inability to detect circulating virus. 
Additionally, PCR requires specialist equipment and trained staff, which are 
often unavailable in countries where RVFV is endemic, hence the majority of 
RVFV diagnosis relies on detection of IgM antibodies. The immune response 
develops rapidly following RVFV infection, with IgM and IgG detectable from 4 
and 8 days post infection respectively (Mansfield et al., 2015). Neutralising 
antibodies are raised primarily against the viral glycoproteins (Gn and Gc) 
(Besselaar and Blackburn, 1992) and are considered the best correlate of 
protection (Pepin et al., 2010). The majority of IgM and IgG antibodies are 
directed against the nucleoprotein, and to a lesser extent to the NSs (Pepin et 
al., 2010). The nucleoprotein is the major immunogen in RVFV infection and 
antibodies raised to the nucleoprotein are therefore utilised in the majority of 
serological assays. IgM antibodies are detectable for around 7 weeks (Niklasson 
et al., 1984) but there is little data regarding the duration of IgG or neutralising 
antibodies in natural infection.  
The gold standard assay for assessing previous RVFV exposure, and for evaluating 
protective titres post vaccination, is the plaque reduction neutralisation test 
(PRNT) (OIE, 2012a). The PRNT detects neutralising antibodies, in sera of any 
species, and is considered the most specific RVFV antibody detection assay. 
However as the PRNT utilises live virus it requires BSL-3 containment facilities 
(HSE, 2013) which are often not available in RVFV endemic countries. 
Furthermore, the assay requires skilled technicians to perform and has an 
incubation period of up to 7 days, further hampering the use of this assay in the 
field. The most commonly utilised method for sero-epidemiology of RVFV is the 
ELISA (Mansfield et al., 2015), commercial RVFV ELISAs based on the viral 
nucleoprotein are available and detect IgM and/or IgG. The majority of these 
ELISAs are validated only for domestic ruminants and humans although a multi-
species capture ELISA is also commercially available. These ELISAs allow for 
large scale serosurveillance outside of high containment facilities and are much 
more convenient for ‘in field’ testing. However many studies have demonstrated 
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poor agreement between PRNT and ELISA results in field samples (Evans et al., 
2008, Gray et al., 2015, Kariithi et al., 2010). Furthermore, non-specific 
background has been observed using such assays which makes result 
interpretation difficult (Faburay et al., 2013). As these ELISAs detect antibodies 
raised to the RVFV nucleoprotein, further concern is raised with regard to 
antibody cross-reactivity, as antibodies raised against other members of the 
Phlebovirus genus have been shown to cross-react (Wu et al., 2014, Xu et al., 
2007, Tesh et al., 1982, Szymczak et al., 2015). During the course of my PhD, I 
produced  ELISAs based on the recombinant nucleoprotein of RVFV and two other 
phleboviruses; sandfly fever Sicilian virus (SFSV) and Toscana virus (TOSV) and 
demonstrated cross-reactivity of RVFV antibodies on SFSV and TOSV ELISAs (data 
not presented in this thesis). Although these viruses do not over-lap 
geographically with the current distribution of RVFV, there may be cross-
reacting antibodies to as yet undocumented phleboviruses on the African 
continent.  
1.4.6 Alternatives to conventional virus neutralisation tests 
Kortekaas et al. (2011) demonstrated the production of replication deficient 
RVFV replicon particles (RRP) expressing GFP and performed a novel VNT using 
these RRPs in place of live virus to test sera from experimentally infected sheep. 
These RRPs were produced by transfecting a plasmid encoding the RVFV 
glycoproteins into a cell line which stably expressed the L and S segments of 
RVFV. The results of the VNT utilising RRPs demonstrated 100% sensitivity and 
specificity when compared to results of the classical VNT, although only 11 
samples were tested in their study. In 2014, Bukbuk et al. reported the 
production of RVFV pseudotypes produced using the VSV pseudotyping system, 
which were also successfully utilised as a substitute for live virus in a RVFV pNT. 
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1.5 Summary and statement of aims 
Serological surveillance of viruses is fundamental for understanding infectious 
disease ecology. However, serological data can be difficult to interpret, 
especially when serological assays have imperfect sensitivity and specificities 
(Viana et al., 2016). The VNT is considered the gold standard for determining 
immunological response to either natural infection or vaccination; however 
these assays are seldom performed for sero-epidemiology of viruses that require 
handling at high containment. The majority of highly pathogenic zoonotic 
pathogens occur in parts of the world where such high containment facilities are 
seldom available, therefore routine serosurveillance of these pathogens are not 
performed, or are performed with inferior tests.  
In this thesis I aimed to develop novel assays to measure VNAb to two important 
zoonotic viruses, rabies and RVFV. Specific, high-throughput, pan-species assays 
that can be performed outwith high containment facilities are required to 
produce robust serological data. Such data are essential to further understand 
the complex, multi-host ecology of these viruses. 
In Chapter 3 the methods described previously by Wright et al. (2008) were used 
to optimise pseudotype neutralisation tests (pNT) for the detection of lyssavirus 
VNAb for use in our laboratory. In addition, pseudotypes were used to 
investigate the viral tropism of these lyssaviruses in a variety of adherent and 
suspension cell lines. 
In Chapter 4 the rabies pNT optimised in Chapter 3 was used to investigate 
rabies VNAb titres in three studies. In the first study a serosurvey of domestic 
and wild animals in the Russian Far East was performed to investigate rabies 
infection patterns in an area in which there are plans to reintroduce the Amur 
leopard. The second study explores the use of rabies serosurveillance in wildlife 
(lions) from the Serengeti National Park (SNP) to provide information on rabies 
infection patterns in an area with an on-going rabies control and elimination 
programme. In the third study the rabies virus pNT was used to study the 
kinetics of rabies VNAb over a 14-month period in a cohort of vaccinated slum 
dogs from Kenya.  
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In Chapter 5 RVFV retroviral pseudotypes were produced and used to 
demonstrate their ability to detect VNAb in sera. The production of VSV 
pseudotypes expressing the glycoproteins of RVFV was also investigated. In 
addition, a novel RVFV neutralisation test was developed using a recombinant 
RVFV expressing luciferase.  
In Chapter 6 the luciferase-expressing RVFV neutralisation test developed in 
Chapter 5 was used to detect RVF VNAb in three studies. In the first two studies, 
seroprevalence of RVFV in wildlife in the SNP was investigated, whilst in the 
third study the presence of RVF VNAb in a longitudinal cohort of domestic 
livestock from areas surrounding the SNP was examined.         
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 Chapter 2. Materials and methods 
 
2.1  Cell culture techniques 
2.1.1 Cell lines 
Human embryonic kidney 293T cells (293T, ATCC CRL-3216), baby hamster 
kidney cells (BHK-21, ATCC CCL-10), Crandell feline kidney cells (CRFK, ATCC 
CCL-94), and canine osteosarcoma D-17 cells were maintained in Dulbecco's 
Modified Eagle Medium (DMEM) supplemented with 10% foetal bovine serum 
(FBS), 100 IU/ml penicillin, 100 μg/ml streptomycin, 2 mM glutamine and 1mM 
sodium pyruvate. BSR-T7/5 cells, a BHK-21-derived cell line stably expressing T7 
RNA polymerase, were maintained in Glasgow’s Modified Eagle Medium (GMEM) 
supplemented with 10% FBS and 10% tryptose phosphate broth. Medium for 293T 
and BSRT-7/5 cells was supplemented with 400 μg/ml G418. BMOX40, MT-4, SUP-
T1 and 3201 cells were maintained in RPMI 1640 medium supplemented with 10% 
FBS, 100 IU/ml penicillin, 100 μg/ml streptomycin, 2 mM glutamine and 1mM 
sodium pyruvate. All cell lines were grown at 37C in a 5% CO2 humid 
atmosphere. Cell lines were subcultured when approaching confluency. Adherent 
cell lines were subcultured by washing with phosphate buffered saline (PBS) and 
treating with 1ml of 0.05% trypsin-EDTA. Suspension cell lines were subcultured 
by centrifugation. Cells were then seeded at the required density. All media and 
supplements were obtained from Life Technologies Ltd., Paisley, UK.  A 
summary of the cell lines used in this study is presented in Table 2.1. 
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Cell Line Species 
Adherent or 
suspension  Reference  
293T Homo sapiens Adherent (Graham et al., 1977) 
3201 Felis catus Suspension (Hardy et al., 1980) 
BHK-21 Mesocricetus 
auratus 
Adherent (Macpherson and 
Stoker, 1962) 
BMOX40 Canis familiaris Suspension (Willett et al., 2006) 
BSR-T7/5 Mesocricetus 
auratus 
Adherent (Buchholz et al., 1999) 
CRFK Felis catus Adherent (Crandell et al., 1973) 
D-17 Canis familiaris Adherent  (Riggs et al., 1974) 
MT-4 Homo sapiens Suspension (Harada et al., 1985) 
SUP-T1 Homo sapiens Suspension (Smith et al., 1984) 
Vero Cercopithecus 
aethiops 
Adherent (Yasumura and 
Kawakita, 1963) 
 
Table 2.1 Cell lines used in this study.  
 
 
2.1.2 Retroviral pseudotype production 
293T cells were seeded 18 h prior to transfection at a density of 1x106 or 2x105 
cells in either a 10 cm dish or per well of a 6 well plate respectively. 
Transfection was carried out using 1mg/ml polyethylenimine (PEI) (Polysciences) 
as the transfection reagent (Boussif et al., 1995). For transfection in a 10 cm 
dish 10 µg of DNA and 60 µl of PEI were added to 300 µl of antibiotic and serum 
free DMEM or 2 µg DNA, 10 µl PEI and 100 µl of antibiotic and serum free DMEM 
for transfection performed in 6 well plates. Transfection mixture was then 
vortexed and incubated at room temperature for 15 min to allow transfection-
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complex formation. Transfection mixture was then added directly to the cells 
and incubated for 72 h at 37C at 5% CO2. Supernatants were harvested, 
centrifuged at 2000 rpm for 10 min, filtered at 0.45 µm and stored at -80°C prior 
to use. Pseudotypes were produced using ratios of 1:1.5:1 µg of gag-pol vector, 
reporter expression construct and glycoprotein respectively, unless otherwise 
stated. For two plasmid transfections a ratio of 1:1 µg was used. Reporter genes 
used in this study expressed the following proteins: green fluorescent protein 
(GFP), red fluorescent protein (RFP), β-galactosidase (lacZ) and luciferase (luc). 
Plasmids used for pseudotype production are presented in Table 2.2. Plasmids 
expressing viral glycoproteins are presented in Table 2.3. Plasmid pMDG is used 
to produce VSV pseudotypes, which are used as a positive control for both 
transfection and transduction. Empty expression plasmids VR1012 or pTM1 are 
used as negative controls for transduction, and referred to as ‘ΔEnv’, as there is 
no insert in place of the plasmid expressing the viral glycoprotein. VSV and ΔEnv 
pseudotypes are produced in parallel with each new batch of pseudotype, if 
there is any expression of reporter genes upon transduction of ΔEnv pseudotype 
then the test batch is not used as transduction cannot be confirmed as being 
glycoprotein mediated. All lyssavirus expression plasmids were kindly provided 
by Dr. Edward Wright (University of Westminster) and pTM1-GnGc was kindly 
provided by Prof. Richard Elliott (University of Glasgow). 
For pseudotypes produced utilising recombinant vaccinia as the source of T7 
polymerase, transfections were performed as previously described using CMVi, 
CNCG and pTM1-GnGc plasmids and incubated for 4 h. Equal volumes of 2 x 107 
pfu/ml recombinant vaccinia virus (vTF7-5) and 0.5% trypsin were incubated at 
37˚C for 30 min, then added to the transfected cells and incubated for a further 
24 h, pseudotypes were harvested as described previously.  
Pseudotypes are denoted VIRUS(glycoprotein), for example MLV(rabies) indicates 
an MLV particle bearing the rabies virus glycoprotein. 
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Plasmid 
name 
Function (reporter) 
Viral 
origin 
Reference 
CMVi gag-pol MLV (Towers et al., 2000) 
HIT60 gag-pol MLV (Soneoka et al., 1995) 
FP93 gag-pol FIV (Poeschla et al., 1998) 
Fb-luc gag-pol and reporter gene 
vector  (firefly luciferase) 
FIV  (Vaillancourt et al., 
2002) 
p8.2 gag-pol (+Vif) HIV-1 (Naldini et al., 1996) 
p8.91 gag-pol (-Vif) HIV-1 ” 
HIV-eGFP gag-pol and reporter gene 
vector  (GFP) 
HIV-1 (Van Parijs et al., 1999) 
(formerly referred to as 
pMIG) 
pNL-Luc-
E-R- 
gag-pol and reporter gene 
vector  (firefly luciferase) 
HIV-1 (Connor et al., 1995) 
CNCG Reporter gene vector  
(GFP) 
MLV (Bock et al., 2000) 
pMFG Reporter gene vector  
(lacZ) 
MLV (Ohashi et al., 1992) 
GinSin Reporter gene vector  
(GFP) 
FIV  (Poeschla et al., 1998) 
LinSin Reporter gene vector  
(Firefly luciferase) 
FIV  ” 
CSRW Reporter gene vector  
(DsRed) 
HIV-1 (Naldini et al., 1996) 
CSGW Reporter gene vector  
(GFP) 
HIV-1 ” 
 
Table 2.2 Plasmids used for retroviral pseudotype production.   
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Plasmid name 
Expression 
plasmid 
Glycoprotein  Reference 
pMD.G pMD VSV (Naldini et al., 1996) 
LBV pI.18 LBV (Wright et al., 2009) 
MOKV pI.18 MOKV ” 
DUVV pI.18 DUVV ” 
CVS-11 pI.18 Rabies virus  (Wright et al., 2008) 
pI.18 RV9 pI.18 EBVL-1 ” 
pI.18 RV1787 pI.18 EBLV-2 ” 
pI.18 RV634 pI.18 ABLV ” 
RVF-M VR1012 RVFV (M segment) This study  
RVF-GnGc VR1012 RVFV (GnGc 
polyprotein) 
” 
RVF-NSm1 VR1012 RVFV (NSM1 protein) ” 
RVF-Gn VR1012 RVFV (Gn) ” 
RVF-Gc VR1012 RVFV (Gc) ” 
pTM1-GnGc pTM1 RVFV (GnGc 
polyprotein) 
(Carnec et al., 2014) 
VR1012 VR1012 None (Hartikka et al., 1996) 
pTM1 pTM1 None (Fuerst et al., 1986) 
 
Table 2.3 Expression plasmids used for retroviral pseudotyping.   
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2.1.3 Rhabdoviral pseudotype production 
Recombinant vesicular stomatitis viruses (VSV) in which the glycoprotein has 
been deleted (rVSV-ΔG) and replaced with GFP (rVSV-ΔG*GFP), RFP (rVSV-
ΔG*DsRed) or luciferase (rVSV-ΔG*luc) were used to produce VSV pseudotypes in 
this study. Recombinant VSV stocks were kindly provided by Dr. Michael Whitt 
(University of Tennessee). Reporter gene expressing recombinant VSV and their 
subsequent pseudotype production have been described (Whitt, 2010). Briefly, 
working stocks of reporter expressing rVSV-ΔG are generated by recovering 
infectious virus using a five plasmid reverse genetics protocol, after which the 
recovered virus is titrated onto cells expressing the glycoprotein of VSV in trans. 
Supernatants are then collected and purified using a plaque purification method.  
Eighteen hours prior to transfection 293T cells were seeded at 2x105 cells per 
well in a 6 well plate. Transfection mixture (2 µg of glycoprotein expression 
vector, 10 µl PEI and 600 µl of antibiotic and serum free DMEM) was vortexed 
and incubated at room temperature for 15 min. Medium was removed from 293T 
cells and replaced with Opti-MEM (Life Technologies) whilst the transfection 
mixture was incubating. Opti-MEM was removed from the cells and transfection 
mixture was added to the cells and incubated for 4 h at 37°C. Supernatants were 
then removed and replaced with DMEM supplemented with 5% FBS an incubated 
for a further 24 h. Cells were then superinfected with ~5x105 infectious units of 
rVSV-ΔG and incubated for 2 h at 37°C. Supernatants were removed and cells 
were washed 6-8 times with serum free DMEM, 1 ml of fresh DMEM was added to 
cells and further incubated for 24 h at 37°C. Supernatants were harvested, 
centrifuged at 2000 rpm for 10 min, filtered at 0.45 µm and stored at -80°C prior 
to use. 
2.1.4 Pseudotype transduction 
Target cell lines were seeded 18 h prior to transduction at a density of 1x105 
cells or 1x104 cells per well in a 12 well or 96-well plate respectively. 
Pseudotypes were added to cell culture medium directly at the specified dilution 
and incubated at 37°C for 48 h, unless stated otherwise. Cells transduced with 
GFP or RFP expressing pseudotypes were examined using fluorescence 
microscopy or analysed by flow cytometry using the Accuri C6 flow cytometer 
(BD, Franklin Lakes, NJ, USA). The percentage of cells was calculated by 
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selecting an initial analysis gate on live cells, then a second analysis gate 
created on a histogram plot using non-transfected control cells, the positive 
cells were considered those which fell into the final gated region. For luciferase 
expressing pseudotypes, target cells were seeded 18 h prior to transduction at 
1x104 cells per well in 50 µl volumes in a white 96-well CulturPlate (Perkin-
Elmer, Waltham, MA, USA), 50 µl of pseudotype was added and incubated at 
37°C for 48 h after which 100 µl of Steadylite Plus luciferase substrate (Perkin 
Elmer) was added and luciferase expression analysed on a Microbeta 1450 Jet 
luminometer (Perkin Elmer). Cells transduced with pseudotypes expressing lacZ 
were visualised by X-gal staining.  Cells were washed in PBS before being fixed 
with 0.5% glutaraldehyde for 30 min, fixative solution was removed and cells re-
washed before the addition of staining solution (PBS containing 0.02% X-Gal (5-
bromo-4-chloro-3-indolyl-β-D-galactopyranoside), 3 mM ferro-cyanide and 1.3 
mM MgCl2). Plates were stored at 4°C overnight before lacZ-expressing cells 
were counted manually.     
2.1.5 Quantification of pseudotype titre 
To determine the infectious titre of GFP pseudotypes the 50% tissue culture 
infective dose (TCID50) was calculated for each new batch of pseudotype 
generated and was specific to each batch of recovered cells. To calculate 
TCID50, cells were seeded at a density of at 1x10
4 cells per well in a 96-well 
plate 18 h prior to addition of 100 µl volumes of doubling dilutions of pseudotype 
in quadruplicate. Cells were incubated at 37°C for 48 h and examined by 
fluorescence microscopy and wells were marked as positive if one or more 
fluorescent cell was observed.  The TCID50 was calculated using the Spearman-
Karber formula (Hierholzer and Killington, 1996 ).  
 
2.2 Molecular cloning techniques  
2.2.1 Polymerase chain reaction  
Five sections of the RVFV M segment were amplified from a plasmid expressing 
the M segment of the MP-12 strain of RVFV. The plasmid pTVT7R-M(MP12) 
(Billecocq et al., 2008) was kindly provided by Dr. Michelle Bouloy (Institut 
Pasteur). Amplified sections corresponded to: the entire ORF of the M segment 
Chapter 2. Materials and methods                                                                                           63 
 
      63
 
of RVFV, GnGc, NSm1, Gn and Gc. RVFV expression plasmids cloned in this study 
are summarised in Table 2.4. Primers were designed, and numbering of 
nucleotides was based on the published RVFV MP-12 sequence (GenBank 
accession number DQ380208). Primers were manufactured by Eurofins MWG, 
Germany. Polymerase chain reaction (PCR) was performed using High Fidelity 
PCR Master (Roche, UK) using the following thermocycling conditions: 
denaturation at 94°C for 2 min, followed by 35 cycles of 94°C for 30 s, annealing 
at 65°C for 60 s and extension at 72°C for 210 s, with a final extension at 72°C 
for 7 min. Thermocycling was conducted using a GeneAmp PCR System 9700 
thermocycler (Applied Biosystems, UK).  
Plasmid 
name 
Expressed 
protein  
Nucleotide 
position 
Primer sequences (5’–3’) 
RVF-M M segment  21-3614 F ACTGGTCGACATGTATGTTTTA
TTAACAATTCTAACCTCG 
   R ACAGCGGCCGCCTATGAGGCCT
TCTTAGTGGC 
RVF-GnGc GnGc polyprotein  411-3614 F 
 
ACTGGTCGACATGGCAGGGATT
GCAATGACAG 
   R ACAGCGGCCGCCTATGAGGCCT
TCTTAGTGGC 
RVF-NSm1 NSm and Gn 
fusion protein 
21-2090 F 
 
ACTGGTCGACATGTATGTTTTA
TTAACAATTCTAACCTCG 
   R ACAGCGGCCGCCTATGCTGATG
CATATGAGAC 
RVF-Gn Gn glycoprotein  411-2090 F 
 
ACTGGTCGACATGGCAGGGATT
GCAATGACAG 
   R ACAGCGGCCGCCTATGCTGATG
CATATGAGAC 
RVF-Gc Gc glycoprotein 2091-3614 F 
 
ACTGGTCGACATGTGTTCAGAA
CTGATTCAGGC 
   R ACAGCGGCCGCCTATGAGGCCT
TCTTAGTGGC 
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Table 2.4 Rift Valley fever virus expression plasmids generated in this 
study. Expression plasmids were generated by cloning sections of the RVFV M 
segment into mammalian expression vector VR1012. Nucleotide positions are 
designated with reference to the RVFV MP-12 sequence (GenBank accession 
number DQ380208). F and R denote forward and reverse primer sequences used 
to amplify RVFV genes. 
 
 
2.2.2 Restriction enzyme digestion and ligation  
The PCR amplification introduced SalI and NotI restriction sites at the 5′ and 3′ 
ends of the genes to facilitate cloning into the mammalian expression vector 
VR1012. PCR products were electrophoresed on 1.5% agarose gels containing 
ethidium bromide, DNA bands were observed on a UV transilluminator (Ultra-
Violet Products Ltd., Upland, CA, USA) and excised using a sterile scalpel. Gel 
extraction was performed using QIAquick Gel Extraction kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions. Purified PCR products 
and VR1012 were digested in 20 µl reactions using 1 µl SalI (15 U/µl), 1 µl NotI 
(10 U/µl), 2 µl 10x Buffer H, 2 µl 0.10% BSA (Invitrogen), 5 µl DNA and 9 µl sterile 
water and incubated at 37°C for 2 h. Digested insert DNA was purified using 
QIAquick PCR purification kit (Qiagen) and digested VR1012 DNA was purified 
from agarose gel as described above. Vector and insert DNA were ligated 
overnight at 16°C using T4 DNA ligase (Life Technologies). 
2.2.3 Transformation 
DNA was transformed into DH5α MAX efficiency competent cells (Invitrogen). 
Competent cells (50 µl) were thawed on ice and 5 µl of ligation product was 
added, cells were incubated on ice for 30 min. Competent cells were then heat 
shocked in a water bath at 42°C for 40 s. Cells were returned to ice for a further 
2 min, after which 400 µl of S.O.C media was added and incubated at 37°C for 1 
h whilst being shaken on an orbital shaker. Cultures were spread on to LB agar 
plates containing 50 µg/ml kanamycin (Sigma-Aldrich, UK) and incubated at 37°C 
overnight. Individual bacterial colonies were added to 3 ml LB nutrient broth 
with kanamycin, broths were incubated overnight at 37°C on an orbital shaker. 
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Plasmid DNA was extracted from cultures using QIAprep Spin Miniprep kit 
(Qiagen) and digested as above. Clones containing inserts were identified by 
agarose gel electrophoresis, 1ml of each positive culture was inoculated into 
500ml of LB nutrient broth with kanamycin and grown overnight at 37°C on an 
orbital shaker. Plasmid DNA was isolated from large scale cultures using a 
PureLink HiPure Plasmid Filter Maxiprep Kit (Invitrogen). Pelleted DNA was 
resuspended in TE buffer and stored at 4°C. All plasmids were verified by Sanger 
sequencing prior to use (GATC Biotech, Konstanz, Germany).     
2.2.4 Western blotting  
Western blots were performed to detect expression of proteins in both cell 
lysates and concentrated pseudotypes. Transfected 293T cells were washed in 
PBS, resuspended in 75 µl NP-40 lysis buffer (150 mM sodium chloride, 1% NP-40, 
50 mM Tris, pH 8.0) and incubated on ice for 30 min. 25 µl of SDS-PAGE loading 
buffer (40% Glycerol, 8% SDS, 5% β-mercaptoethanol, 0.04% bromophenol blue, 
240 mM Tris/HCl, pH 6.8) was added to each sample. Samples were then 
sonicated for 30 s, incubated at 90°C for 10 min and centrifuged at 14000 rpm 
for 10 min. Pseudotypes were concentrated by centrifugation through a sucrose 
cushion. 1 ml of pseudotype was added to 400 µl of cold 20% sucrose and 
centrifuged for 1 h at 4°C. Supernatants were removed and pellets washed in 1 
ml PBS by centrifugation, after which 40 µl of SDS-PAGE loading buffer was 
added to each sample. Samples were loaded in to NuPAGE 4-12% Bis-Tris precast 
polyacrylamide gels (Life Technologies) for electrophoresis at 2 h at 100 V in MES 
SDS running buffer (Life Technologies). Proteins were transferred to PVDF 
membranes using the Trans-Blot Turbo Transfer System (Bio-Rad Laboratories, 
Hercules, CA, USA). Membranes were blocked in 1x casein solution (blocking 
buffer) (Vector Laboratories Ltd., Peterborough, UK) for 2 h. Primary antibodies 
were diluted in blocking buffer to 1:1000 and incubated at room temperature for 
1 h. Membranes were washed in PBS-Tween three times prior to incubation with 
the secondary antibody. Biotinylated horse anti-mouse IgG antibody (Vector 
Laboratories Ltd.) was diluted in blocking buffer to 1:1000 and incubated at 
room temperature for 1 h, then washed in PBS-Tween three times prior to 
development. The Vectastain ABC-Amp Immunodetection kit (Vector 
Laboratories Ltd.) was utilised for visualisation of proteins, a preformed 
streptavidin/biotinylated alkaline phosphatase complex was incubated with the 
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membrane for 20 min, washed in PBS-Tween three times prior to addition of the 
chromogenic alkaline phosphatase substrate (5-bromo-4-chloro-3-indolyl 
phosphate/nitroblue tetrazolium), which was incubated in the dark until 
sufficient protein staining was observed.  
The primary antibodies used to detect rabies virus and RVFV glycoproteins were 
the mouse anti-rabies virus glycoprotein clone IC5 (Bio-Rad Laboratories) and the 
mouse monoclonal anti-RVFV Gn glycoprotein clone 4D4 (Battles and Dalrymple, 
1988) kindly provided by Dr. Felix Kreher (University of Glasgow). A cell lysate of 
A549 cells infected for 72 h with the MP-12 strain of RVFV was used as positive 
control material for RVFV western blots and was kindly provided by Dr. Ben 
Brennan (University of Glasgow). 
 
2.3 Antibody detection assays  
2.3.1 Lyssavirus pseudotype neutralisation test 
In a 96-well plate 85 µl of 100 TCID50 MLV(lyssavirus) pseudotype was added to 
85 µl of doubling dilutions of sera (final concentrations of 1:10 to 1:640 were 
used as standard, although sera were tested at higher dilutions where required). 
25 µl of 100 TCID50 MLV(VSV) pseudotype was added to 25 µl of test serum 
diluted at the three lowest concentrations (final concentrations 1:10, 1:20. 
1:40). Serum/pseudotype mixtures were incubated at 37°C for 1 h to allow 
neutralisation to occur, 50 µl of serum/pseudotype mix were added to CRFK cells 
in triplicate. Cells had been seeded at a density of at 1x104 cells per well in a 50 
µl volume in 96-well plates 18 h previously. Cells were incubated at 37°C for 48 
h and examined by fluorescence microscopy, wells were marked as positive if 
one or more fluorescent cell was observed. The VNAb titre was recorded as the 
reciprocal of the highest dilution at which at least two of the three wells were 
negative for fluorescent cells. This interpretation is based upon the RFFIT 
protocol provided by OIE, which states that the end-point titre is defined as the 
dilution factor of the highest serum dilution at which 50% of wells are 
neutralised (OIE, 2012a). However, in this assay the serum was tested in 
triplicate, which both reduced the volume of serum required and also allowed 
four samples to be tested per plate, therefore the titre was defined as the 
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dilution factor of the highest serum dilution at which >50% of wells were 
neutralised.  
With each assay performed three control sera were tested in parallel. Two 
canine sera which had previously been tested by the FAVN (Wright et al., 2009) 
and measured >640 and <10 on the rabies virus pNT were used as positive and 
negative controls respectively. A further sample from a vaccinated human, 
which had been diluted to measure 40 on the rabies virus pNT, was also used.  
An aliquot of the OIE standard reference dog serum, diluted to 0.5 IU/ml was 
kindly provided by Dr. Daniel Horton (Animal Health and Veterinary Laboratories 
Agency).  
Each serum sample was individually tested for non-specific neutralisation using 
MLV(VSV) pseudotypes. Dilutions of sera up to 1:40 are incubated with MLV(VSV) 
pseudotypes, if rabies VNAb titre was >20 and the VSV control was also recorded 
as >20, the sample was repeat tested with MLV(VSV) pseudotypes with further 
serum dilutions of up to 1:640, in order to detect non-specific neutralisation. If 
rabies VNAb titre was four-fold higher than the VSV titre then the rabies VNAb 
titre was reported, if not the sample was recorded as inconclusive, as non-
specific neutralisation cannot be excluded as the cause of the result.  
2.3.2 Recombinant RVFV expressing Renilla luciferase virus neutralisation test 
The recombinant virus rMP12ΔNSs:hRen was kindly provided by Dr. Ben Brennan 
(University of Glasgow). This virus was generated using a recombinant rMP12 S 
segment in which the NSs coding sequence was replaced with that of Renilla 
luciferase (Brennan et al., 2011). This altered S segment was subsequently used 
in the generation of a recombinant RVFV rMP12ΔNSs:hRen, by rescue of 
infectious rMP-12 as described by Billecocq et al. (2008). The recombinant virus 
rBUNΔNSs:hRen (Dietrich et al., 2016) was kindly provided by Dr. Xiaohong Shi 
(University of Glasgow). 
In a 96-well plate 55 µl of rMP12ΔNSs:hREN containing 8x104 PFU in PBS/2% FBS 
was added to 55 µl of a 1:50 dilution of test sera (final concentration of 1:100). 
Serum/virus mixtures were incubated at 37°C for 1 h to allow neutralisation to 
occur. Media was removed from BHK-21 cells, seeded 18 h previously at a cell 
density of 1x104 cells per well, and 50µl of serum/virus were added to cells in 
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duplicate. Virus was adsorbed onto cells for 1 h at 37°C before being removed 
and replaced with 100 µl culture media. Cells were then incubated for a further 
5 h, after which medium was removed and cells were lysed in 100 µl passive lysis 
buffer (Promega, Madison, WI, USA) and left at room temperature for 10 min. 
45µl of cells were transferred to a white flat bottomed 96-well plate containing 
45µl of Renilla-Glo reagent (Promega), sealed and incubated at room temp for 
10 min. Plates were analysed on a luminometer using the Glomax software and 
the Renilla-Glo Promega protocol, with integration time at 10 s per well.  
With each assay performed, positive and negative control sera were tested in 
parallel, in addition to a ‘cell only’ control and a ‘virus only’ control to allow for 
calculation of percent neutralisation. All assays were performed at containment 
level three under the supervision of either Dr. Stephen Welch or Prof. Brian 
Willett.   
2.3.3 Plaque reduction neutralisation test 
The plaque reduction neutralisation test (PRNT) was performed using BHK-21 
cells, seeded 18 h prior to infection in 12 well plates at a cell density of 7x105 
cells per well. The monoclonal anti-Gn RVFV neutralising antibody (4D4) was 
serially diluted in PBS/2% FBS from 1:2 to 1:2048 and 200 µl of diluted antibody 
was incubated with 200 µl rMP-12 (in cell culture medium containing 480 
PFU/ml) for 1 h at 37°C,  to allow neutralisation to occur.  After which 150 µl of 
antibody/virus mix was added to each well and incubated for 1 h at 37°C, the 
inoculum was then removed and replaced with overlay medium comprising GMEM 
supplemented with 2% FBS and 0.6% Avicel (FMC Corporation, Philadelphia, PA, 
USA). Cells were incubated for 72 h at 37°C, then fixed in 8% formaldehyde for 
at least 4 hrs before the plaques were visualized by staining with crystal violet 
solution. The PRNT was performed by Dr. Felix Kreher (University of Glasgow).  
2.3.4 Rift Valley fever recN IgG ELISA  
African buffalo samples were tested using the RVF recN IgG indirect ELISA (BDSL, 
Ayrshire, Scotland) which were performed according to the manufacturer’s 
instructions.  
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2.4 Serum samples 
All serum samples were heat inactivated at 56°C for 30 min prior to testing.   
2.4.1 Tanzanian canine sera (tested in 3.2.2)   
Serum samples from domestic dogs living in the Serengeti district of Tanzania 
were collected during the annual vaccination campaign undertaken by the Viral 
Transmission Dynamics Project. Samples were collected immediately prior to 
vaccination against rabies virus (Nobivac Rabies, Intervet, Netherlands).  
Additional samples were collected 20-21 days post vaccination. A selection 
(n=104) of sera from these dogs were used in this study and had previously been 
tested for rabies VNAb using the FAVN at the Animal Health and Veterinary 
Laboratories Agency, Weybridge and also using the HIV(luc) pNT at University 
College London (Wright et al., 2009).  
2.4.2 Russian wildlife and domestic animal sera (tested in 4.2.1)  
Sera for testing were provided by Martin Gilbert (Wildlife Conservation Society, 
New York) and Dr. John Lewis (International Zoo Veterinary Group) (n=203). 
Samples had been opportunistically collected between 1989 and 2010 and prior 
to testing had been stored at -70°C. 
2.4.3 Tanzanian lion sera (tested in 4.2.2 and 6.2.1)  
Lion sera (n=107) were collected opportunistically from animals within the 
Serengeti ecosystem between 1997 and 2011 during disease monitoring 
operations, veterinary interventions (e.g. snare removals) and research activities 
(e.g. fitting radiocollars). Samples were collected by the veterinary units of 
Tanzania National Parks (TANAPA) and the Tanzania Wildlife Research Institute 
(TAWIRI). Samples were stored in an archived serum bank maintained at the 
University of Glasgow.  
2.4.4 Kenyan slum dog sera (tested in 4.2.3)   
Serum samples were available from an archive of samples originally collected 
from dogs from the Kibera slum in Nairobi, Kenya in 2007. The original samples 
formed part of a large study to assess the use of dogs in Kenya as sentinels of 
infectious diseases (Halliday, 2010). As an incentive to dog owners to participate 
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in the study, dogs were vaccinated against rabies virus at enrolment (Rabisin, 
Merial Ltd., France). A selection of dogs (n=67) from the original study were 
included for use in this study.   
2.4.5 UK canine sera (tested in 4.2.3.1)  
Thirty anonymised canine serum samples, which had been sent to the University 
of Glasgow Veterinary Diagnostic Services for various serological tests, were 
kindly provided by Michael McDonald. These samples were presumed to be from 
dogs born and bred in the UK. No history was available in relation to vaccination 
status or travel.   
2.4.6 Tanzanian lion sera (tested in 5.2.3)  
Nineteen lion samples, collected as part of ongoing lion surveillance programmes 
for canine distemper virus in the Serengeti National Park (SNP) in 1998, were 
kindly provided by Prof. Craig Packer (University of Minnesota). These samples 
had previously been tested for RVF VNAb using the PRNT by Prof. Clarence 
Peters (University of Texas Medical Branch). 
2.4.7 African buffalo and gazelle sera (tested in 5.2.3 and 6.2.2)  
Serum samples collected from buffalo (n=99) and gazelle (n=74) were available 
from an archived bank of sera collected from the SNP and Ngorongoro 
conservation area between 1993 and 2012. Sera had originally been collected as 
part of ongoing disease surveillance programmes for foot-and-mouth disease and 
peste des petits ruminants. A selection of these samples (n=34) had previously 
been tested for RVFV antibodies using the ID SCREEN RVFV IgM capture ELISA (ID 
Vet, Grabels, France) at The Pirbright Institute.  
2.4.8 Tanzanian longitudinal livestock sera (tested in 6.2.3)  
Sera were collected as part of a longitudinal study of livestock from the 
Serengeti district and Loliondo areas of Tanzania in 2009-2010. The original 
project was coordinated, and sera were kindly provided, by Dr. Harriet Auty 
(Scotland’s Rural College). Animals enrolled in the study were ear tagged at 
recruitment so they could be individually identified throughout the study period. 
Aging of livestock was performed by consultation with the owners and then 
checked by dental aging. Animals had not been previously vaccinated against 
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RVFV. All field sampling was conducted by a Tanzanian veterinarian in 
collaboration with Sokoine University of Agriculture. Samples were stored at -
20°C at the Nelson Mandela African Institute of Science and Technology, until 
exported to the University of Glasgow.  
 
2.5 In silico techniques 
2.5.1 Phylogenetic analysis 
Nucleotide sequences which correlated to the glycoprotein sequence of the 
plasmid used to produce lyssaviruses pseudotypes in this study were gathered 
from GenBank. Accession numbers: CVS-11 (EU352767), LBV (EF547428), MOKV 
(GQ500108), DUVV (EU623444), EBLV-1 (EU352768), EBLV-2 (EU352769), ABLV 
(AF426311). VSV-G was used as an outgroup (V01214). Sequences were aligned 
using ClustalW (Larkin et al., 2007). A phylogenetic tree was produced in MEGA6 
(Tamura et al., 2013), using the Neighbour-Joining method (Saitou and Nei, 
1987) with 1000 replicates to allow calculation of bootstrap values. Evolutionary 
distances were computed using the maximum composite likelihood method 
(Tamura et al., 2004). The tree is to scale and branch lengths indicate the 
number of base substitutions per site.  
Pairwise amino acid distances were calculated using the maximum composite 
likelihood model in MEGA6 (Tamura et al., 2013) using the ectodomain 
sequences of the lyssaviruses. 
2.5.2 Graphs and statistics 
Graphs were constructed using GraphPad Prism 6 (GraphPad Software, La Jolla 
California, USA,). Where shown, error bars represent the standard deviation 
unless otherwise stated. Sensitivity was calculated using the formula 
TP/(TP+FN)x100 and specificity using TN/(TN+FP)x100, where TP are true 
positives, TN are true negatives, FP are false positives and FN are false 
negatives. 95% confidence intervals were calculated using the Clopper-Pearson 
method.  
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2.5.3 Statistical models 
Statistical modelling was completed using R version 3.1.1 (R, 2014). Correlates 
of continuous response variables were investigated using general linear models. 
Correlates of binary response variables were investigated using generalised 
linear mixed-effects models fitted using the glmm package and the function 
glmm() and generalised linear models fitted using the base R function glm(). 
Pairs of nested models were compared using likelihood ratio tests (LRTs) and p-
values reported result from these tests. Model quality was also assessed through 
calculation of AIC scores (Akaike, 1974). For generalised linear mixed-effects 
models LRTs were conducted using the anova() function. As anova() cannot be 
used for LRTs of models fitted using glm(), LRTs were instead performed 
manually by calculation of log likelihood scores and the pchisq() function.      
2.5.4 Geographical information system maps 
Maps in Figures 6.2 and 6.4 were produced using GPS map coordinates imported 
into QGIS (QGIS, 2016) combined with base map data. The QGIS project file was 
then imported into Adobe Illustrator to produce the final figures. Both figures 
were kindly produced by Mr. Mike Shand (University of Glasgow).  
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 Chapter 3. Development of lyssavirus 
pseudotype neutralisation tests 
 
3.1 Introduction   
Rabies virus belongs to the Lyssavirus genus, a member of the Rhabdoviridae 
family. Lyssaviruses are neurotropic viruses which can cause diseases in all 
mammals including humans. Once symptoms occur the disease has an almost 
100% case fatality rate. Although rabies has been eliminated in most developed 
countries, it is still the cause of around 59,000 human deaths annually (Hampson 
et al., 2015). The majority of these deaths are caused by canine rabies in Asia 
and Africa, with bat rabies being the principal source of infection in the 
Americas. In humans, rabies has the highest fatality rate of all known viruses, 
however the disease in humans is entirely preventable through effective 
vaccination. This includes pre-exposure vaccination of people at risk and post-
exposure prophylaxis administered immediately after the bite of a suspected 
rabid animal (PHE, 2013).   
The primary correlation of protection against rabies virus is the presence of 
rabies virus neutralising antibodies (VNAb) (Johnson et al., 2010), which can 
occur through natural exposure or post vaccination. Virus neutralisation tests 
(VNT) are the preferential method of testing for rabies VNAb, with the 
fluorescent antibody virus neutralisation test (FAVN) and the rapid fluorescent 
focus inhibition test (RFFIT) being the two methods prescribed by the World 
Organisation for Animal Health (OIE) for international trade (OIE, 2012b).  Both 
the FAVN and RFFIT require the use of live rabies virus, which is a Category 4 
pathogen under the Specified Animal Pathogens Order 2008 (SAPO) and 
necessitates high containment facilities for virus handling. This limits the use of 
the current VNTs in endemic areas within developing countries, both because of 
a lack of high containment laboratories and the high cost of these assays. Other 
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available assays, such as ELISA-based tests, lack the sensitivity of the FAVN 
(Wasniewski et al., 2014). 
Wright et al. (2009) have previously described a rabies VNT in which live virus is 
replaced with viral pseudotypes. Neutralisation assays utilising pseudotypes as a 
substitute for live virus have also been described for other high containment 
viruses including chikungunya, Japanese encephalitis virus and highly pathogenic 
strains of influenza A (Hu et al., 2014, Lee et al., 2014, Temperton et al., 2007). 
Pseudotyping involves co-expressing the glycoprotein of the virus of interest, 
with vectors encoding retroviral gag and pol genes. The resulting pseudotypes 
are infectious but replication defective, therefore can be handling at biosafety 
level 2 (BSL-2). A reporter gene, such as that encoding green fluorescent protein 
(GFP) can also be expressed in the pseudotype, allowing easy detection and the 
potential for absolute quantification. 
The aim of this study was to produce viral pseudotypes bearing a GFP reporter 
gene, from seven species of lyssavirus and to assess their ability to replace live 
virus in a pseudotype-adapted neutralisation test. These pseudotype 
neutralisation tests (pNT) could provide a robust, cost-effective and flexible 
method of measuring lyssavirus VNAb.  
 
3.2 Results  
3.2.1 Production of GFP pseudotypes expressing the rabies virus glycoprotein 
Rabies virus glycoprotein was incorporated into MLV particles to produce high 
titre rabies glycoprotein bearing MLV pseudotypes (MLV(rabies)) following 
protocols established previously in our laboratory (Stewart et al., 2012). Briefly, 
pseudotypes were produced by three plasmid co-transfection; a CMV promoter-
driven MLV gag-pol packaging vector; CMVi, an MLV vector encoding a GFP 
reporter gene; CNCG, and a plasmid expressing the glycoprotein of the CVS-11 
strain of rabies virus. Pseudotypes were then transduced into target cells where 
GFP expression was observed (Figure 3.1).  
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Figure 3.1 Schematic representation of MLV(rabies) pseudotype 
production. A three plasmid system was adopted to generate pseudotypes 
expressing the rabies virus glycoprotein. An MLV gag-pol packaging construct, a 
construct expressing GFP and a plasmid bearing the rabies virus glycoprotein 
were transfected, using PEI, into 293T cells. After 72 h the supernatant was 
harvested, filtered and frozen. Pseudotypes were then transduced into a target 
cell line where GFP expression is used to measure infectivity. 
 
 
Initial work on pseudotypes in our laboratory has highlighted the importance of 
concurrently producing positive and negative controls when generating the 
rabies virus pseudotypes. These are required to control the process of 
pseudotype production, including transfection cell line quality, transfection 
efficiency and to detect any non-specific fluorescence seen in transduced cells. 
Therefore with each batch of MLV(rabies) pseudotype produced, additional 
positive and negative control pseudotypes are produced in parallel. Vesicular 
stomatitis virus glycoprotein (VSV) was used as a positive control as VSV 
pseudotypes are produced to high titres and are able to mediate cell entry into 
all cell lines currently studied (Coil and Miller, 2004). A negative control was 
produced by transfecting a plasmid containing no insert in place of the plasmid 
expressing the viral glycoprotein; these pseudotypes are referred to as “ΔEnv”. 
During this study we found that certain batches of 293T cell lines used for 
transfection produced ΔEnv pseudotypes that expressed GFP in the target cell 
line (data not shown). These ‘bald particles’ have been documented previously 
(Voelkel et al., 2012) and therefore rabies virus pseudotypes were only used 
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when the concurrently produced ΔEnv negative control pseudotype produced no 
GFP expression upon transduction, ensuring the GFP expression observed in the 
transduced cell line is mediated entirely by the glycoprotein on the pseudotype 
membrane.  
Western blots were performed to confirm the presence of rabies virus 
glycoprotein in the pseudotypes. Protein expression was analysed in both cells 
transfected with CMVi, CNCG and rabies virus glycoprotein expression vector and 
the resulting pseudotypes generated. A protein of approximately 58 kDa 
correlating to rabies virus glycoprotein was expected, however no such protein 
band was visualised by Western blot analysis. Although a band of approximately 
the same size was present in the MLV(rabies) pseudotypes (lane 2), a non-
specific band was also present in the ΔEnv pseudotype (lane 4) (Figure 3.2). 
Additionally, we did not have any live virus infected cell lysate to act as a 
positive control for the Western blot analysis. The anti-rabies virus glycoprotein 
primary antibody used was not validated for use in Western blots and therefore 
we could not assume the protein was not being expressed, however antibodies to 
rabies virus glycoprotein which had been used successfully in Western blots by 
other studies (Koraka et al., 2014, Wright et al., 2008) were not available. 
Specificity of the MLV(rabies) pseudotypes at this point in the study were 
alternatively confirmed by specific neutralisation of serum known to be positive 
for rabies VNAb (data not shown).       
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Figure 3.2 Expression of rabies virus glycoprotein in pseudotypes and 
producer 293T cells. Western blot analysis of rabies virus glycoprotein in 293T 
cells and concentrated cell lysates were performed to confirm rabies virus 
glycoprotein expression. Transfected 293T cells used to produce rabies virus 
pseudotypes (lane 1) and the resulting concentrated MLV(rabies) pseudotype 
particles (lane 2) were analysed in addition to negative controls (ΔEnv) in which 
cells were transfected with an empty expression vector in place of the rabies 
virus glycoprotein expression vector. Transfected cell lysate (lane 3) and 
supernatant (lane 4) of ΔEnv transfections. Membranes were probed with mouse 
anti-rabies virus glycoprotein antibody. 
 
 
The infectivity of these pseudotypes was investigated by transduction into CRFK 
cells, a cell line shown to be susceptible to rabies virus pseudotypes in previous 
experiments performed in our laboratory. Fluorescence microscopy was 
performed, cells transduced with both MLV(rabies) and MLV(VSV) pseudotypes 
expressed GFP, whereas no GFP expression was observed in cells transduced 
with ΔEnv pseudotype (Figure 3.3). As ΔEnv pseudotypes were produced 
concurrently with the MLV(rabies) pseudotypes, we can assume that the lack of 
GFP expression was due to a lack of glycoprotein mediated cell entry. GFP 
expression decreased in a titratable fashion as the pseudotype concentration 
was decreased (Figure 3.4), demonstrating that these high titre pseudotypes 
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could be diluted significantly and still contain viable pseudotype. This is an 
important consideration, as the virus concentration employed in the FAVN is a 
highly diluted dose of 30-300 TCID50 per well (OIE, 2012b). If a similar 
concentration was used in our neutralisation assay, one round of MLV(rabies) 
pseudotype production would supply enough pseudotype for hundreds of 
neutralisation tests.  
 
 
a)       b)            c)  
 
 
 
 
 
Figure 3.3 CRFK cells transduced with rabies virus, VSV-G or ΔEnv bearing 
MLV pseudotypes. CRFK cells were transduced with a) MLV(rabies) pseudotypes 
b) MLV(VSV) pseudotypes or c) MLV(ΔEnv) negative control pseudotypes and 
analysed by fluorescence microscopy at 48 h.   
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Figure 3.4 Serial dilution of MLV(rabies) and MLV(VSV) pseudotypes 
transduced into CRFK cells. Five-fold serial dilutions of each pseudotype were 
titrated onto CRFK cells and analysed by flow cytometry at 48 h post 
transduction.   
 
 
To determine the most effective target cell line for use in our neutralisation 
test, a variety of cell lines, both adherent (BHK-21, Vero, CRFK, D17) and 
suspension (MT-4, BMOX40, 3201, SUP-T1), were used for transduction of 
MLV(rabies) and MLV(VSV) pseudotypes. The results demonstrate that the 
proportion of GFP expressing cells varied with the target cell line. MLV(rabies) 
pseudotypes infected all of the adherent cell lines, whereas the suspension cell 
lines appear to be refractory to infection with MLV(rabies) pseudotypes (Figure 
3.5).  BHK-21 cells are routinely used for the FAVN and were initially the first 
choice of target cell line for the pNT, however BHK-21 cells showed a low level 
of GFP expression (3.6%) and were therefore discounted for use in the pNT. 
Vero, CRFK and D17 cell lines expressed similar levels of GFP when transduced 
with MLV(rabies) pseudotypes and although D17 cell lines displayed the highest 
level of GFP expression, this cell line was discounted as a target cell line for use 
in the pNT as the origin of our stock of D17 cells could not be verified. Whilst 
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GFP expression in Vero cells was high by flow cytometry, it proved difficult to 
interpret by fluorescence microscopy. Some of the transduced Vero cells 
expressed GFP at a low level and cell boundaries could be difficult to distinguish 
(Figure 3.6). CRFK cells were chosen as the target cell line for the pNT as we 
had a validated stock of cells sourced from the American Type Culture 
Collection, GFP expression was of a high intensity and individually fluorescing 
cells were easily identifiable by fluorescence microscopy. The results of our cell 
line infectivity experiment show a decreased titre of MLV(rabies) compared to 
MLV(VSV) pseudotypes. However it is important to note that the concentrations 
of the input pseudotype were not matched (only volume was matched), 
therefore the difference may be due to a higher concentration of MLV(VSV) 
pseudotypes being produced following transfection rather than an increased 
ability for MLV(VSV) pseudotypes to mediate cell entry.  
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Figure 3.5 Ability of pseudotypes bearing rabies virus or VSV glycoproteins  
to transduce adherent and suspension cell lines. MLV(rabies) and MLV(VSV) 
pseudotypes were transduced into the adherent cell lines; BHK-21, Vero, CRFK 
and D17, and the suspension cell lines; MT-4, BMOX40, 3201, SUP-T1, and GFP 
expression measured by flow cytometry at 48 h post transduction. Assay was 
performed in 96-well plates with 100 µl of pseudotype added (n=1).  
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a)                                       b)                                      c) 
 
 
 
 
 
 
 
 
Figure 3.6 Fluorescence and phase contrast micrographs of MLV(rabies) 
pseudotypes transduced into three potential target cell lines. GFP 
expression following transduction with MLV(rabies) pseudotypes was observed 
using fluorescence microscopy at 48 h post transduction in a) BHK-21 b) Vero and 
c) CRFK cell lines. Line represents scale bar (400 µm). 
 
 
To determine the optimum incubation time for infection with viral pseudotypes 
in our pNT, CRFK cells were transduced with MLV(rabies) and MLV(VSV) 
pseudotypes in duplicate. One well was analysed by flow cytometry at 48 h and 
the other at 72 h. There was a slight, but non-significant, decrease in GFP 
expression at 72 h compared to 48 h in cells transduced with either MLV(rabies) 
or MLV(VSV) pseudotypes (Figure 3.7). As the expression levels were similar, and 
to decrease the turn-around time of the assay, an incubation time of 48 h was 
chosen for neutralisation assays.  
To investigate the effect of freeze thawing on our MLV(rabies) pseudotypes, 
pseudotypes were exposed to 15 freeze-thaw cycles and GFP expression 
measured by flow cytometry. The results demonstrated a significant decrease in 
titre of the MLV(rabies) pseudotypes, with a greater than 50% decrease in 
pseudotype titre by the fifth freeze-thaw cycle (Figure 3.8). MLV(VSV) 
pseudotypes were more stable than MLV(rabies) pseudotypes, with an average 
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loss in pseudotype titre of 2.15% per freeze thaw cycle compared to 6.67% 
observed with MLV(rabies) pseudotypes. As the rabies virus pNT will be based on 
a specific, low input pseudotype concentration, small changes in titre will have 
a dramatic effect on test accuracy. Therefore all neutralisation tests were 
performed using aliquots of pseudotypes that have been thawed only once. 
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Figure 3.7 Expression of GFP in CRFK cells transduced with MLV(rabies) 
and MLV(VSV) pseudotypes for 48 h and 72 h.  CRFK cells were infected with 
MLV(rabies) or MLV(VSV) pseudotypes and GFP expression was measured at 48 h 
and 72 h post transduction by flow cytometry. Assay was performed in 12 well 
plates with 500 µl of pseudotype added. Each bar represents the mean +/- 
standard error (n=3). 
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Figure 3.8 Effect of multiple cycles of freeze-thawing on the stability of 
MLV(rabies) and MLV(VSV) pseudotypes. MLV pseudotypes bearing the 
glycoprotein of rabies virus or VSV were exposed to multiple freeze-thaw cycles 
prior to transduction of CRFK cells. The percentage of the initial pseudotype 
titre remaining was measured by flow cytometry at 48 h. Measurements were 
performed in triplicate; each point represents the mean +/- standard error. 
 
 
3.2.2 Development and validation of a rabies virus pseudotype neutralisation 
test 
In this study we used the MLV(rabies) pseudotypes described in 3.2.1 in a pNT for 
the detection of VNAb against rabies virus in serum samples. To facilitate inter-
test comparisons, our pNT was broadly based on protocols used in the gold 
standard FAVN test. Briefly, in the FAVN test serum samples are serially diluted 
three-fold and added to four wells of a 96-well plate. A fixed dose of rabies virus 
is then added to each well and incubated for 1 h at 37°C. Following incubation, 
BHK-21 cells are added to each well and incubated for a further 48 h. Plates are 
then washed in PBS, fixed in acetone, stained with a FITC-conjugated anti-rabies 
antibody and incubated for 30 min. Plates are again washed in PBS and read by 
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fluorescence microscopy. A well is considered positive if there are one or more 
fluorescent cells per well. A titre is determined as the highest dilution at which 
100% of virus is neutralised in at least 50% of the wells (Cliquet et al., 1998). In 
addition to replacing live rabies virus with MLV-based rabies virus pseudotypes, 
our assay was further modified from the FAVN. Briefly, in the pNT cells were 
seeded 18 h prior to commencing the assay, serum samples are serially diluted 
two-fold and incubated with a fixed dose of pseudotype for 1 h at 37°C. The 
serum/pseudotype mix is then added directly to three wells of a 96-well plate. 
After 48 h incubation plates are read directly, no washing of cells is required and 
removal of the culture medium is not necessary. As in the FAVN, a well is 
considered positive (and therefore not neutralised) if one or more fluorescent 
cells are present.  A titre is reported as a reciprocal of the highest dilution at 
which 100% of virus is neutralised in at least two of the three wells. By using 
three wells per sample instead of four, the volume of serum required per test is 
decreased and further dilutions of sera can be analysed. Additionally each serum 
is tested against VSV-G bearing pseudotypes at the lowest serum dilutions, this 
control is included in the assay to detect non-specific neutralisation, as there 
have been reports of non-specific neutralisation, toxicity and inhibition in the 
FAVN and RFFIT (Shiraishi et al., 2014a, Bedeković et al., 2013, Mani and 
Madhusudana, 2013). If the serum neutralises the MLV(VSV) pseudotypes at a 
titre of >20, the sample is repeat tested against MLV(VSV) pseudotypes with 
further serum dilutions of up to 1:640, to determine if the observed 
neutralisation is specific. The VSV control is also useful for detecting 
cytotoxicity, as MLV(VSV) pseudotypes cannot infect dead cells and therefore 
the wells would be negative for GFP expression, which could be misinterpreted 
as rabies VNAb specific neutralisation to an inexperienced user in the absence of 
the VSV control. A rabies VNAb positive and negative control canine serum is 
added to one plate per run. A schematic diagram of a plate map for the rabies 
pNT is shown in Figure 3.9. To calculate a working concentration of pseudotype 
for use in the pNT, the TCID50 was calculated for the MLV(rabies) and MLV(VSV) 
pseudotypes. A fixed pseudotype concentration of 100 TICD50 was added per well 
to mirror the titre of live virus used in the FAVN.  
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        Serum               Sample s            Controls 
       dilution          1                    2                     3                + - 
1:10 
1:20 
1:40 
1:80 
1:160 
1:320 
1:640 
             VSV 
           1:10 1:20 1:40 1:10 1:20 1:40 1:10 1:20 1:40  
 
Figure 3.9 Schematic representation of the plate set up for MLV(rabies) 
pseudotype neutralisation test. Each test sample is serially diluted two-fold 
from 1:10 to 1:640 and tested in triplicate. Each test serum is also tested against 
MLV(VSV) pseudotypes at serum dilutions of 1:10 to 1:40 as a measure of non-
specific neutralisation. Rabies antibody positive and negative sera are also 
added to one plate per assay run as test controls. 
 
 
To validate this assay serum samples which had previously been tested for rabies 
VNAb by FAVN were tested using the rabies virus pNT. These samples had also 
previously been tested using another pseudotype-based neutralisation assay, this 
pNT was performed using a lentiviral pseudotype bearing a luciferase reporter 
gene (HIV(luc) pNT) (Wright et al., 2009). The serum samples tested were from 
domestic dogs living within the Serengeti district of Tanzania. The dogs had been 
enrolled in an annual vaccination campaign and were kindly provided by the 
Viral Transmission Dynamics Project (Table 3.1). 
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Table 3.1 Sex and age data of canine sera tested by rabies virus 
pseudotype neutralisation test.  
 
 
The result of the FAVN is converted from a dilution factor to IU/ml, the VNAb 
titre of both pNTs is reported as the reciprocal of the dilution factor. Samples 
that failed to neutralise the pseudotype at the lowest dilution, 1:10, were given 
a titre of <10 and assigned an arbitrary titre of 1 for data analysis. Of the 104 
serum samples tested on the rabies virus pNT, one sample failed the initial VSV 
control (#71). This sample was additionally tested against VSV with further 
serum dilutions and a VSV VNAb titre of 640 was recorded (alongside a rabies 
VNAb titre of 320). Given that the cell monolayer looked healthy and confluent, 
we concluded that this result was most likely due to non-specific neutralisation 
or inhibition. This reinforces the requirement of adequate controls as the same 
sample tested by FAVN had a titre of 0.13 IU/ml (considered a non-protective 
rabies VNAb titre), without the VSV control the result of the rabies pNT would 
have been misinterpreted as rabies VNAb positive.   
Our results demonstrate that as the rabies VNAb titre increases in the FAVN test, 
the titre recorded by our pNT also increases (Figure 3.10). The correlation 
between our pNT and the FAVN test and HIV(luc) pNT was 0.776 and 0.833 
respectively (p<0.0001). In order to assess the robustness of our assay we 
repeated a small number (n=12) of serum samples using the same method 
utilising a new batch of MLV(rabies) pseudotypes and using Vero cells as the 
 Age Total 
S
e
x
 
 2-6 m 7-12 m 1-4 y 5-8 y  
Male 12 8 20 6 46 (44%) 
Female 18 13 21 6 58 (56%) 
Total  30 (29%) 21 (20%) 41 (39%) 12 (12%) 104 (100%) 
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target cell line. The high correlation between VNAb titres seen by both assays 
(R2=0.904, p<0.0001) demonstrates the reproducibility of the assay (Figure 3.11). 
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Figure 3.10 Correlation of rabies VNAb antibody titres determined by the 
rabies virus pNT, the FAVN test and the HIV(luc) pNT. Rabies VNAb titres 
obtained by the rabies virus pNT were compared with a) the FAVN test (n=103, 
R2=0.603, p<0.0001) and b) the HIV(luc) pNT (n=103, R2=0.695, p<0.0001). 
Correlation and p-values were calculated using Pearson’s product-moment 
correlation.    
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Figure 3.11 Correlation of rabies VNAb titres obtained using either CRFK 
or Vero cells as the target cell line for the rabies virus pseudotype 
neutralisation test. A new batch of MLV(rabies) pseudotypes were produced, 
TCID50 calculated and the pNT performed on Vero cells. Rabies VNAb titres were 
compared to titres previously measured on the pNT using CRFK cells. A high 
degree of correlation of VNAb titre was observed between the assays (n=12, 
R2=0.904, p<0.0001).Correlation and p-values were calculated using Pearson’s 
product-moment correlation.   
 
 
At the time of testing the canine sera, we were unable to obtain the OIE 
reference serum of dog origin, the international standard used in the FAVN for 
converting rabies VNAb titres in IU/ml. This reference serum is diluted to a titre 
of 0.5 IU/ml, the minimum antibody titre considered to give protection against 
rabies virus challenge (WHO, 2010). Ideally, as in the FAVN, this sample would 
have been tested alongside all test sera to determine an accurate rabies VNAb 
titre in IU/ml. After testing these samples we were able to source a small 
volume of this reference serum which was then tested using our rabies virus 
pNT. The serum was tested in triplicate on three separate days, to allow for 
inter-assay variation, and at each test the titre of the sample was 40. We 
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therefore used a neutralising titre of 40 in our rabies virus pNT to correlate to 
0.5 IU/ml. Using this cut-off we were then able to calculate the false positive 
and false negative rates in our assay. Positivity was classified as a VNAb titre of 
≥0.5 IU/ml by FAVN or ≥40 by rabies virus pNT.  
Of the 104 serum samples tested, one was inconclusive due to failing the VSV 
control. There were 9 discordant samples among the remaining 103 samples, 8 of 
which tested positive by the FAVN and negative by rabies virus pNT and one of 
which tested negative by the FAVN and positive by rabies pNT (Table 3.2). The 
rate of false negatives compared to the gold standard FAVN was 0.077 (n=8) and 
the rate of false positives was 0.001 (n=1) (Figure 3.12). When our results were 
compared with the HIV(luc) pNT the false negative and positive rates were 0.029 
(n=3) and 0.001 (n=1) respectively. The majority of the discordant results 
clustered around the assay cut-off titre (0.5 IU/ml), with 63% of the false 
negative results being assigned to the two lowest FAVN titres considered positive 
(0.5 and 0.66 IU/ml). Although these false negatives decreased the sensitivity of 
the test to 81.82% (95% CI: 67.28 % to 91.78 %), the specificity remained high at 
98.21% (95% CI: 90.88 % to 99.72 %). 
 
 
Sample 
number Age Sex 
Previous 
vaccination 
FAVN   
test  
HIV(luc) 
pNT 
Rabies virus 
pNT 
69 9m F N 0.66 20 20 
75 3y F Y 0.5 <10 <10 
94 2y F Y 0.5 <10 10 
102 7m F N 0.87 10 <10 
121 1y F N 0.22 20 40 
171 6m M N 0.5 <10 20 
212 4y F Y 1.97 40-80 20 
314 5m F Y 1.97 80-160 20 
381 2y M Y 0.66 40 10 
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Table 3.2 Details of serum samples for which discordant results were 
observed between the rabies virus pNT and the FAVN test. Age, sex and 
vaccination history of dogs whose VNAb response by the rabies virus pNT was 
discordant with results of the FAVN test. Results of rabies VNAb titres measured 
by the HIV(luc) pNT are also included.  
 
0 . 1 1 1 0
1
1 0
1 0 0
1 0 0 0
R a b ie s  V N A b  t i t r e
m e a su re d  b y  F A V N
R
a
b
ie
s
 V
N
A
b
 t
it
r
e
m
e
a
s
u
r
e
d
 b
y
 p
N
T
F a lse  p o s it iv e
F a lse  n e ga tive
 
Figure 3.12 False positive and false negative rates between the rabies 
virus pseudotype neutralisation test and the FAVN test. When samples were 
classified as positive or negative by VNAb titre (≥0.5IU/ml by FAVN and ≥40 by 
rabies virus pNT) there was a false negative rate of 0.077 and a false positive 
rate of 0.001 between the rabies virus pNT and the FAVN test (n=103).  
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3.2.3 Optimisation of the rabies virus pseudotype neutralisation test 
The volume of OIE reference standard we were able to obtain was limited, 
therefore we had no reference standard to run on future rabies virus pNT. To 
mimic the OIE reference serum, which consistently gave a VNAb titre of 40 on 
the rabies virus pNT, a human serum sample from a vaccinated individual was 
diluted to give a titre of 40 on the rabies virus pNT. This human standard was 
subsequently included in all future tests along with positive and negative canine 
serum controls, if this standard did not give a titre of 40, the test samples were 
repeated, as a cut-off for adequate protective antibody could not be 
extrapolated.  
A volume of 90 µl of serum is required for the pNT to allow for serial dilutions of 
sera in triplicate, VSV controls and an additional 10% to allow for pipetting error. 
A volume of 50 µl of diluted serum and 50 µl of pseudotype was initially used in 
the pNT. Due to the potential for small volumes of serum to be received for 
testing on the rabies virus pNT, the volumes used in the assay were halved 
decreasing the volume of serum required for testing to 45 µl. To determine 
whether the lower volumes would affect the reproducibility of the test, 19 
canine serum samples, in addition to the three test controls, were tested in 
duplicate using both the original and half volumes of sera. The rabies VNAb 
titres were identical for all samples in each test resulting in a correlation of 
100% (data not shown). For all future pNT these lower volumes were 
implemented, resulting in an input dose of 50 TCID50.     
3.2.4 Pseudotype-based neutralisation tests for non-rabies lyssaviruses 
After successfully establishing a protocol for the rabies virus pNT, we developed 
a pNT for measuring VNAb to other members of the Lyssavirus genus. Plasmids 
encoding 6 other lyssavirus glycoproteins were kindly provided by Dr. Edward 
Wright (University of Westminster). Pseudotypes were produced as previously 
described with substitution of the CVS-11 plasmid with that of another lyssavirus 
glycoprotein. There are 14 species of lyssavirus, a pNT for rabies and 6 of the 
other major species were developed in this study; Lagos bat virus (LBV), Mokola 
virus (MOKV), Duvenhage virus (DUVV), European bat lyssavirus type-1 (EBLV-1), 
European bat lyssavirus type-2 (EBLV-2) and Australian bat lyssavirus (ABLV). 
Lyssavirus species fall into two distinct phylogroups (Badrane et al., 2001), 
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phylogroup 1 contains rabies virus, DUVV, EBLV-1, EBLV-2 and ABLV, and 
phylogroup 2 contains LBV and MOKV (Figure 3.13). TCID50 was calculated for 
each MLV(lyssavirus) pseudotype and CRFK cells were infected with matched 
concentrations of each of the 7 MLV(lyssavirus) pseudotypes to determine if this 
cell line was permissive to all MLV(lyssavirus) pseudotypes. In all cases GFP was 
detectable by flow cytometry and fluorescent microscopy (Figure 3.14).  
 
Figure 3.13 Phylogenetic analysis of the seven lyssavirus species 
investigated in this study. The full length lyssavirus glycoprotein gene 
sequences used to produce viral pseudotypes in this study were used to 
construct a phylogenetic tree. The tree was determined by the neighbour-joining 
method, where branch length is proportional to evolutionary distances between 
lyssaviruses. The numbers at each node represent the percentage bootstrap 
values (1000 replicates). Evolutionary analysis was conducted in MEGA6 (Tamura 
et al., 2013). 
 
 
 LBV
 MOKV
Phylogroup 2
 EBLV-1
 DUVV
 EBLV-2
 ABLV
 Rabies virus
Phylogroup 1
 VSV
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a) 
 
b) 
 
Figure 3.14 Transduction of CRFK cells with MLV-based pseudotypes 
bearing lyssaviral glycoproteins. 1000 TCID50 of each MLV(lyssavirus) 
pseudotype was incubated with CRFK cells and GFP expression was assessed at 
48 h by a) fluorescence microscopy (pictures are displayed in the same order as 
depicted in the graph). The line represents scale bar (400 µm), and b) flow 
cytometry, each bar represents the mean +/- standard error (n=3).   
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The percentage of target cells expressing GFP following transduction was 
approximately 4% for the majority of MLV(lyssavirus) pseudotypes, although 
expression seen in cells transduced with MLV(ABLV) and MLV(VSV) pseudotypes 
were twice this level, suggesting that their TCID50 calculation may have been 
incorrect. The TCID50 was repeated with both pseudotypes and found to be the 
same as the original value, although the results by flow cytometry were higher 
(Figure 3.14b), the number of GFP expressing cells observed by fluorescence 
microscopy was similar to that seen with the other lyssaviruses (Figure 3.14a).  
We previously demonstrated that the infectivity of MLV(rabies) pseudotypes was 
dependent on target cell line (Figure 3.5). To investigate the permissiveness of 
cell lines to the other lyssaviral pseudotypes, we infected 8 cell lines with 100 µl 
of each MLV(lyssavirus) pseudotype. As the concentration of the inoculum was 
not matched, the GFP expression was normalised against the expression level 
observed in CRFK cells. The infectivity profiles seen in the adherent cell lines 
(CRFK, BHK-21, Vero, D17) were similar for all MLV(lyssavirus) pseudotypes, with 
BHK-21 being least permissive and similar expression levels demonstrated in 
CRFK, Vero and D17 cells. The expression levels observed in suspension cell lines 
differed considerably between the lyssaviral pseudotypes. MLV(rabies) 
pseudotypes infected only MT-4 cell lines and at less than 1%. All other 
MLV(lyssavirus) pseudotypes infected both MT-4 and SUP-T1 cells, both T cell 
lymphoblast cell lines, with MLV(DUVV) and MLV(LBV) exhibiting the highest 
titres. In BMOX40 and 3201 cell lines, MLV(DUVV) was the only pseudotype to 
infect these cells at greater than 1% (Figure 3.15).  
       96
 
C
rF
K
B
H
K
V
e
ro
D
1
7
0
5 0
1 0 0
1 5 0
2 0 0
N
o
r
m
a
li
s
e
d
 G
F
P
 e
x
p
r
e
s
s
io
n
(
%
)
R a b ie s  v ir u s
L B V
M O K V
D U V V
E B L V -1
E B L V -2
A B L V
V S V
a )
       97
 
M
T
-4
B
M
O
X
4
0
3
2
0
1
SU
P
-T
1
0
1 0
2 0
3 0
4 0
N
o
r
m
a
li
s
e
d
 G
F
P
 e
x
p
r
e
s
s
io
n
 (
%
)
R a b ie s  v ir u s
L B V
M O K V
D U V V
E B L V -1
E B L V -2
A B L V
b )
Chapter 3. Development of lyssavirus pseudotype neutralisation tests                                98 
 
      97
 
Figure 3.15 Expression of GFP in target cell lines following 
transduction with MLV(lyssavirus) pseudotypes. Pseudotypes were 
transduced into eight cell lines a) four adherent cell lines (BHK-21, CRFK, 
Vero, D17) and b) four suspension cell lines (MT-4, BMOX40, 3201, SUP-T1). 
GFP expression was normalised against the expression levels measured in 
CRFK cells, as the pseudotype concentrations were not matched. 
 
 
With high titre pseudotypes for seven species of lyssavirus, we were keen to 
test their use in a pNT, however unfortunately VNAb positive serum to these 
lyssaviruses is uncommon. As we were unable to obtain any neutralising sera 
to these lyssaviruses, we used the previously tested Tanzanian dog sera to 
test against pseudotypes bearing the LBV, MOKV and DUVV glycoproteins in 
the pNT. Rabies VNAb have been shown to cross-neutralise other lyssaviruses 
from phylogroup 1 but do not cross-neutralise viruses from phylogroup 2 
(Lafon et al., 1988, Brookes et al., 2005b, Hanlon et al., 2005). We compared 
rabies VNAb titres measured by the rabies virus pNT to VNAb titres of DUVV 
(phylogroup 1) and LBV and MOKV (phylogroup 2) (Figure 3.16). There was a 
significant positive correlation in VNAb titres observed in the rabies virus and 
DUVV pNT (R2=0.388, p<0.0001), as would be expected as DUVV is a 
phylogroup 1 lyssavirus. However there was no correlation observed between 
rabies VNAb titres and either of the phylogroup 2 lyssaviruses (LBV R2=0.018 
p=0.484, MOKV R2=0.007 p=0.6704). Correlation and p-values were calculated 
using Pearson’s product-moment correlation. There is currently no 
recommended titre considered to provide adequate protection to challenge 
for any of the lyssaviruses other than rabies virus, but if we use the same cut-
off as for rabies virus (titre ≥40) none of the samples tested were considered 
cross-neutralising to either of the phylogroup 2 lyssaviruses, even from 
samples demonstrating the highest rabies VNAb titre. 
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Figure 3.16 Cross-neutralisation of lyssavirus pseudotypes by sera raised 
against rabies virus. Serum samples were tested by pNT using a) MLV(rabies) 
and MLV(DUVV) pseudotypes (n=103, R2=0.388, p<0.0001) and b) MLV(LBV) (n=30, 
R2=0.018, p=0.4844) and MLV(MOKV) pseudotypes. (n=30, R2=0.007, p=0.6704). 
These pNT were performed prior to the change in volumes mentioned in section 
3.2.3 and were therefore tested with 50 µl of test sera and 100 TCID50 of 
pseudotype. 
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3.3 Discussion  
The development of reliable, accessible and economical assays for rabies virus 
serosurveillance will contribute to improving rabies prevention and control 
strategies (OIE, 2008). This study demonstrates that pseudotypes bearing the 
glycoprotein of lyssaviruses can be used successfully as a substitute for live virus 
in neutralisation tests. Handling lyssaviruses requires a SAPO licence and the 
requirements for work involving lyssaviruses is particularly stringent (DEFRA, 
2015), therefore currently rabies VNAb testing is limited to the few laboratories 
where adequate containment facilities exist. The rabies virus pNT negates the 
requirement for high containment facilities, which are often unavailable in 
countries where rabies is still endemic. Additionally the cost of rabies VNAb 
testing is prohibitive for many serosurveillance studies, with the price of one 
FAVN test costing £45 (Biobest, 2015). In contrast, the cost of consumables for 
the pNT developed in this study is less than £1 per sample.  
The flexibility of the assay also allows for the measurement of VNAb to any of 
the lyssaviruses by simply replacing the rabies virus glycoprotein with the 
glycoprotein of the chosen lyssavirus. Therefore, if a new lyssavirus is identified, 
only the sequence of the glycoprotein is required to set up a pNT, whereas in 
the FAVN the virus needs to be isolated and cultured to a high titre, which can 
prove time consuming. The requirement for robust assays for determining 
exposure to novel lyssaviruses has become more pressing, with 5 of the 14 
species of lyssavirus isolated within the last 14 years (Marston et al., 2012, 
Kuzmin et al., 2010, Freuling et al., 2011, Botvinkin et al., 2003). Flexibility of 
the assay is also further improved by easy modification of the reporter gene 
utilised in the pNT, which can be changed depending on the preference of the 
laboratory, previous rabies pNTs have also been described using both luciferase 
and lacZ (Wright et al., 2008). The preference for utilising GFP as the reporter 
gene in this study was determined by the lack of post-assay processing required 
and the lower cost of fluorescence microscopy compared to luciferase assay 
development. The drawback of using GFP as the reporter is that the assay needs 
to be read by fluorescence microscopy and the entire area of each well must be 
screened as the presence of one fluorescent cell is significant. This manual 
screening not only increases the time taken to read the assay but also leaves 
some subjectivity in assay interpretation. However the assay could be optimised 
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for analysis by flow cytometry if required, which would be especially beneficial 
if a suitable suspension cell line could be obtained.  
The MLV-based pseudotype system was shown to give a low reporter background 
in this study as no non-specific fluorescence was demonstrated in cells 
transduced with MLV(ΔEnv) pseudotypes. The disadvantage of the MLV 
pseudotypes, evidenced in this study, is that they do not appear to be as stable 
through successive cycles of freeze-thawing, as other pseudotype systems based 
on HIV and VSV (Molesti et al., 2014, Ogino et al., 2003).  
The robustness of the rabies virus pNT was demonstrated by the correlation of 
VNAb titres obtained between the rabies pNT and the gold standard FAVN test. 
Low inter-assay variation is also supported by the high degree of correlation of 
VNAb titres when the pNT was performed using two different cell lines. Rabies 
VNAb titres measured by our pNT and the HIV(luc) pNT were also very closely 
correlated, despite using different retroviral systems, reporters and cell lines. 
The discordant results between our rabies virus pNT and the FAVN test were 
mostly clustered around the test cut-off titre, which has previously been 
reported when other pseudotype assays have been compared to the FAVN test 
(Wright et al., 2008, Wright et al., 2010). The samples used in this study had 
previously undergone at least 3 freeze-thaw cycles, which may have accounted 
for the VNAb in these samples becoming undetectable, as previous studies have 
shown that multiple freeze-thaw cycles can decrease the detectable titre of 
antibodies in serum (Boadella and Gortázar, 2011, Brey et al., 1994).  
Our pNT includes MLV(VSV) as a non-specific neutralisation control which has 
been utilised in other pNTs as a measure of non-specific neutralisation (Logan et 
al., 2016). The presence of non-specific neutralisation and toxicity has been 
observed in many assays and has been recognised as having a role in false 
positivity in the FAVN test (Shiraishi et al., 2014a, Thrusfield, 1986). The non-
specific neutralisation of one of the serum samples tested in this study highlights 
the necessity of this control, as without this control the sample would have been 
incorrectly reported as positive for rabies VNAb.  
A further benefit of the pNT is that the volume of serum required per test is 
lower than with the FAVN or RFFIT (Cliquet et al., 1998). In this study we were 
able to reduce the volume of serum initially required by half, making the volume 
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of serum required for our assay just 45 µl compared to the 300 µl required in the 
FAVN test (OIE, 2012b). The overall objective of this study was to produce an 
assay which could be used to measure rabies VNAb in animals, particularly 
wildlife, therefore producing assays that require small volumes of sera are highly 
desirable, as in wildlife sampling only small volumes of sera are often available.  
Ideally results from the pNT would be reported in IU/ml, but this would require 
the international OIE reference standard to be included in each assay, 
unfortunately during this study we were unable to obtain any additional control 
serum. We therefore had to use a surrogate control in our assay; this serum was 
diluted to a titre of 40, the same titre the OIE reference serum achieved in the 
rabies virus pNT. On all occasions this control measured 40, hence we are 
confident that this cut-off is representative of adequate protection. 
Additionally, the Advisory Committee on Immunisation Practices suggest sera 
that completely neutralises rabies virus at a dilution of 1:5 should be considered 
positive for rabies-specific antibodies, therefore our cut-off titre, a dilution of 
1:40, is sufficient. If the OIE reference serum were to become available, this 
reference serum would replace our local control serum.  
Our cross-neutralisation experiment confirms previous evidence that VNAbs to 
rabies virus cross-react with other phylogroup 1 lyssaviruses, but provide no 
protection against lyssaviruses belonging to phylogroup 2 and presumably the 
more recently isolated lyssaviruses belonging to a putative third phylogroup 
(Horton et al., 2010). The FAVN is generally used for measuring rabies VNAb in 
response to vaccination, but for serosurveillance it should be borne in mind that 
the FAVN or rabies virus pNT cannot distinguish between VNAb to lyssaviruses of 
the same phylogroup. This may not be discriminatory enough for screening 
wildlife species, especially bats, from areas where multiple lyssaviruses are 
circulating. In these circumstances a positive VNAb result should be further 
investigated to determine the definitive source of the VNAb response. As 
reported here and in other studies (Wright et al., 2008, Wright et al., 2010) the 
highest VNAb titres are demonstrated to the particular lyssavirus eliciting the 
initial immune response.  
Vero and BHK-21 are commonly used cell lines for culture-adapted strains of 
rabies virus (Thoulouze et al., 1998), however rabies strains have been shown to 
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infect a variety of cell lines of various origins (Jackson and Wunner, 2007). 
Although BHK-21 cells were our first choice of cell line for the rabies virus pNT, 
they proved to be unsuitable as pseudotype titres were considerably lower in 
BHK-21 cells than in other cell lines. The poor transduction efficiency of 
MLV(lyssavirus) pseudotypes in BHK-21 cells has also been previously reported in 
other MLV-based pseudotype systems, including those bearing rabies, Ebola and 
feline leukaemia virus glycoproteins (Wright et al., 2008, Wool-Lewis and Bates, 
1998, Hussain et al., 2011). Interestingly, in rabies virus pseudotyping this was 
reversed when the MLV core was replaced with an HIV core (Wright et al., 2008), 
suggesting that the poor infectivity may be the result of inadequate integration 
or expression of the MLV genome, or post-entry restriction of MLV, as opposed to 
a direct effect of viral entry. It has also been reported that the use of BHK-21 
cells in the FAVN is not recommended for measuring VNAb response to rabies 
vaccination if the administered vaccine was cultured in BHK-21 cells. It has been 
demonstrated that serum samples from animals immunised with such vaccines 
may possess anti-BHK-21 specific antibodies (Shiraishi et al., 2014a) which may 
interfere with the assay and distort genuine rabies VNAb titres. Therefore the 
use of CRFK cells in the pNT is preferential, as the same cell line can be used for 
all serum samples. 
The results of our cell line infectivity experiment demonstrated that in adherent 
cell lines the infectivity profile of MLV(rabies) pseudotypes is similar to that of 
pseudotypes bearing the glycoproteins of the other 6 lyssavirus species 
investigated in this study. Conversely, there is a difference in the ability of the 
lyssaviral pseudotypes to infect the suspension cell lines. Rabies virus 
pseudotypes barely infected any of the suspension cell lines tested, whereas 
some of the other lyssaviral pseudotypes were able to transduce some of these 
cell lines. Both MLV(LBV) and MLV(DUVV) pseudotypes infect MT-4 and SUP-T1 
cells to a significant titre, with MLV(DUVV) pseudotypes also infecting BMOX40 
and 3201 cells. These results support the evidence of differential tropism 
patterns of the lyssaviruses (Koraka et al., 2012, Weir et al., 2013). There have 
been various cellular receptors proposed for rabies virus including nAChR, NCAM 
and p75NTR, but none have been demonstrated as essential for cell entry in all 
lyssavirus species (Lafon, 2005). The low-affinity nerve-growth factor receptor 
p75NTR has been shown to be an in vitro receptor for both rabies virus and 
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EBLV-2 (Tuffereau et al., 1998), but not for the other 5 lyssavirus species tested 
here. Our results also show a similar cellular tropism of rabies virus and EBLV-2, 
which both infect MT-4 cells at a very low level and do not significantly infect 
any of the other suspension cell lines. It is evident from this study that 
MLV(DUVV) pseudotypes are capable of entering all 8 cell lines investigated, 
previous studies have also revealed different tropism patterns of rabies and 
DUVV (Koraka et al., 2012). The cellular receptors of DUVV have not been 
determined definitively, but considering the natural route of infection of DUVV 
is via bat scratches as opposed to direct viral inoculation through a rabid animal 
bite, it is reasonable to consider there may be different viral tropisms between 
these two viruses. Unfortunately we do not have the capacity to test the tropism 
of live lyssaviruses to see if the infectivity patterns mimic that seen in 
pseudotype infection, although this would be of great interest. Considering the 
suspension cell lines tested were generally non-permissive to MLV(rabies) 
pseudotypes, an automated high-throughput method of screening for rabies 
VNAb using suspension cells and flow cytometry was not appropriate. A similar 
automated approach was considered using adherent cell lines, but in this case 
cells are required to be removed from the well and resuspended, which often 
results in clumping of the cells and an inability to test via flow cytometry, 
therefore we concluded the post-assay processing proved prohibitive for the 
pNT. Titres of MLV(VSV) pseudotypes in suspension cell lines were lower than 
that seen in the adherent cell lines (with the exception of BHK-21 cells) but 
were still considerable, therefore although they were poorly transduced by the 
MLV(lyssavirus) pseudotypes we were confident that the cells themselves were 
adequate. 
Rabies is classified as a neglected disease which is responsible for thousands of 
human deaths per year. Improved serosurveillance is required to further assess 
the circulation and reservoirs of rabies virus, and serological surveys are also 
important in determining the effectiveness of different rabies vaccination 
campaigns and delivery strategies. The pNT developed in this study provides a 
sensitive and cost-effective method of measuring VNAb to lyssaviruses, which 
can be used in BSL-2. The majority of rabies infections occur in developing 
countries, where the high containment facilities required for handling live rabies 
virus are unavailable, this assay provides the capacity for these countries to 
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improve rabies virus surveillance in a cost-effective manner. The assay is also 
flexible and can be readily adapted for the detection of VNAb to novel 
lyssaviruses that are ever emerging.  
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 Chapter 4. Practical applications of 
lyssavirus pseudotype neutralisation 
tests 
 
4.1 Introduction   
Testing for rabies virus antibodies is routinely used to confirm an immune 
response in both humans and animals following rabies vaccination. As 
international human and animal health agencies now work towards the global 
elimination of canine rabies (WHO, 2013), with mass dog vaccination a key 
element of the strategy (One Health, 2016), serological testing will continue to 
be important to ensure the immunogenicity and effective delivery of rabies 
vaccines in the field. Preliminary data suggest that village dogs in Africa respond 
well to commercial vaccines delivered under field conditions (Morters et al., 
2014a), however uncertainty still remains regarding the immunogenicity of 
rabies vaccines delivered in a wide range of settings throughout Africa and Asia. 
Readily accessible serological assays are required to provide critical information 
about immune response and the effectiveness of vaccine delivery strategies in 
achieving the 70% vaccination coverage required to control canine rabies (WHO, 
2004). However, such serological investigations in vaccinated dogs are seldom 
performed due to the lack of veterinary diagnostic facilities and the high cost of 
rabies virus neutralisation tests (VNTs).  
There is a widespread perception that in an infected host rabies antibody 
develops only shortly before, or at the onset, of clinical symptoms, at which 
stage the disease is invariably fatal. For this reason serosurveys are rarely used 
to investigate the epidemiology of rabies virus, whilst they are commonly used 
to investigate infection patterns for other pathogens. However, there have been 
studies that suggest non-fatal rabies exposures occur in both humans and 
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animals (Table 1.2). Serosurveillance in unvaccinated populations, particularly 
wildlife, may have a role in rabies elimination programmes to provide supportive 
evidence to declare a region rabies-free. Although active surveillance and 
contact-tracing studies may be sufficiently powerful to detect rabies cases in 
dogs and other domestic species, over the two-year period required to declare 
an area free of rabies (Townsend et al., 2013), there remains concern that cases 
in wildlife could remain undetected.  
In this Chapter we demonstrate the utility of the rabies virus pseudotype 
neutralisation test (pNT), optimised in Chapter 3, to detect rabies virus 
neutralising antibody (VNAb) in three distinct studies. In the first study a wide 
variety of species from the Russian Far East were screened for rabies VNAb as 
part of a disease management strategy. The second study comprises a serosurvey 
of 71 lion samples collected from the Serengeti National Park (SNP) over a nine 
year period. In the third study the longitudinal serological response to rabies 
vaccination was investigated in a cohort of slum dogs in Kenya.  
 
4.2 Results  
4.2.1 Rabies virus neutralising antibody screening in the Russian Far East 
After validation of the rabies virus pNT we were approached by Wildlife Vets 
International (WVI), a British charity involved in wildlife conservation, who asked 
us to test a panel of wildlife sera for the presence of antibodies to rabies virus. 
This serology would form part of the disease surveillance strategy of the Amur 
leopard reintroduction programme in the Russian Far East. 
The Amur leopard (Panthera pardus orientalis) is on the critically endangered 
list (Jackson and Nowell, 2008) and is considered the world’s rarest wild cat. 
There are fewer than 70 animals remaining in the wild, the majority of which 
are in the Russian Far East with a handful of Amur leopards in the adjacent areas 
of China (WWF, 2015). A reintroduction programme for the Amur leopard was 
formally approved in 2015 (ZSL, 2015) and aims to repopulate the historic range 
of the Amur leopard in the Primorsky Krai region of the Russian Far East using 
zoo stock (Kelly et al., 2013). Reintroducing captive bred animals is considered a 
last resort for wildlife conservation (Rahbek, 1993), but due to low numbers and 
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the substantial loss of the Amur leopard’s habitat, it is considered the only 
remaining option to avoid extinction of this species (Uphyrkina and O'Brien, 
2003). An important aspect of the reintroduction programme is the disease 
management strategy, which aims to identify diseases which may threaten the 
reintroduced and remaining leopards. This is achieved by identifying diseases 
present in wildlife and domestic species in the proposed reintroduction region. 
Of the 22 infectious diseases recognised as important to the disease 
management strategy, rabies was ranked third in order of importance, below 
feline immunodeficiency virus and feline leukaemia virus (Miquelle and Murzin, 
2003). Dr. Lewis of WVI stated that finances for veterinary investigations will be 
limited and therefore it is essential that the money available is used to the 
greatest effect (Miquelle and Murzin, 2003). The cost of rabies VNAb testing 
using conventional methods such as the RFFIT, FAVN or MNT would be prohibitive 
for such disease management strategies, however the rabies virus pNT is a low 
cost alternative. Additionally, such conventional methods require larger volumes 
of sera than are required in the pNT, in situations such as these, where a single 
serum sample requires multiple testing for a range of diseases, assays utilising 
low serum volumes are preferable. As our rabies virus pNT is both inexpensive 
and uses only 45 µl of serum, we were able to test serum samples for rabies 
VNAb as part of the disease management strategy of the Amur leopard 
reintroduction programme. 
Rabies is still a significant disease in Eurasia, with urban dog rabies affecting 
Asia and wildlife rabies the predominant form in Europe (Kuzmin et al., 2004). In 
Russia rabies is primarily maintained by wild canids, with different rabies strains 
maintained by different species in different areas. In the Russian Far East arctic 
rabies is the predominant strain which is maintained by the red fox, racoon dog 
and the wolf, with mustelids and other terrestrial mammals only occasional 
hosts (Kuzmin et al., 2004). Figure 4.1 illustrates the number of rabies cases in 
Russia from 1989-2010, in both domestic and wild animals, showing the dramatic 
increase in wildlife rabies since 1995 (Vedernikov et al., 1999). While these data 
represent the whole of the Russian Federation, rabies serosurveillance data for 
the Russian Far East is particularly limited, with the Primorsky Krai region 
reporting only 12 rabies cases between 1989-2007, with only a minority of these 
cases in wildlife (Lubchenko, 2008). 
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Figure 4.1 The number of rabies cases recorded in the Russian Federation 
from 1989-2010. The number of rabies cases in domestic and wild animals was 
collated from the Rabies Information System of the WHO Collaborating Centre 
for Rabies Surveillance and Research, representing the time period of collection 
of serum samples in this study (1989-2010). 
 
 
To determine whether rabies was circulating in the area around the proposed 
release site of the Amur leopards (Figure 4.2), a total of 203 serum samples 
were tested for rabies VNAb by pNT. The panel of samples consisted of serum 
from 17 different domestic and wildlife species collected between 1989 and 
2010 (Table 4.1), these samples had been collected and stored at -70°C for 
serosurveillance studies when funding became available. A cut-off threshold of 
40 was chosen for the rabies virus pNT as evidence of rabies-specific VNAb in 
sera. One sample had a rabies VNAb titre of ≥640, nine samples tested were 
inconclusive and the remaining 193 samples all had VNAb titres of ≤20 (Figure 
4.3). The majority of these samples (n=170) did not neutralise rabies 
pseudotypes at a dilution of 1:10, the lowest dilution in the assay, and were 
therefore assigned a VNAb titre of <10. Nineteen samples had a rabies VNAb titre 
of 10 and 4 samples measured 20 on the pNT. The sample with a high rabies 
VNAb titre was collected from a domestic dog sampled from a town in 2010. It is 
possible that this dog had previously been vaccinated as mass door-to-door 
vaccination campaigns are performed in that area (Lubchenko, 2008), however 
vaccination history from that dog was not available.  
A positive VNAb titre in any of the wildlife serum samples would be a significant 
concern for WVI with respect to the Amur leopard reintroduction programme. To 
ensure that the neutralisation demonstrated in some samples at low serum 
dilutions (1:10 and 1:20) was not due to genuine rabies VNAb, two samples were 
additionally tested using the FAVN. As the FAVN is expensive, and funding for the 
disease management strategy of the Amur leopard reintroduction programme 
was so limited, only two samples were sent to Biobest, a private veterinary 
diagnostic laboratory, for testing on the FAVN. In this study four samples 
measured 20 by rabies virus pNT, these consisted of two samples from raccoon 
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dogs, one from a tiger and one from a vole. The decision of which samples test 
by FAVN was reached considering both the species from which the sample 
originated and the volume of serum available, as a minimum of 300 µl was 
required for FAVN testing. One raccoon dog sample was chosen for testing 
(#125), as raccoon dogs are the principal reservoirs for the arctic-like strain of 
rabies virus present in the Russian Far East (Kuzmin et al., 2004) and therefore 
the most likely species to have been exposed to the virus. The tiger sample (#09) 
was also selected for testing due to the implications for the Amur leopard if 
other wild felids in the area had been exposed to rabies virus. Both samples 
were negative when tested by FAVN, with a titre of 0.07 IU/ml.    
       11
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a)          b) 
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Figure 4.2 Locations of animals screened for rabies virus neutralising 
antibody. a) Map of the area of Russia where serum samples were collected 
and b) Map representing a zoomed in area of the square placed on Map a). 
Location points were plotted using latitude and longitude data provided with 
samples. The thick dark grey line represents the proposed area for 
reintroduction of the Amur leopard. Individual samples are represented by 
filled circles coloured by Family (n=189). Fourteen samples were not included 
as location data were not recorded for these samples. Maps were produced in 
Google My Maps (Map data ©2015 Google et al.). 
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Total 
1989   4 4                8 
1990   5 1                6 
1991    3                3 
1993   1 1              1  3 
1995   3                 3 
1996    6              1  7 
1997   1 6     2           9 
1998   1 2     2         2  7 
2000   1               2  3 
2001         1      1   4  6 
2002             2 1    6  9 
2003  6  3         3 1 7  1 2  23 
2004 1 17           2 2 14 1  2  39 
2005  2 2 1              4  9 
2006   1      1  1       1  4 
2007                1  1  2 
2008     1 3 1   1  1       1 8 
2009     24  1 1            26 
2010     15  10             25 
Unknown     2  1             3 
Total 1 25 19 27 42 3 13 1 6 1 1 1 7 4 22 2 1 26 1 203 
Chapter 4. Practical applications of lyssavirus pseudotype neutralisation tests                       115 
 
      11
4
 
Table 4.1 Species and year of collection of serum samples tested in this 
study.  Serum samples from domestic animals and wildlife from the Russian Far 
East were submitted for testing for rabies VNAb, various numbers of samples 
were collected from 17 different species between 1989 and 2010 (n=203). 
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Figure 4.3 Rabies VNAb titres of serum samples tested in this study. Serum 
samples from domestic animals and wildlife from the Primorsky Krai region of 
the Russian Far East, collected between 1989 and 2010, were tested for rabies 
VNAb by the pNT (n=194). The vertical dashed line represents the cut-off titre of 
40 utilised in this study. 
 
 
Nine of the 203 samples (4%) tested for rabies VNAb were recorded as 
inconclusive, the causes of these inconclusive results included non-specific 
fluorescence, cytotoxicity or sample haemolysis of serum, with non-specific 
fluorescence causing the majority of inconclusive results in this study (Table 
4.2). Non-specific fluorescence describes fluorescence observed in the test well 
which is not attributed to the GFP expressing pseudotype. Figure 4.4 illustrates 
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examples of non-specific fluorescence observed whilst testing the serum samples 
in this study. As demonstrated in the micrographs, fluorescent material present 
in the serum can entirely obscure the cell monolayer, therefore transduction of 
the target cells with MLV(rabies) pseudotypes cannot be observed (Figure 4.4 b). 
There may also be fluorescent components of serum which resemble GFP 
expression to an inexperienced user (Figure 4.4 c & d). The pNT could still be 
interpreted for some samples with non-specific fluorescence, for example the 
sample in Figure 4.4 d. Non-specific fluorescence can be removed by further 
diluting the serum, but this was not appropriate in this instance as we were 
interested in the neutralising activity of the serum at the lowest dilutions. 
 
Sample 
number 
Species 
Date 
Collected 
Reason for inconclusive 
result 
10 Tiger 19/03/1998 Non-specific fluorescence  
14 Tiger 10/10/2001 Non-specific fluorescence 
32 Himalayan black bear 08/08/1989 Cytotoxicity  
48 Brown Bear 28/05/2003 Non-specific fluorescence 
69 Himalayan Black Bear 02/06/2003 Cytotoxicity 
110 Raccoon dog 16/10/2003 Non-specific fluorescence 
114 Raccoon dog 02/11/2003 Non-specific fluorescence 
115 Raccoon dog 02/11/2003 Cytotoxicity 
202 Hare 23/12/2008 Sample haemolysed 
 
Table 4.2 Serum samples which were inconclusive for rabies virus 
neutralising antibody. Species, date of collection and the reason for an 
inconclusive result for serum samples which were recorded as inconclusive for 
rabies VNAb by pNT. 
  
      11
7
 
 
 
a)         b)     c)         d) 
 
 
 
 
 
 
 
Figure 4.4 Fluorescence and light micrographs of the rabies virus pNT with test serum samples.  Micrographs of wells of the rabies 
virus pNT for four serum samples (a-d) at the 1:10 dilution under fluorescence and inverted light microscope. a) CRFK cells infected with 
MLV(rabies) pseudotypes b-d) non-specific fluorescence in serum. Line represents scale bar (a, b, c: 400 µm, d: 200 µm).  
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4.2.2 Rabies virus neutralising antibody screening in African lions 
In Tanzania rabies is endemic in the domestic dog population (Cleaveland et al., 
2002) and there have been confirmed spillover infections in wildlife species 
within the SNP which have included a jackal, bat-eared fox, aardwolf, civet and 
leopards  (Lembo et al., 2008). There have been few reported cases of rabies 
infection in lions globally (Berry, 1993, Pfukenyi et al., 2009), with reported 
cases from Namibia being directly attributed to hunting infected prey (Berry, 
1993). East et al. (2001) have described rabies VNAb in spotted hyenas in the 
SNP with the absence of clinical disease. We hypothesise that due to similar 
ecosystems and prey species, lions may also show evidence of natural, non-fatal, 
rabies exposure.  
Lion sera (n=71) collected between 1997 and 2005 from animals within the SNP 
were tested for rabies VNAb by pNT. The characteristics of the lions tested in 
this study are presented in Table 4.3. Rabies VNAb titres ≥40 were considered 
evidence of rabies exposure in this study. The overall seroprevalence of rabies 
VNAb in lions was 20% (95% CI 11-31%), with titres in rabies VNAb positive lions 
ranging from 40 to ≥640, the highest recordable titre on the rabies virus pNT 
(Figure 4.5). Lion samples with VNAb were collected over many different years, 
with 21% of female lions and 12% of males seropositive.  
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Year Age Total 
 1-3 y 3-5 y 5+ y Unknown  
1997 - 1 (100) 5 (20) 3 (67) 9 
1998 11 (64) 6 (50) 4 (50) 4 (33)* 
25 
1999 - 1 (0) 3 (0) 1 (0) 
5 
2000 - 1 (100) - 1 (0) 
2 
2002 - - - 1 (0) 
1 
2003 - 5 (0) 5 (20) 4 (50)** 
14 
2004 7 (71) 2 (0) 1 (0) 3 (0) 
13 
2005 - - 2 (0) - 
2 
 18 16 20 17 71 
 
Table 4.3 Year of sampling, sex and age data of lions tested for rabies 
VNAb in this study. Lion samples collected opportunistically from the Serengeti 
National Park between 1997 and 2005 were tested for rabies VNAb in this study. 
Lion populations have been monitored in the Serengeti since 1966 and most lions 
in this study have been observed since birth so exact age data were collected, 
lions without exact ages were classified as unknown. Numbers in brackets 
represent the percentage of male lions, values were calculated based on the 
total number of lions of known sex, *indicates that the sex of one or **two lions 
in the group were unknown.    
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Figure 4.5 Rabies virus neutralising antibody titres of Serengeti lions. Lion 
samples collected between 1997 and 2005 were tested for rabies VNAb using the 
pNT. The red dashed line represents a titre of 40, the cut-off in this study for 
seropositivity to rabies virus. A subset of these samples was tested by Lynne 
Ferguson as part of a Masters project.    
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4.2.3 Investigating the virus neutralising antibody response to rabies vaccination 
in Kenyan slum dogs 
Rabies vaccination of dogs in endemic areas is critical for controlling rabies, 
however the effectiveness of the vaccine in field conditions is poorly 
understood. Various individual level factors, such as malnutrition, may affect the 
serological response and duration of immunity (Morters et al., 2014a).  In this 
study we utilise the rabies virus pNT to assess the VNAb response to rabies 
vaccination in a cohort of Kenyan slum dogs.   
A large study, conducted in 2007, in which 637 dogs were sampled over the 
course of approximately 14 months, was undertaken to assess the use of dogs in 
Kenya as sentinels of infectious diseases (Halliday, 2010). Dogs were recruited 
from the informal settlement of Kibera in Nairobi, Kenya (Figure 4.6). Dogs in 
the study were classified as owned but were free-roaming, which is common 
place in slums such as Kibera (Morters et al., 2014b, Makau et al., 2015). As an 
incentive to dog owners to participate in the study, dogs were vaccinated 
against rabies virus at enrolment. This vaccination did not form part of the 
original study but with the development of the rabies virus pNT we were able to 
use these stored serum samples to explore the response to rabies vaccination in 
these dogs over the 14-month time period.  
A total of 7 visits were made during the study period and attempts to collect 
serum samples from all recruited dogs were made at each visit. For this study, 
dogs were included if at least six serum samples had been collected over the 
course of the original study (n=67). The longitudinal nature of the original study 
not only allowed us to assess the immunological response to rabies vaccination 
but also to analyse the kinetics of rabies VNAb over time. In addition to serum 
samples being collected at each visit, in depth epidemiological data was also 
recorded at each time point.  
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Figure 4.6 Map of Kenya illustrating the location of the Kibera study site.  
 
 
The Kibera study site was sub divided into 10 clusters (Figure 4.7) and each dog 
in the study was assigned to a cluster based on their household location. A total 
of 67 dogs were included in this study each having 5 (n=1), 6 (n=36) or 7 (n=30) 
serum samples collected during the original study (one sample was missing from 
dog #160 therefore only 5 samples were available for this dog). Serum samples 
and epidemiological information was collected at each time point (tp), data 
collected from dogs included dog identifier, age, sex, cluster, body condition, 
whether dogs were from a single or multi-dog household and the date of sample 
collection. Age, sex and cluster of the dogs included in this study are described 
in Table 4.4. Males and females were fairly evenly represented in the study 
cohort with 54% of dogs being male. The majority of the dogs in the study were 
adults, with only 15 (22%) dogs aged less than one year at enrolment. Age was 
reported by the owner at enrolment and ages were extrapolated from this point 
throughout the study. Dogs were grouped into age categories of 3-6 m, 6-12 m, 
1-4 y, 4+ y, or Adult where no specific age was given but the dog was not 
juvenile. Body condition was measured on a scale of 1-5 where 1 is thin, 3 is 
ideal and 5 is obese (GFAH, 2007). 
Nairobi 
Mombasa 
Kisumu 
Kibera slum 
KENYA 
ETHIOPIA 
TANZANIA 
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At initial enrolment (tp 0) serum samples were collected immediately prior to 
rabies vaccination being administered to all dogs in the study; further samples 
were then collected at tp 1-6. Serum samples collected at tp 0-4 were spaced at 
approximately 28 day intervals, there was then a gap of approximately 9 
months, after which samples at tp 5 and 6 were collected, again with 
approximately 28 days between sampling. Households were visited in a similar 
order at each time point therefore the number of days between sampling was 
similar for each dog. Not all dogs were available for sampling at every visit, a 
total of 431 samples were included in this study (Table 4.5). Each sample 
collected was tested for rabies VNAb by pNT. Samples from the same dog were 
tested on the same assay run to reduce inter-assay variation between VNAb 
measurements from the same dog. Samples were initially tested at serum 
dilutions of 1:10 to 1:640. Samples with a VNAb titre of ≥640, the highest 
measurable titre on the assay, were repeat tested with increasing serum 
dilutions up to 1:40960, therefore the highest recordable VNAb titre in this 
cohort was ≥40960. Samples that were negative at the first dilution of 1:10 were 
recorded as having a rabies VNAb titre of <10. For statistical analysis these 
samples were assigned an arbitrary rabies VNAb titre of 1. 
 
 
 
 
 
 
 
 
Figure 4.7 Map demonstrating Kibera study site clusters. The Kibera study 
site was divided into 10 clusters based on existing geographical boundaries. Each 
dog in the study was assigned to a cluster based on the location of the owner’s 
household. Figure adapted from the original map created by the Kenya Bureau of 
Statistics.  
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    Age   Total 
C
lu
st
e
r 
 3-6 m 6-12 m 1-4 y 4+ y Adult  
1 - - - 4 (50) - 4 (50) 
2 4 (75) 2 (100) 3 (67) 4 (75) 6 (50) 19 (68) 
3 1 (0) - - 1 (100) - 2 (50) 
4 2 (50) - 1 (100) 1 (100) 3 (0) 7 (43) 
5 1 (100) 1 (100) - 3 (67) 3 (33) 8 (63) 
6 1 (0) 3 (67) 2 (50) 1 (100) 6 (17) 13 (38) 
7 - - - 1 (100) 1 (0) 2 (50) 
8 - - 1 (0) 2 (100) 1 (0) 4 (50) 
9 - - 1 (0) - 2 (50) 3 (33) 
10 - - 2 (0) 1 (100) 2 (100) 5 (60) 
Total  9 (56) 6 (83) 10 (40) 18 (78) 24 (33) 67 (54) 
 
Table 4.4 Characteristics of dogs enrolled in this study. Distribution of dogs 
in the study based on cluster, sex and age at enrolment. Numbers in brackets 
represent the percentage of male dogs. 
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Time point 
Days post 
vaccine 
Number of 
dogs sampled 
Median titre Titre range 
0 0 67 40 <10-320 
1 28-29 65 2560 40-≥40960 
2 56-57 65 320 20-20480 
3 84-90 63 160 20-2560 
4 113-118 49 160 10-2560 
5 369-403 62 80 <10-320 
6 397-438 60 160 10-≥40960 
Total number of samples 431   
 
Table 4.5 Distribution of sample data for each time point in the study. 
Serum samples were collected from dogs at enrolment prior to administration of 
rabies vaccine and then at a further 6 time points post vaccination. Not all dogs 
were available for sampling at every time point. 
 
 
4.2.3.1 Pre-vaccination rabies virus neutralising antibody titres in dogs 
As a baseline value rabies VNAb titres were measured in dogs at tp 0, collected 
immediately prior to vaccination.  Thirty four (51%) of the dogs in this study had 
a pre-vaccination titre of ≥40, the VNAb titre in the rabies virus pNT which 
corresponds to ≥0.5 IU/ml (the titre considered protective). Two dogs had titres 
as high as 320 (Figure 4.8). Rabies VNAb titres in unvaccinated slum dogs was 
unexpected as all dogs included in this study were recorded as having never 
received a rabies vaccination, and rabies vaccination campaigns had not been 
conducted in the area prior to the study. To consider whether this finding was an 
artefact of the pNT, we tested 30 serum samples from UK dogs as a comparison. 
Of these samples, 29 had rabies VNAb titres of <10, the lowest recordable titre 
on the rabies virus pNT and one sample had a rabies VNAb titre of ≥640. It is 
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likely that the sample with the very high rabies VNAb titre is from a dog 
vaccinated against rabies, although as the samples were anonymised prior to 
testing we were unable to confirm this. The lack of rabies VNAb titres in the UK 
dogs increased our confidence that the rabies VNAb titres observed in the 
unvaccinated Kenyan dogs were genuine and not an artefact of the assay. As the 
MLV(VSV) control pseudotype was also included in our assay we could be 
confident that these rabies VNAb titres were not the result of non-specific 
neutralising activity. 
.  
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Figure 4.8 Rabies virus neutralising antibody titres in pre-vaccination 
samples. Rabies VNAb titres were measured in dog sera collected immediately 
prior to rabies vaccination (n=67). The dashed line represents the titre 
considered to be protective against rabies virus challenge (≥40). 
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The rabies VNAb titres detected in reportedly unvaccinated dogs from the Kibera 
study site may be the result of natural exposure to rabies virus in these dogs, or 
possibly the detection of cross-neutralising antibodies to other lyssaviruses or 
even other pathogens. We cannot rule out owners incorrectly reporting 
vaccination status of the dog, however, we consider it unlikely that many dogs in 
this community would have previously received rabies vaccination. Furthermore, 
these results are consistent with reports of rabies VNAb in previously 
unvaccinated dogs elsewhere in rabies endemic settings in Africa (Morters et al., 
2014b, Cleaveland et al., 1999, McNabb, 2008). 
4.2.3.2 Kinetics of rabies virus neutralising antibody in vaccinated dogs 
Dogs were followed for over one year. The median rabies VNAb titres increased 
sharply between pre-vaccination (tp 0) and 28 d post vaccination sampling (tp 1) 
and then declined from tp 1 to tp 5 (Figure 4.9 and Figure 4.10).  
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Figure 4.9 Variation in rabies virus neutralising antibody titre at each 
time point from pre-vaccination to approximately 1 year post vaccination. 
Tukey’s boxplot demonstrating median, upper and lower quartiles of rabies 
VNAb titres for all dogs sampled at time points 0-5. Whiskers represent 1.5x 
interquartile range and circles represent outliers (n=371). 
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Figure 4.10 Rabies virus neutralising antibody titres for individual dogs 
from pre-vaccination to approximately 1 year post vaccination. Rabies 
VNAb titres of all dogs in the study for which a serum sample was collected at 
time point 1 (n=65). Individual dogs are represented by dashed lines and circles 
indicate day of sampling. The median titre is represented by the solid black line.  
 
 
All dogs, except one, demonstrated an increase in rabies VNAb titre from the 
pre-vaccination titre to the 28 d post vaccination titre; the dog that did not 
exhibit an increase in titre had a titre of 320 at both tp 0 and tp 1. At 28 d post 
vaccination all dogs achieved a rabies VNAb titre of at least 40, which in this 
assay is equivalent to the 0.5 IU/ml considered protective against rabies virus 
challenge. However, there was significant variation in rabies VNAb titre between 
dogs at tp 1, with titres ranging from 40 to ≥40960 with a median titre of 2560 
(Figure 4.9).  
Variation in the magnitude of VNAb response to rabies vaccination in these dogs 
was investigated using general linear models. The difference in log titre between 
tp 0 and tp 1 VNAb titres was used as the response variable (hereafter referred 
to as magnitude of response). Log titre at pre-vaccination sampling (tp 0) was 
tested as a continuous explanatory variable. Sex, condition, and age 
(categorised into 3-6 m, 6-12 m and >12 m) at vaccination were considered as 
categorical explanatory variables. Interactions between pre-vaccination titre 
and each of the categorical variables were also tested. Interactions between 
categorical variables were not considered, as a high proportion of combinations 
of levels had either no or very few observations. All dogs with complete 
information for all variables were included in the model (n=61), three dogs were 
excluded from the model as there was no condition recorded at the time of 
vaccination and one dog was excluded as the magnitude of response was zero. 
Under a backward elimination procedure, nested models were compared using 
likelihood ratio tests to determine which of the explanatory variables should be 
included in the final model (Table 4.6). Model selection indicated that pre-
vaccination titre (p<10-10) and dog condition (p<0.005) were significantly 
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correlated with the magnitude of response to rabies vaccination, this optimal 
model is represented in Figure 4.11. A negative relationship was observed 
between pre-vaccination titre and the magnitude of response to vaccination 
(Figure 4.12), with an increase in pre-vaccination titre of 1 log resulting in a 
reduced response to vaccination of 0.96 log on average (95% CI 0.72 - 1.19). The 
magnitude of response to vaccination for dogs of condition 2 or 3 was higher 
than of condition 1 dogs. After accounting for variation in response attributable 
to differences in pre-vaccination titre, condition 2 dogs exhibited a response to 
vaccination 2.14 log higher than condition 1 dogs (95% CI 0.87-3.42) and 
condition 3 dogs showed a response 1.56 higher than condition 1 dogs (95% CI 
0.27-2.84). Confidence intervals for the coefficients for conditions 2 and 3 
overlapped considerably indicating that dogs of these conditions did not react 
significantly differently to vaccination. The coefficient of determination for this 
model (R2=0.57) indicated that pre-vaccination titre and condition at vaccination 
explained a considerable amount of the variation in the magnitude of VNAb 
response. 
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Model AIC 
Log 
likelihood 
Degrees of 
freedom p-value 
T0+S+C+A+(T0*S)+(T0*C)+(T0*A) 231.2 -102.6 13 0.907 
T0+S+C+A+(T0*S)+(T0*A) 227.5 -102.7 11 0.192 
T0+S+C+A+(T0*A) 227.5 -103.8 10 0.374 
T0+C+A+(T0*A) 226.5 -104.2 9 0.600 
T0+C+A 223.6 -104.8 7 0.433 
T0+C 221.5 -105.7 5 0.005 
T0 228.9 -111.4 3 1.53-10 
Intercept model 269.6 -132.8 2 - 
 
Table 4.6 Values associated with model selection used to derive the 
model of magnitude of response to rabies vaccination. Model formulae 
demonstrate variables included in the model (T0=pre-vaccination titre, S=sex, 
C=condition, and A=age, interaction variables take the form (T0*S)). For each 
model, AIC, log likelihood and degrees of freedom used in the model are shown. 
p-values are shown for the emboldened and underlined term in each model. 
These were derived from likelihood ratio tests between the model shown inline 
and the nested model below.  
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Figure 4.11 Variation in magnitude of response to vaccination. Increase in 
rabies VNAb titre plotted against pre-vaccination titre. A small amount of 
random displacement in the x-axis has been added to the position of points to 
allow visualisation of overlapping data points. Dog condition at vaccination is 
indicated by colour (1=black, 2=red, 3=green). Lines indicate the fitted values 
from a general linear model with parameters for pre-vaccination titre and 
condition at vaccination. 
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Figure 4.12 Magnitude of rabies virus neutralising antibody response at 28 
days post vaccination in relation to pre-vaccination virus neutralising 
antibody titre. The magnitude of vaccine response was calculated using the 
fold increase in the log value of the VNAb titre at time point 1 compared to the 
log value of the pre-vaccination titre (tp 0) (n=65). Bars are coloured relating to 
their pre-vaccination VNAb titre.  
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The range of titres at tp 5 (approximately 1 year post vaccination) resembled 
pre-vaccination titres (Figure 4.9), ranging from <10-320 with a median titre of 
80 (Figure 4.13). Fifty two dogs (84%) in the study had a rabies VNAb titre of ≥40 
at tp 5, equivalent to a titre considered adequate protection against rabies 
challenge. However, using this cut-off ten dogs would be considered to have an 
inadequate rabies VNAb titre at 1 year post vaccination.   
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Figure 4.13 Rabies virus neutralising antibody titres for dogs in the study 
at approximately one year post vaccination. Rabies VNAb titres for dogs in 
the study, for which a sample was collected at time point 5 (n=62), which 
ranged from 369-403 days post vaccination. The dashed line represents the titre 
considered to be protective against rabies virus challenge (≥40). 
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A generalised linear model was used to test a variety of biologically plausible 
explanatory variables as predictors of a protective antibody response at 1 year 
post vaccination. Dogs were classified as protected (VNAb titre ≥40) or not 
protected (VNAb titre <40) at tp 5 and this binary value was modelled as the 
response variable. Log titre at 28 d post vaccination (tp 1) was tested as a 
continuous explanatory variable. Sex, condition, and age (categorised into 3-6 
m, 6-12 m and >12 m) at vaccination were considered as categorical explanatory 
variables. Once again interactions between categorical variables were not tested 
due to high proportions of level combinations with zero or very few 
observations. Given that the interaction term between tp 1 titre and categorical 
variables resulted in fitted probabilities of 0 or 1, these interaction terms were 
not included in the model. All dogs with complete information for all variables 
were included in the model (n=57). Nested models were compared using 
likelihood ratio tests to determine which of the explanatory variables should be 
included in the final model. There were no statistically significant variables in 
this model that predicted protection (VNAb titre ≥40) at tp 5. The same 
explanatory variables were tested again using a general linear model with the 
binary response variable (protected/not protected) replaced by log titre at tp 5. 
In this model VNAb titre at tp 1 was statistically significant (p<0.05). On 
average, an increase of 1 in log titre at tp 1 resulted in a 0.32 increase in log 
titre at tp 5 (95% CI 0.07-0.57), however the relationship between titre at tp 1 
and tp 5 explained only a very small proportion of the observed variation in titre 
at tp 5 (R2=0.087). The rabies VNAb titres in the 10 dogs in this study considered 
not protected at tp 5 are shown in Table 4.7. 
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Dog ID Age Sex Condition 
Time point 
5 titre 
Time point 
0 titre 
Time point 
1 titre 
29 Adult F 2 <10 <10 ND 
76 Adult F 2 <10 20 320 
103 3-6 m M 1 <10 <10 160 
112 4+ y M 3 20 40 5120 
114 4+ y M 2 10 <10 10240 
122 Adult M 3 <10 <10 5120 
140 4+ y F 3 10 40 5120 
185 Adult M 3 20 10 640 
207 Adult F 2 20 20 1280 
217 Adult M 2 20 20 2560 
 
Table 4.7 Characteristics of dogs with rabies virus neutralising antibody 
titres of <40 at approximately 1 year post vaccination. Data regarding age, 
condition, pre-vaccination and 28 d rabies VNAb titre for dogs which had a rabies 
VNAb titre of <40 (n=10) at time point 5 (ranging from 393-400 days post 
vaccination in these dogs). Age and condition data represents classification of 
the dog at the time of vaccination. ND=not done. 
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4.2.3.3 Repeatability of the pseudotype neutralisation test and use of the VSV 
control in field samples 
In Chapter 3 we tested a small number of serum samples (n=12) in duplicate to 
assess the robustness of the rabies virus pNT. To improve our confidence in the 
reproducibility of the assay, in this study we retested a further 47 serum 
samples with varying titres ranging from <10 to 10240. Samples were tested on a 
different day using a new batch of MLV(rabies) pseudotype. Twenty-three 
samples had identical rabies VNAb titres on repeat testing, 23 samples had a 
titre that varied by one dilution and one sample was three dilutions higher on 
repeat testing (Figure 4.14). A high degree of correlation of VNAb titres was 
observed between the assays performed on different days (n=47, R2=0.83, 
p<0.0001). Utilising a cut-off of 40 to classify titres as protective or not 
protective, three of the 47 samples had discordant test results between assays. 
These three samples would have been classified as negative for rabies VNAb on 
the first test but positive on the second assay. These samples all measured 40 on 
secondary testing and were therefore at the lowest titre considered positive.    
In the rabies virus pNT each serum sample is additionally tested against VSV. If 
the rabies VNAb titre is >20 and the VSV titre is ≥40, the sample is repeat tested 
against MLV(VSV) pseudotypes at higher serum dilutions, in order to detect non-
specific neutralisation which is a documented cause of false positivity in the VNT 
(Mani and Madhusudana, 2013). In this study it was necessary to perform further 
MLV(VSV) pseudotype testing on four (0.9%) of the Kenyan dog samples (#121, 
#231, #256 tp 2 and #256 tp 3). Three samples had VSV titres of 40 on repeat 
testing (#121, #231, #256 tp 2) with rabies VNAb titres of 160, 320 and 20480 
respectively.  Sample #256 tp 3 had a VSV VNAb titre of 80 (rabies VNAb titre 
2560). In each case the rabies VNAb titre was at least four-fold higher than VSV, 
therefore we can deduce that the rabies titres recorded are genuine, as any 
non-specificity had been diluted out. 
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Figure 4.14 Repeatability of the rabies virus pseudotype neutralisation 
test. A selection of serum samples were tested twice for VNAb by the rabies 
virus pNT to determine the repeatability of the assay (n=47, R2=0.83, p<0.0001) . 
Coefficient of determination and p-values were calculated using Pearson’s 
product-moment correlation. 
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4.2.3.4 Evidence of natural exposure to rabies virus over the course of the study 
Final serum samples were collected in the study at tp 6, prior to a booster rabies 
vaccination being administered to a subset of dogs in the study group. These 
samples were collected between 397-438 days post initial vaccination. At this 
time point, 25% of dogs (n=15) had a four-fold or greater increase in rabies VNAb 
titre compared to tp 5 titres (Figure 4.15), suggesting a re-exposure to rabies 
antigen. In these dogs the fold increase in titre between tp 5 and 6 ranged from 
4-fold to 10240-fold (Table 4.8). A four-fold increase in titre was not seen at any 
other time point in the study other than at initial seroconversion to rabies 
vaccination, with the exception of two dogs (#07 and #276) whose titres peaked 
at day 56 as opposed to day 28. There were no recorded rabies booster 
vaccinations administered to these dogs in the detailed epidemiological 
information collected in the study, suggesting that the increase in rabies VNAb 
titre is likely to be from a natural exposure to rabies virus. In a genuine 
anamnestic immune response the VNAb titre on secondary exposure would be 
expected to be greater than at primary vaccination (Zhang et al., 2011, 
Derbyshire and Mathews, 1984), 8/13 (62%) of these dogs had a higher VNAb titre 
at tp 6 than at tp 1 (two dogs were excluded from analysis as they did not have 
rabies VNAb titres measured at tp 1).  
 
       14
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Figure 4.15 Rabies virus neutralising antibody titres of dogs from pre-
vaccination to time point 6. Titres of all dogs (n=67) at each time point in 
the study (n=431). Individual dogs are represented by dashed lines, circles 
indicate day of sampling, dogs which had a four-fold or greater increase in 
titre between time point 5 and 6, and a titre of ≥40 at tp 6 are displayed by 
red dashed lines (n=15). 
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Dog ID Age Sex Condition Cluster 
Multi-dog 
household 
Time point 
0 titre 
Time point 
1 titre 
Time point 
0-1 fold 
increase 
Time point 
5 titre 
Time point 
6 titre 
Time point 
5-6 fold 
increase 
12 1-4 y M 3 2 Y 80 1280 16 320 20480 64 
57 4+ y M 2 4 N 320 ND - 160 5120 32 
91 1-4 y M 2 5 N 320 320 1 40 5120 128 
116 Adult M 3 10 N 40 2560 64 40 160 4 
122 Adult M 3 9 Y <10 5120 5120 <10 10240 10240 
148 4+ y M 2 8 N 20 2560 128 160 ≥40960 256 
157* 4+ y M 3 5 Y 10 1280 128 320 ≥40960 128 
158* 4+ y M 3 5 Y 40 1280 32 160 10240 64 
162 Adult F 2 7 N <10 ND - 40 640 16 
174 4+ y M 2 6 Y 10 20480 2048 80 320 4 
244 Adult F 2 6 N 80 5120 64 320 1280 4 
247 1-4 y F 2 6 N 40 10240 256 320 5120 16 
260 Adult F 1 6 N 80 2560 32 40 160 4 
265** Adult F 2 6 Y 160 320 2 80 1280 16 
266** Adult F 2 6 Y 80 160 2 80 ≥40960 512 
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Table 4.8 Characteristics of dogs with a four-fold or greater increase in 
rabies virus neutralising antibody titre between time point 5 and time 
point 6. Data for dogs which had a four-fold or greater increase in rabies VNAb 
titre between time point 5 (369-403 days post vaccination) and time point 6 
(397-438 days post vaccination). Age represents the age category of the dog at 
time point 6. ND=not done. * and ** denote pairs of dogs from the same 
household.  
 
 
Evidence of natural exposure to rabies virus in these dogs is strengthened by the 
clustering of these high titre dogs relative to their household location with three 
dogs in cluster 5, two dogs in cluster 6 and one dog from clusters 2, 8 and 9 
(Figure 4.16). Additionally, two pairs of dogs (dogs #157 and #158, and dogs #265 
and #266) who demonstrated an anamnestic response at tp 6 were from the 
same household, one pair from cluster 5 and one from cluster 6, possibly 
suggesting that these dogs were exposed to rabies antigen from the same 
source. 
 
a) 
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b) 
 
Figure 4.16 Heat maps of dogs with a four-fold or greater increase in 
rabies virus neutralising antibody titres between time point 5 and time 
point 6. Heat maps representing the household clusters of study dogs from the 
Kibera slum. a) Percentage of dogs per cluster with a four-fold or greater 
increase in rabies VNAb titre between time point 5 and 6 (15/60) b) Percentage 
of dogs per cluster with a four-fold or greater increase in rabies VNAb titre 
between time point 5 and 6, and a rabies VNAb titre greater at time point 6 than 
at time point 1 (8/13). 
 
 
4.2.3.5 Cross-neutralisation of virus neutralising antibody elicited by rabies 
vaccination against different lyssavirus pseudotypes  
Dogs in the study were vaccinated using a monovalent inactivated rabies virus 
vaccine (Rabisin, Merial). To investigate whether the VNAb elicited following 
vaccination would cross-neutralise other members of the Lyssavirus genus, eight 
serum samples collected 28 d post vaccination were tested for VNAb using six 
other MLV(lyssavirus) pseudotypes; LBV, MOKV, DUVV, EBLV-1, EBLV-2 and ABLV. 
Figure 4.17 demonstrates cross-neutralising activity of the dog serum against all 
phylogroup 1 lyssaviruses, with the VNAb titres to each lyssavirus generally 
correlating to the amino acid similarity of that virus to rabies virus (Table 4.9). 
All serum samples achieved a VNAb titre of ≥40 for all phylogroup 1 lyssaviruses 
>40% 
 
20-40% 
 
<20% 
 
0%  
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and all samples had a VNAb titre to the phylogroup 2 lyssaviruses (LBV, MOKV) of 
≤20, with the exception of one serum sample (#247) which had a VNAb titre of 
40 to LBV. Dogs with the highest rabies VNAb titre generally had the highest 
VNAb titres to other phylogroup 1 lyssaviruses (Figures 4.17 and 4.18).  
 
 
Amino acid similarity to rabies virus (%) 
Phylogroup 1 
ABLV 68 
EBLV-2 67 
EBLV-1 63 
DUVV 61 
Phylogroup 2 
LBV 46 
MOKV 44 
 
Table 4.9 Amino acid similarities between the ectodomain of the rabies 
virus glycoprotein and the ectodomain of six other lyssavirus species. The 
amino acid sequences of the strains of lyssaviruses used to produce the 
pseudotypes in this study were compared by pairwise analysis using a maximum 
composite likelihood model in MEGA6 (Tamura et al., 2013).  
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Figure 4.17 Comparison of rabies virus neutralising antibody titre and 
titres against other lyssaviruses in dogs vaccinated against rabies virus. 
Serum from dogs 28 d post rabies vaccination (n=8) were tested for VNAb against 
phylogroup 1 lyssaviruses: rabies virus, DUVV, EBLV-1, EBLV-2, ABLV; and 
phylogroup 2 lyssaviruses: LBV, MOKV. A small amount of random displacement 
in both axes has been added to the position of points to allow visualisation of 
overlapping data points. Solid line represents a titre of 40.   
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Figure 4.18 Virus neutralising antibody titre to 7 lyssaviruses in dogs 
vaccinated against rabies virus. Serum from dogs vaccinated against rabies 
virus was tested for VNAb at 28 d post vaccination (n=8). These samples were 
tested by pNT for VNAb against rabies virus, LBV, MOKV, DUVV, EBLV-1, EBLV-2 
and ABLV. Lyssaviruses on X-axis are ordered by decreasing amino acid similarity 
to rabies virus as calculated in Table 4.9. 
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4.3 Discussion  
The three serosurveys presented in this Chapter demonstrate the practical 
application of the pNT. In total we tested 705 samples from 18 different species 
for rabies VNAb. Only a small proportion of samples (n=9) tested were 
inconclusive by rabies virus pNT, all of which were wildlife samples. Inconclusive 
results were due to cytotoxicity, sample haemolysis or non-specific 
fluorescence. It is well documented in the literature that cytotoxicity and 
haemolysis commonly affect VNTs (Shiraishi et al., 2014a). Cytotoxicity affects 
the viability of the cell monolayer, pseudotypes therefore cannot infect cells 
and the pNT cannot be interpreted. Haemolysis is due to the degradation of 
erythrocytes, causing the release of haemoglobin and other cellular components 
into plasma which can cause non-specific inhibition of virus. Fragments of 
degraded erythrocytes can also obscure the cell monolayer in the pNT and 
haemolysed samples can negatively affect many laboratory assays, not only VNTs 
(Lippi et al., 2006). Haemolysis can occur in vivo or in vitro and is more common 
in wildlife samples due to poor quality serum being collected under challenging 
field conditions or when collected post-mortem (Boadella and Gortázar, 2011). 
Therefore visual inspection of serum samples should be performed routinely 
prior to testing using the rabies virus pNT.      
A limitation of our assay is the lack of inclusion of the OIE reference serum, 
which is required to convert the highest dilution of serum achieving 
neutralisation into the internationally accepted unit for rabies VNAb titre 
(IU/ml). Our results are therefore recorded as simply the reciprocal of the 
highest dilution at which neutralisation occurred. It would have been preferable 
to have converted our titres to IU/ml to make our results directly comparable to 
other studies, this would be particularly useful regarding the measurement of 
cross-neutralising antibodies. The 0.5 IU/ml threshold is the titre considered 
protective in vaccinees but is itself a rather arbitrary value and warrants further 
critical discussion in Chapter 7. The VNAb titre employed as evidence of natural 
exposure to rabies virus is variable among studies, ranging from 0.06 IU/ml to 
0.8 IU/ml (Ellison et al., 2014, Reynes et al., 2004). The Advisory Committee on 
Immunisation Practices suggest sera that completely neutralises rabies virus at a 
dilution of 1:5 should be considered positive for rabies-specific VNAb (ACIP, 
1999), although non-specific inhibition at such low titres have been documented 
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in the literature (WHO, 2007, EFSA, 2006, Mani and Madhusudana, 2013). 
Therefore it has been suggested that a more conservative dilution of 1:25 should 
be considered positive (Gilbert et al., 2012). The results obtained from our study 
on the Russian wildlife sera support such a suggestion, with rabies VNAb titres of 
1:20 proving negative when tested by the FAVN test. It is possible that the level 
of rabies VNAb present in natural exposure could be less than the threshold of 
1:40 employed in this study but due to the possibility of false-positives we 
concluded a conservative cut-off of 40 was appropriate, as in these serosurveys 
we considered specificity to be more important than sensitivity.  
There were no seropositive samples amongst the sera collected from the Russian 
Far East. No cases of rabies have been officially documented in the Primorsky 
Krai region of the Russian Far East in the last 10 years (Miquelle and Murzin, 
2003), therefore the results presented in this study are consistent with these 
data. There was a fatal case of rabies caused by Irkut virus, a phylogroup 1 
lyssavirus (Liu et al., 2013), in a girl in the region in 2007 after contact with a 
bat (Leonova et al., 2009). As cross-neutralisation across the phylogroup 1 
lyssaviruses is well documented, knowledge of circulating lyssaviruses in the 
region would be an important consideration for interpretation of seropositive 
results. If we had detected positive serology in the Russian samples, the serum 
should have been further tested for neutralisation against any other circulating 
lyssaviruses, the virus with the highest VNAb titre would be assumed to be the 
primary inducing antigen. Such tests would be easy to perform on the pNT as the 
only difference in the protocol would be the alteration of the glycoprotein gene 
included during transfection.        
The lion serology from the SNP, was in stark contrast to the negative serology of 
the Russian Far East, with an overall seroprevalence of 20%. Berentsen et al. 
(2013) described rabies VNAb titres in 37% of lions tested in Zambia and reported 
no clinical disease in these animals . In their study samples were tested by RFFIT 
using a threshold of 0.2 IU/ml as evidence of seropositivity, regardless of this 
low cut-off 63% of these lions had titres ≥0.5 IU/ml. Additionally, a further study 
screening 149 lions from Tanzania, Botswana and Zimbabwe, showed an overall 
seroprevalence of around 13% (Monique Léchenne, 2016, personal 
communication). Moreover, evidence of seroconversion to rabies virus in these 
lions was also reported from the same study. The results of our study suggest a 
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proportion of lions in the SNP have been exposed to rabies virus, further 
contributing to evidence of rabies VNAb titres in African lions presented in 
previous studies. Lembo et al. (2008) report rabies cases in other wildlife species 
in the SNP in years correlating to the seropositive lions in our studies, further 
supporting these results. The route of virus exposure in lions is unknown and 
could be related to hunting infected prey, as lions typically suffocate or strangle 
their prey, bringing the lion’s mouth and eyes in contact with infected saliva 
(Berry, 1993), or due to ingestion of infected prey. Alternatively, lions could 
become exposed due to social licking and biting as suggested by East et al. 
(2001) in hyenas, or indeed lions could be bitten by a rabid animal, which is the 
most common route of rabies virus infection.   
The study of the cohort of dogs from Kibera was intended to provide in depth 
serological data on the VNAb response to rabies vaccination in free-roaming dogs 
in a rabies endemic setting. There have been previous studies regarding response 
to rabies vaccine, however most have focused on experimental dogs (Hu et al., 
2008, Shiraishi et al., 2014b) or domestic animals from non-endemic 
communities (Berndtsson et al., 2011) and concerns have been raised over 
whether such immune responses would be mimicked in free-roaming dogs.  In 
Africa where dogs are the primary reservoir of rabies, mass dog vaccination is 
critical for rabies elimination. It has been estimated that levels of only 20-45% 
vaccination coverage could be required to eradicate rabies (Hampson et al., 
2009), this figure is highly achievable but in resource limited settings vaccination 
strategies must be used to the greatest effect. Our study aimed to provide data 
to improve evidence based vaccination policy in such settings. Morters et al. 
(2014a) have recently published a longitudinal serological study with cohorts 
similar to those presented herein, focusing on dogs from South Africa and 
Indonesia. The results of our longitudinal serosurvey support Morters’ study, 
demonstrating an initial rapid increase in rabies VNAb at seroconversion, a fairly 
swift decline to around day 60 and then a further gradual decline throughout the 
study.  
Our results demonstrate that all immunised dogs mount a protective antibody 
response to rabies at 4 weeks post vaccination regardless of age, sex or 
condition at vaccination. Although all dogs had a protective titre, there was 
significant variation in the magnitude of response to vaccination, we 
Chapter 4. Practical applications of lyssavirus pseudotype neutralisation tests                       151 
 
      14
6
 
investigated the source of this variation using statistical models. Our results 
complement previous studies conducted on rabies vaccine response 
demonstrating that sex and age are not significant factors in rabies vaccination 
response (Tepsumethanon et al., 1991, Morters et al., 2014a, Berndtsson et al., 
2011).  Our models suggest that a small amount of variation is attributed to the 
body condition of the dogs at vaccination, with dogs of poorest condition 
responding significantly less effectively than dogs with a condition score of 2 or 
3. However, the majority of the variation in the magnitude of vaccine response 
could be attributed to the pre-vaccination titre, with a high pre-vaccination titre 
being negatively correlated to the magnitude of response. We cannot find any 
other studies which consider the pre-vaccination rabies VNAb titre in vaccine 
naive dogs as an attributing factor to vaccine response, presumably as all 
vaccine naive dogs are assumed to be serologically negative. However, studies of 
bacterial vaccines have also reported a significant inverse relationship between 
pre-vaccination titre and antibody response (Hall et al., 2001). 
At one year post primary vaccination the majority of dogs retained a rabies VNAb 
titre of ≥40.  It has been suggested that rabies VNAb drops rapidly to insufficient 
levels in animals who do not mount an efficient initial vaccination response. Our 
models demonstrated that although the peak VNAb titre in these dogs accounted 
for a very small proportion of the variation in titre at one year, when this result 
was considered a binary value of ‘protected’ or ‘not protected’ there was no 
significant relationship. This observation is important when considering 
population coverage achieved in vaccination campaigns. Further studies of 
persistence of VNAb following booster vaccination would also be valuable data to 
consider in such a cohort.  
Although 0.5 IU/ml is considered the threshold of protection, many rabies 
challenge studies have reported previously vaccinated dogs with rabies VNAb 
titres below this threshold surviving challenge, whilst unvaccinated controls 
almost always succumb to the disease (Sikes et al., 1971, Brown et al., 1973). A 
challenge study by Lawson and Crawley (1972) demonstrates survival of dogs 
vaccinated five years previously despite 50% of these dogs having undetectable 
antibodies prior to challenge.  Hence the rate of protection in our dog cohort at 
one year post vaccination is likely to be an underestimate of true protection.  
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The work presented in this Chapter also demonstrates the utilisation of the pNT 
for non-rabies lyssaviruses, demonstrating the ability to measure neutralising 
activity to 7 different lyssaviruses. Our results support previous other studies 
demonstrating that vaccination with rabies virus elicits antibodies with cross-
neutralising activity against the other phylogroup 1 lyssaviruses but not against 
phylogroup 2 lyssaviruses (Reynes et al., 2004, Malerczyk et al., 2009, Wright et 
al., 2008, Badrane et al., 2001). There is no VNAb titre considered protective for 
non-rabies lyssaviruses but if we employ the accepted protective titre for rabies 
virus of 0.5 IU/ml (and the pNT equivalent cut-off of 40), all dogs tested would 
have an adequate VNAb response to protect from challenge with phylogroup 1 
lyssaviruses at 28 d post rabies vaccination. The level of neutralisation against 
each lyssavirus correlated to the amino acid sequence homology between the 
tested lyssavirus and rabies virus, demonstrating increased protection against 
the viruses with increasing genetic similarity to rabies virus, such antigenic 
relationships were was first described by Badrane et al. in 2001. These results 
strengthen the recommendations that individuals at risk of non-rabies 
lyssaviruses, such as bat handlers, are vaccinated with rabies vaccine and 
treated with rabies post-exposure immunoglobulin if a high risk exposure occurs 
(PHE, 2013). Protection against EBLV-2, a phylogroup 1 lyssavirus, is of particular 
importance in the UK as in 2002 there was a fatal case of EBLV-2 in Scotland in 
an unvaccinated bat handler (Nathwani et al., 2003), and EBLV-2 seropositivity 
has been reported in Scottish bats (Brookes et al., 2005a). As the VNAb activity 
to other phylogroup 1 lyssaviruses is less effective than for rabies virus, boosters 
may be required more frequently and further studies are necessary to determine 
the kinetics of rabies vaccination response to these lyssaviruses. Although the 
majority of sera from dogs immunised against rabies failed to neutralise the 
phylogroup 2 lyssaviruses one dog sample neutralised LBV at a titre of 40, this 
dog had the highest rabies VNAb titre (10240) of all dogs tested in the cross-
neutralisation experiment. Cross-neutralisation of LBV by rabies VNAb has also 
been documented in previous studies, especially when high VNAb against rabies 
are present (Morters et al., 2014a, Hanlon et al., 2005). Similar studies have also 
shown a low level of cross-neutralising activity of rabies VNAb against MOKV 
(Hanlon et al., 2005). There are no biologics designed specifically for phylogroup 
2 lyssaviruses, with the absence of any therapeutic agents for these viruses 
rabies vaccination and post-exposure immunoglobulins may be given in the hope 
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that a considerable immune response ensues and some cross-protection occurs. 
More research is required to further understand cross-neutralisation of non-
phylogroup 1 lyssaviruses and the pNT proves a good candidate for such 
experiments as they can be performed in any BSL-2 laboratory, at low cost, 
without risk to personnel.  
In addition to measuring the immune response to vaccination, we also measured 
pre-vaccination rabies VNAb titres in our dog cohort as a baseline to calculate 
the increase in titre between pre- and post-vaccination samples. Over half the 
dogs in our cohort had a pre-vaccination rabies VNAb titre of ≥40, which would 
be considered a protective antibody titre. Reports of rabies VNAb in previously 
unvaccinated dogs have also been documented in other serological studies from 
rabies endemic populations (Morters et al., 2014a, McNabb, 2008, Cleaveland et 
al., 1999). To further confirm the specificity of our assay we tested 30 serum 
samples from UK dogs and all but one sample gave the lowest recordable titre on 
the pNT. Dogs born in the UK are not the best control group, as these dogs are 
generally well cared for, non free-roaming and not in contact with the plethora 
of infectious diseases to which slum dogs are exposed. However, gaining serum 
samples from similar slum dogs from a rabies free location, although preferable, 
was unachievable. One of the major advantages of the pNT over the FAVN is that 
each sample is simultaneously tested for non-specific neutralising activity using 
the VSV control, hence we are confident that these pre-vaccination titres are 
genuine and not due to non-specific neutralisation.   
There are various potential explanations for the relatively high pre-vaccination 
titres observed in this study which include previous vaccination, detection of 
cross-neutralising antibodies, an inappropriate cut-off titre for use in this 
population or finally a genuine, natural past exposure to rabies antigen. The 
authors of the initial study are confident there were no previous rabies 
vaccination campaigns at the Kibera study site and as these dogs are slum dogs it 
is very unlikely they would have been privately vaccinated. The detection of 
cross-neutralising antibodies is a possible explanation for these pre-vaccination 
positives, and Duvenhage virus has been isolated from bats in Kenya (Van Eeden 
et al., 2011). Alternatively, the cut-off of 40 used in this study could be too low 
for this dog population, as the cut-off of 0.5 IU/ml is designed to demonstrate a 
Chapter 4. Practical applications of lyssavirus pseudotype neutralisation tests                       154 
 
      14
6
 
protective antibody titre post-vaccination in domestic dogs from non-endemic 
settings.  
A further possibility to consider is the potential for these dogs to have been 
naturally exposed and to have seroconverted to rabies virus. As the dogs were 
alive and well for at least one year after sampling, if natural infection had 
occurred it appears to have been without significant clinical symptoms. Such 
abortive infections are an accepted phenomenon of rabies infection in bats 
(Turmelle et al., 2010) and have also been demonstrated in humans (CDC, 2010) 
and experimentally infected mice (Vanag et al., 1981). In previously exposed 
dogs an anamnestic response would be expected upon vaccination, and this has 
been documented previously in Tanzanian dogs with low titres following 
presumed natural exposure (Cleaveland, 1996). However, as demonstrated in the 
general linear model this was not the case in all dogs in this study, with the five 
dogs not achieving a four-fold increase in titre at tp 1 all having pre-vaccination 
titres of >80. However, vaccination after natural exposure to rabies virus has not 
been studied and the response to re-exposure may be atypical, such atypical 
reactions have been observed in other RNA virus infections (Murtaugh and 
Genzow, 2011). 
Further evidence of natural exposure to rabies occurred at the final sampling 
point in the study, where an increase in VNAb titre was observed in a high 
proportion of the dog cohort, possibly indicating viral exposure. A four-fold 
increase in titre was seen at initial vaccination and tp 6 only, so this is unlikely 
to be an artefact of the assay or natural fluctuation in VNAb titres. There were 
no other known rabies vaccination campaigns during the study period and there 
was no record of rabies vaccination in the detailed epidemiological data 
collected along with the samples, therefore these responses are highly unlikely 
to be vaccine induced. The majority of these dogs demonstrated an anamnestic 
response however 38% did not, although as the date of any possible exposure is 
unknown we may have sampled at the start of the secondary immune response.  
The geographical clustering of the high titre dogs is also indicative of a central 
source of exposure, in addition to two pairs of dogs from the same households 
both experiencing increased titres. It would have been of interest to continue 
monitoring the antibody response in these dogs and to determine whether they 
were protected from disease, especially as one dog had an undetectable VNAb 
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titre at tp 5. The authors of the original study were not aware of any formal 
reports of rabies cases in Kibera during the study period, however this may be 
due to a lack of reporting or because all exposed dogs were protected through 
vaccination.  
A major finding in this Chapter is the evidence of rabies VNAb in both healthy 
lions and unvaccinated dogs, from rabies endemic settings. The significance of 
these results requires critical discussion. As previously mentioned rabies VNAb 
titres have been previously reported in unvaccinated dogs and wildlife, with 
VNAb to non-rabies lyssaviruses being reported in bat species globally (Brookes 
et al., 2005a, Hayman et al., 2008, Arguin et al., 2002, Pérez-Jordá et al., 1995, 
Markotter et al., 2013). Non-fatal rabies infection is an accepted outcome of 
rabies infection in bats, but such abortive infection in other species challenges 
the central theory that rabies infection is always fatal in terrestrial mammals. 
Gilbert et al. (2012) have described rabies VNAb in bat-exposed communities in 
Peru suggesting non-lethal rabies infections in humans. The value of titres in 
their study ranged from 0.1-2.8 IU/ml with most measuring around 0.5 IU/ml, 
however the majority of these samples were negative when tested for rabies 
ribonucleoprotein IgM and IgG by the fluorescent antibody test. Cleaveland et al. 
(1999) also reported high rabies VNAb titres in unvaccinated dogs in Tanzania 
when tested by RFFIT, but no detectable antibody when tested by nucleoprotein 
ELISA. The level of neutralising antibodies to rabies is considered the best 
correlate of protection (Johnson et al., 2010), therefore when measuring 
vaccination response VNTs are the method of choice. However, these previous 
studies may suggest that measuring rabies antibodies directed against the 
nucleoprotein may be a more specific indicator of natural rabies exposure than 
the neutralisation assay. In relation to our studies, if time and cost were not an 
issue, it would have been worthwhile re-testing the VNAb positive lion sera and 
the positive pre-vaccination dog sera on an alternative assay. Additionally for 
poor quality samples, such as some of the wildlife samples tested here, an ELISA 
is considered a superior alternative to neutralisation tests, as it is less affected 
by poor quality sera (Cliquet et al., 2000) and also requires a lower volume of 
sera, which in wildlife testing is preferable.   
The results reported in this Chapter demonstrate the practical applicability of 
the rabies virus pNT as a robust alternative to live virus neutralisation tests. The 
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wildlife serosurveys presented demonstrate the valuable results that can be 
obtained using the pNT, without relying on expensive assays which are restricted 
to very few specialised laboratories. Increasing the availability of these assays 
will undoubtedly improve our understanding of the ecology of rabies virus. The 
applicability of the pNT is increased by being easily adapted to measure VNAb to 
any of the lyssaviruses, demonstrated here using vaccinated dog sera. 
Furthermore, the results obtained in these three serosurveys gave results 
consistent with similar studies reported in the literature in which live virus 
neutralisation assays were employed.  
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 Chapter 5. Novel approaches to 
detecting neutralising antibodies to 
Rift Valley fever virus 
 
5.1 Introduction  
Rift Valley fever virus (RVFV) is an arbovirus from the Bunyaviridae family. RVFV 
causes a disease which predominantly affects ruminants, however it is also an 
important zoonotic infection. Although most RVFV infections in humans are 
asymptomatic (Ikegami and Makino, 2011), severe illness can occur which may 
progress to haemorrhagic fever and death (Peters et al., 1989, Anyangu et al., 
2010). In recent RVFV outbreaks human mortalities have reached several 
hundred (Kebede et al., 2010). The gold standard method for assessing exposure 
to RVFV is through detection of virus neutralising antibodies (VNAb) (OIE, 2012a). 
The virus neutralisation test (VNT) used for detecting RVF VNAb is the plaque 
reduction neutralisation test (PRNT). This assay requires test serum to be 
incubated with RVFV which is then incubated with a susceptible cell line and 
after 3-5 days the cell monolayer is examined for viral plaques. As RVFV is 
classified as a hazard group three pathogen, the PRNT must be performed at 
biosafety level 3 (BSL-3) (HSE, 2013). The lack of availability of the PRNT in 
RVFV endemic settings hampers its use for serosurveillance of RVFV, both during 
outbreaks and also during inter-epidemic periods. The use of enzyme linked 
immunosorbent assays (ELISA) is favoured for large scale serosurveillance of 
RVFV, however these assays are host species-specific and lack the ability to 
distinguish the many viral species within the Phlebovirus genus.    
The aim of this study was to generate RVFV pseudotypes and to use these to 
replace live RVFV in a pseudotype neutralisation test (pNT). However, 
pseudotypes of RVFV were produced to very low titres and although we were 
able to demonstrate specific neutralisation of these pseudotypes by RVFV 
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specific VNAb, the large volumes of pseudotype required for the assay made it 
impractical. As an alternative to the pNT we developed a neutralisation test 
utilising a recombinant Renilla luciferase expressing RVFV, which allows for 
specific, rapid and high-throughput screening for RVF VNAb in the serum of any 
host species. 
 
5.2 Results  
5.2.1 Production of retroviral pseudotypes bearing the glycoproteins of Rift 
Valley fever virus 
After the success of the rabies virus pNT we attempted to produce RVFV 
pseudotypes using the same methodology. Although a large number of viruses 
have been pseudotyped, including some bunyaviruses (Higa et al., 2012, 
Cifuentes-Muñoz et al., 2010, Tani, 2014, Ma et al., 1999), on commencing this 
study there were no published accounts of RVFV pseudotypes or pseudotypes of 
any of other phlebovirus to our knowledge. Hofmann et al. (2013) have since 
described the production of pseudotypes of severe fever with thrombocytopenia 
virus (SFTSV), a newly emerged member of the Phlebovirus genus and Bukbuk et 
al. (2014) have described the development of a RVFV pseudotype neutralisation 
test.  
Phleboviruses are enveloped tripartite, single stranded RNA viruses, comprising 
of Large (L) Medium (M) and Small (S) segments. The M segment encodes two 
glycoproteins; Gn and Gc, in addition to two non-structural proteins; NSm1 and 
NSm2 (Kakach et al., 1989) (Figure 5.1). These proteins are produced from a 
single open reading frame by alternate use of the five initiation codons upstream 
of Gn (Ikegami, 2012). We amplified five sections of the RVFV M segment, from a 
plasmid encoding the entire cDNA sequence of the M segment of the MP-12 strain 
of RVFV (pTVT7R-GM). The five sections amplified were; the complete M 
segment, GnGc, NSm1, Gn and Gc. As pseudotyping bunyaviruses had not been 
previously attempted in our laboratory, we were unsure which of these proteins 
would be optimal for pseudotype production. Studies using a retroviral vector 
system to pseudotype Andes virus (ANDV) utilised the entire M segment for 
optimal pseudotype production (Cifuentes-Muñoz et al., 2010), however 
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Takehara et al. (1990) reported low expression of RVFV proteins when the entire 
M segment was expressed by recombinant baculovirus, but high expression when 
Gc was individually expressed. All five sections were cloned into the mammalian 
expression vector VR1012 and plasmids were designated RVF-M, RVF-GnGc, RVF-
NSm1, RVF-Gn and RVF-Gc.   
 
      
Figure 5.1 Schematic representation of mRNA transcription from the M 
segment of Rift Valley fever virus. Schematic diagram of the antigenomic M 
segment of RVFV mRNA and the proteins produced via alternate use of the five 
initiation codons. Gaps between segments represent post-translational cleavage 
sites. Figure adapted from Kreher et al. (2014). 
 
 
Pseudotypes were produced using the method previously applied to 
MLV(lyssavirus) pseudotype production, with co-transfection of the MLV gag-pol 
packaging plasmid; CMVi, the GFP expression construct; CNCG, and the RVFV 
glycoprotein expression constructs. BHK-21 and Vero cells are widely used cell 
lines of choice for RVFV culture; hence we used these two cell lines for 
transduction of the MLV(RVFV) pseudotypes. As with all previous experiments a 
plasmid containing the glycoprotein of vesicular stomatitis virus (VSV) and an 
empty VR1012 vector (ΔEnv) were transfected and transduced in parallel as 
positive and negative controls. Cells were examined for GFP expression at 24 h, 
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48 h and 72 h post transduction using fluorescence microscopy. Little GFP 
expression was observed in any cell line transduced with MLV(RVFV) pseudotypes 
at any time point, however positive control MLV(VSV) pseudotypes were 
produced to a high titre (Figure 5.2). The only MLV(RVFV) pseudotype to 
demonstrate GFP positive cells following transduction was the pseudotype 
produced using the GnGc polyprotein plasmid (RVF-GnGc), however only very 
few fluorescent cells were detected and only when transduced into Vero cells 
(Figure 5.2). The number of GFP expressing cells was not considered high enough 
to warrant analysis by flow cytometry, hence only visual inspection was noted.  
To confirm RVFV glycoprotein expression during transfection, Western blots were 
performed to detect protein expression in both cells transfected with RVF-GnGc 
and the resulting pseudotypes generated. A protein of approximately 54 kDa 
correlating to Gn was expected (Kreher et al., 2014). Cell lysate of RVFV 
infected A549 cells were included in the Western blot as a positive control 
(Figure 5.3). A band matching the expected size for Gn observed in RVF-GnGc 
transfected 293T cells (lane 1) and also in the A549 positive control (lane 5), and 
was not present in the cell lysate or supernatant of cells transfected with an 
empty vector (lanes 3 and 4).  A slightly larger band was observed in the 
concentrated MLV(RVFV) pseudotype (lane 2) and was initially thought to 
correspond to RVFV glycoproteins, however non-specific bands of the same size 
have been observed in supernatants of cells transfected with both rabies virus 
glycoprotein and empty plasmids (Figure 3.2). Therefore we concluded that 
RVFV glycoproteins were being expressed in transfected cells however were not 
being readily incorporated into the retroviral pseudotype particles. 
       16
1
 
 
 
Figure 5.2 Transduction of Vero and BHK-21 cell lines with prospective Rift Valley fever virus pseudotypes. Undiluted 
supernatants bearing prospective MLV(RVFV) pseudotypes were plated onto Vero and BHK-21 cell lines and visually inspected for 
fluorescence at 48 h. MLV(RVFV) pseudotypes were produced using M, GnGc, NSm1, Gn and Gc segments; VSV and ΔEnv were used as 
positive and negative control pseudotypes respectively. 
Chapter 5. Novel approaches to detecting neutralising antibodies to Rift Valley fever virus    162 
 
      16
1
 
 
 
Figure 5.3 Expression of Rift Valley fever virus glycoproteins in 
pseudotypes and producer 293T cells. Western blot analysis of RVFV 
glycoproteins in 293T cells transfected with RVF-GnGc to produce MLV(RVFV) 
pseudotypes (lane 1), and the resulting RVFV concentrated pseudotype particles 
(lane 2). Cell lysates of 293T cells transfected to produce ΔEnv pseudotypes 
(lane 3) and the resulting ΔEnv concentrated pseudotype particles (lane 4). Cell 
lysate of A549 cells infected with the MP-12 strain of RVFV at 72 h (lane 5) was 
utilised as a positive control. Membranes were probed with mouse anti-Gn 
monoclonal antibody (4D4). Arrows represent bands specific for RVFV 
glycoprotein. 
 
 
Various methods to improve the titre of the MLV(RVFV) pseudotypes were 
employed and in each experiment only the MLV(RVFV) pseudotypes produced 
using the RVF-GnGc expression construct expressed GFP following transduction 
of the target cells. These improvements included trialling different plasmid 
ratios during transfection, the optimum being a ratio of 1:1.5:1 of CMVi, CNCG 
and glycoprotein expression construct respectively. We also examined 
transfection with plasmids encoding Gn and Gc independently (RVF-Gn and RVF-
Gc) in a four plasmid transfection (CMVi + CNCG + RVF-Gn + RVF-Gc), however no 
Chapter 5. Novel approaches to detecting neutralising antibodies to Rift Valley fever virus    163 
 
      16
1
 
GFP expression was detected following transduction, mirroring the results 
observed when RVF-Gn and RVF-Gc plasmids were transfected individually. In 
addition, we screened a variety of different target cell lines for pseudotype 
transduction and of these only Vero and CRFK cells were permissive to 
MLV(RVFV) pseudotypes. Furthermore, we also attempted to concentrate the 
pseudotypes by ultracentrifugation, however this did not improve the 
pseudotype titre significantly.  
As the GnGc pseudotypes were the only pseudotypes that produced GFP 
expression upon transduction, the RVF-GnGc expression construct was used in all 
future experiments to produce MLV(RVFV) pseudotypes. In attempts to improve 
the yield of MLV(RVFV) pseudotypes, transfections were carried out using a 
variety of construct combinations, as demonstrated in Table 5.1, as previous 
studies have demonstrated improved pseudotype production for individual viral 
glycoproteins with particular vector backbones (Carbonaro Sarracino et al., 
2014, Cifuentes-Muñoz et al., 2010, Sandrin and Cosset, 2006). Pseudotypes 
derived from HIV-1, FIV and MLV were produced with various reporters including 
lacZ, DsRed and luciferase, in addition to GFP, to assess whether any 
improvement in reporter expression would be observed in transduced cells. 
Pseudotypes were transduced into Vero and CRFK cells and assessed at 48 h post 
transduction. No GFP expression was observed in cells transduced with FIV-
derived pseudotypes. In HIV-1-derived pseudotypes bearing GFP and DsRed, a 
small number of reporter expressing cells were observed in the transduced cells, 
however there were also positive cells seen when HIV-1-ΔEnv pseudotypes were 
transduced in CRFK cells. Our laboratory and others (Kahl et al., 2004, 
Cifuentes-Muñoz et al., 2010) have experienced poor transduction efficiency of 
HIV-1-derived pseudotypes in Vero cells. Hofmann et al. (1999) have suggested 
this may be due to an intracellular inhibitor to HIV-1 in Old World monkey 
derived cell lines. As optimal transduction of RVFV pseudotypes appeared to 
occur in Vero cells, the HIV-1-derived pseudotypes were therefore discounted for 
production of RVFV pseudotypes. All RVFV pseudotypes produced using luciferase 
as the reporter gene demonstrated a similar level of luciferase expression to 
that of the negative control (ΔEnv), as demonstrated in Figure 5.4, and were 
therefore not pursued any further.  
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Gag-pol vector Reporter expression 
construct 
Reporter gene Viral origin 
CMVi CNCG GFP MLV 
CMVi pMFG lacZ MLV 
Fb-luc Luciferase MLV 
HIT60 CNCG GFP MLV 
FP93 GinSin GFP FIV 
FP93 LinSin Luciferase FIV 
HIV-eGFP GFP HIV-1 
HIV-luciferase Luciferase HIV-1 
p8.2/p8.91 CSRW DsRed HIV-1 
p8.2/p8.91 CSGW GFP HIV-1 
 
Table 5.1 Retroviral constructs co-transfected with RVF-GnGc to produce 
Rift Valley fever virus pseudotypes. The gag-pol packaging and reporter 
plasmid combinations used, in addition to the plasmid encoding the RVFV 
glycoprotein sequence (RVF-GnGc), in attempts to produce functional RVFV 
pseudotypes.   
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Figure 5.4 Luciferase expression at 48 h post transduction with Rift Valley 
fever virus and control pseudotypes. Undiluted pseudotypes were plated onto 
the specified target cell line and luciferase activity was measured at 48 h post 
transduction. Pseudotypes were produced using HIV-luciferase constructs co-
transfected with the specified glycoprotein expression plasmid. The plasmid 
RVF-GnGc was used to produce MLV(RVFV) pseudotypes. MLV(VSV) and 
MLV(ΔEnv) are the positive and negative control pseudotypes respectively.  
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After all attempts at optimisation, the highest titre of MLV(RVFV) pseudotypes 
were produced by transfecting 293T cells with plasmids CMVi, CNCG and RVF-
GnGc, while transducing either CRFK or Vero target cells (Figure 5.5). These 
transfections resulted in batches of pseudotype with titres of anywhere between 
approximately 50 and 1500 IU/ml. To determine whether the infectivity of these 
MLV(RVFV) pseudotypes was due to genuine expression of RVFV glycoprotein on 
the pseudotype surface, and not the result of ‘bald’ pseudotype particle 
infection (Voelkel et al., 2012), we investigated whether these MLV(RVFV) 
pseudotypes could be neutralised by RVF VNAb. Two lion serum samples, one 
RVF VNAb positive and one negative, which had previously been tested by PRNT 
were used to determine whether MLV(RVFV)  pseudotypes could be neutralised. 
Briefly, neat MLV(RVFV) pseudotypes were incubated with serial dilutions of test 
sera for 1 h at 37˚C, the pseudotype/serum mixture was then added to Vero 
cells and incubated for a further 48 h. Cell monolayers were examined by 
fluorescence microscopy and the number of GFP expressing cells was counted 
manually. No GFP expression was observed when pseudotypes were incubated 
with the lowest dilutions of RVF VNAb positive sera. The number of GFP positive 
cells gradually increased as the concentration of serum decreased, suggesting 
that the MLV(RVFV) pseudotypes were neutralised in a concentration-dependent 
manner by the VNAb present in the serum (Figure 5.6). GFP expressing cells 
were observed at all serum dilutions in the VNAb negative sample, although at 
dilutions of 1:5 and 1:10 numbers of GFP expressing cells were slightly lower 
than observed in the ‘no serum’ control well. A further five serum samples, 
collected from buffalo and previously tested for RVFV antibodies by a RVFV IgM 
capture ELISA, were tested for neutralising activity against MLV(RVFV) 
pseudotypes. Samples were diluted to a final dilution of 1:100 and incubated 
with 100 µl undiluted pseudotype and matched concentrations of MLV(rabies) 
pseudotype as a control for non-specificity (VSV was not used as this virus is 
known to infect Bovidae). Three of the samples had tested positive and two 
negative by RVFV ELISA. Both ELISA negative serum samples did not demonstrate 
neutralisation of the MLV(RVFV) pseudotypes, two of the ELISA positive serum 
samples completely neutralised MLV(RVFV) pseudotype, however one ELISA 
positive sample did not show neutralising activity against MLV(RVFV) 
pseudotypes. All five samples showed no neutralisation against matched 
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concentrations of MLV(rabies) pseudotype, increasing evidence that the 
neutralisation observed was specific.      
 
 
 
 
Figure 5.5 Rift Valley fever virus pseudotypes transduced into CRFK and 
Vero cell lines. Undiluted pseudotypes were transduced into CRFK and Vero 
cells, micrographs were taken at 48 h post transduction. Pseudotypes were 
produced by three plasmid transfection of CMVi, CNCG, and glycoprotein 
expression plasmid. MLV(RVFV) pseudotypes were produced using RVF-GnGc, 
MLV(VSV) pseudotypes were produced using VSV-G and MLV(ΔEnv) pseudotypes 
were produced using the empty plasmid vector VR1012. MLV(VSV) and MLV(ΔEnv) 
pseudotypes were employed as positive and negative controls respectively. 
 
 
These results demonstrate the applicability of MLV(RVFV) pseudotypes as a 
substitute for live virus in a neutralisation test, however the titres of the 
MLV(RVFV) pseudotypes were considerably variable between batches and were 
significantly lower than those produced when pseudotyping lyssaviruses. Prior to 
use in a pNT, each batch of pseudotype requires the batch specific TCID50 to be 
calculated to determine the concentration of pseudotype required in the assay. 
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Rough estimations based on average MLV(RVFV) pseudotype titres suggest that if 
100 TCID50 were to be used in a RVFV pNT, it would be necessary to use 
pseudotypes at neat concentrations, and depending on batch titre, with volumes 
possibly exceeding 100 µl. In the rabies virus pNT, over 1 ml of 100 TCID50 
pseudotype is used per sample, as samples are tested using doubling serum 
dilutions from 1:10 to 1:640 in triplicate. As titres of the MLV(rabies) 
pseudotypes are so high, the neat pseudotype is significantly diluted before use 
in the assay. If samples were tested in the same manner for a RVFV pNT, a batch 
of MLV(RVFV) pseudotype produced in a 10 cm dish, after calculation of TCID50, 
would only be sufficient to test a handful of serum samples.  Therefore although 
a RVFV pNT is feasible; the low titre achieved using retroviral pseudotypes make 
such an assay laborious, costly and time consuming.   
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Figure 5.6 Neutralisation of Rift Valley fever virus pseudotypes by 
antibodies in lion serum. Lion sera, identified previously by PRNT as RVF VNAb 
positive or negative, were incubated with MLV(RVFV) pseudotypes to determine 
whether MLV(RVFV) pseudotypes could be neutralised by RVF specific VNAb. 100 
µl of neat MLV(RVFV) pseudotype was incubated with 100 µl of serially diluted 
serum for 1 h at 37˚C to allow neutralisation to occur, the pseudotype/serum 
mix was then added to Vero cells and incubated for a further 48 h, after which 
GFP expressing cells were counted manually by fluorescence microscopy. a) 
Fluorescence micrographs of wells containing MLV(RVFV) pseudotypes with 
increasing dilutions of serum, b) number of GFP expressing cells per well. The 
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‘no serum’ control contained 100 µl of culture medium in place of serum and 
was tested in parallel to the test samples.   
 
 
In contrast to retroviruses, which assemble and bud at the plasma membrane, 
budding of bunyavirus particles occurs at the Golgi apparatus, the newly formed 
virions are then transported to the plasma membrane in Golgi derived vesicles 
(Nakitare and Elliott, 1993, Salanueva et al., 2003) (Figure 5.7). Sandrin and 
Cosset (2006) demonstrated that the intrinsic cell localisation of the 
glycoprotein expressed during pseudotype production, affected the 
incorporation of the glycoprotein into pseudotype particles. Previous studies 
have shown that mammalian plasmid expression of RVFV glycoproteins have 
resulted in non-detectable expression levels at the cell surface (Gerrard and 
Nichol, 2002, Filone et al., 2006). However, Filone et al. (2006) overcame this 
problem by saturating the Golgi retention mechanisms usually preventing 
transport of glycoproteins to the cell surface, by overexpressing GnGc using 
alphavirus replicons. In attempts to express the glycoproteins on the plasma 
membrane by overexpression of GnGc, we used a T7 polymerase/promoter 
system routinely used in RVFV research (Billecocq et al., 2008). A plasmid 
containing RVFV GnGc under the control of the T7 promoter (pTM1-GnGc) was 
kindly provided by Prof. Richard Elliott (University of Glasgow). The pTM1 vector 
is the expression plasmid of choice for many scientists working on RVFV as it 
provides high level protein expression (Billecocq et al., 2008). This vector 
requires the addition of T7 RNA polymerase (T7 pol) for expression, which can be 
supplied by transfecting the plasmid into a cell line that stably expresses T7 pol, 
or through co-transfection of a T7 pol-expressing plasmid. pTM1 was used in 
attempts to increase the expression of RVFV glycoproteins and subsequently 
improve the titres of MLV(RVFV) pseudotypes. 
To determine whether the genes expressed in pTM1 plasmids would be expressed 
in BSR-T7/5 cells (a BHK-21-derived cell line stably expressing T7 pol) and in 
293T cells in which T7 pol was provided in trans by co-transfection of a T7 pol 
expression plasmid, a pTM1 plasmid expressing GFP was transfected into both 
cell lines.  A high level of GFP expression was observed in transfected BSR-T7/5 
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cells without the addition of a T7 pol plasmid, while GFP was expressed in 293T 
cells when T7 pol was provided in trans by plasmid co-transfection (Figure 5.8a). 
To investigate whether BSR-T7/5 cells could replace 293T cells for transfection, 
MLV(VSV) pseudotypes, which are always produced to a high titre, were 
produced in both BSR-T7/5 and 293T cells and the resulting pseudotype titres 
compared by transduction into CRFK cells. BSR-T7/5 cells did not successfully 
produce MLV(VSV) pseudotypes, there was very little GFP expression from 
MLV(VSV) pseudotypes produced in BSRT-7/5 cells, in contrast to those produced 
in 293T cells, which are the cell line of choice for pseudotype production (Figure 
5.8b). Therefore BSRT7/5 cells were discounted as producer cells, however 293T 
cells could still be used for transfection using pTM1 plasmids when T7 pol was 
provided in trans.  
 
 
Figure 5.7 Schematic diagrams of retrovirus and bunyavirus budding. a) 
During retrovirus assembly, glycoproteins are expressed at the plasma 
membrane, the capsid protein is transported to the plasma membrane and the 
assembled virion pinches off. b) In contrast, during bunyavirus assembly the 
glycoproteins are expressed on the Golgi membrane, internal proteins are 
transported to the Golgi apparatus where virions assemble and bud into Golgi 
membrane derived vesicles, which migrate to the cell surface and fuse with the 
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plasma membrane for viral release. Figures adapted from Hutter et al. (2013) 
and Elliott (2014). 
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Figure 5.8 Expression of GFP in transfected BSR-T7/5 and 293T cell lines 
and titres of resulting MLV(VSV) pseudotypes produced in both cell lines. 
a) BSR-T7/5 and 293T cells were transfected with pTM1-eGFP, a GFP expression 
plasmid under the control of the T7 promoter, with and without co-transfection 
of a T7 pol expressing plasmid. Three plasmids; CMVi, CNCG and VSV-G, were co-
transfected in both cell lines to produce MLV(VSV) pseudotypes. b) The resulting 
MLV(VSV) pseudotypes were then used to transduce CRFK cells where GFP 
expression was measured by flow cytometry.     
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To produce MLV(RVFV) pseudotypes using the T7 polymerase/promoter system, 
CMVi, CNCG, pTM1-GnGc and T7 pol were transfected into 293T cells at varying 
ratios. Supernatants were harvested as previously described and were 
transduced into CRFK and Vero cells. A small number of GFP expressing cells was 
observed in wells transduced with MLV(RVFV) pseudotypes, however GFP 
expression was also noted in cells transduced with the negative control 
pseudotype (ΔEnv). The ΔEnv pseudotype was produced using an empty pTM1 
vector in place of the pTM1-GnGc plasmid. The experiment was repeated using a 
new batch of 293T cells and GFP expression was still noted in the negative 
control wells. To determine if the GFP expression in the cells transduced with 
MLV(RVFV) pseudotypes was greater than in negative controls, transduced cells 
were analysed by flow cytometry. The GFP expression in RVFV transduced cells 
was of a similar magnitude to the negative control pseudotypes therefore we 
concluded that production of these pseudotypes was unsuccessful (Figure 5.9). 
To confirm expression of RVFV-GnGc from pTM1-GnGc, Western blot analysis was 
performed on cell lysates of cells transfected with CMVi, CNCG, pTM1-GnGc and 
T7 pol and the resulting concentrated supernatant (Figure 5.10). As a negative 
control the same plasmids were transfected but lacking the T7 pol plasmid. As in 
Figure 5.3, a protein of the expected size (~54 kDa) was visualised in both cell 
lysates of pTM1-GnGc transfected cells and live virus infected cells, however no 
protein expression was observed in cell supernatants. 
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Figure 5.9 Expression of GFP in Vero and CRFK cells transduced with Rift 
Valley fever virus pseudotypes. Undiluted pseudotype was incubated with the 
specified cell line and GFP expression was measured by flow cytometry at 48 h 
post transduction. Pseudotypes were produced in 293T cells using CMVi, CNCG, 
pTM1-GnGc and T7 pol. X-axis displays the plasmid ratio of CMVi:CNCG:pTM1-
GnGc:T7 pol respectively. VSV and ΔEnv are included as positive and negative 
control pseudotypes respectively.  
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Figure 5.10 Expression of Rift Valley fever glycoprotein in pseudotypes 
and producer 293T cells. Western blot analysis of RVFV glycoproteins in RVFV 
concentrated pseudotype particles (lane 1), produced from 293T cells 
transfected with pTM1-GnGc with the addition of T7 pol (lane 2). As a negative 
control 293T cells were transfected as previously (lanes 1 and 2) but without the 
addition of the T7 pol plasmid, negative control concentrated supernatant (lane 
3) and cell lysate (lane 4). Cell lysate of A549 cells infected with the MP-12 
strain of RVFV at 72 h (lane 5) was utilised as a positive control. Membranes 
were probed with mouse anti-Gn monoclonal antibody (4D4). Arrows represent 
bands specific for RVFV glycoprotein.  
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Previous studies demonstrated increased expression of genes from the pTM1 
vector when the transfected cells were co-infected with a recombinant vaccinia 
virus expressing T7 pol in trans (Elroy-Stein and Moss, 2001). To determine 
whether expression of GnGc could be increased from the pTM1 plasmid, this 
method was investigated. Transfections were performed as previously described 
using CMVi, CNCG and pTM1-GnGc plasmids and incubated for 4 h. Equal volumes 
of recombinant vaccinia virus and 0.5% trypsin were incubated at 37˚C for 30 
min, then added to the transfected cells and incubated for a further 24 h, 
pseudotypes were harvested as previously described. Pseudotypes were 
produced using different plasmid ratios to determine whether higher 
concentrations of pTM1-GnGc would improve pseudotype production, ratios of 
1:1.5:1, 1:1:1 and 1:1:4 of CMVi:CNCG:pTM1-GnGc respectively were used in 
these experiments. Pseudotypes were transduced into BHK-21, Vero and CRFK 
cells. MLV(RVFV) pseudotypes produced using the vaccinia expression system 
produced pseudotypes able to transduce Vero and CRFK cells, and no GFP 
expression was observed with transduction of the negative control pseudotype 
(Table 5.2). Titres of pseudotypes remained similar to those previously produced 
using the VR1012 expression plasmid, therefore expressing RVFV glycoproteins 
using the T7 polymerase/promoter system did not appear to significantly 
improve the titre of retroviral pseudotypes. 
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Plasmid ratio Cell line RVFV ΔEnv VSV 
  Number of GFP expressing cells 
1:1.5:1 
BHK-21 8 0 >1000 
CRFK 90 0 >1000 
Vero 49 0 >1000 
1:1:1 
BHK-21 13 0 >1000 
CRFK 23 0 >1000 
Vero 16 0 >1000 
1:1:4 
BHK-21 0 0 >1000 
CRFK 0 0 >1000 
Vero 2 0 >1000 
 
Table 5.2 Number of GFP expressing cells in cell lines transduced with Rift 
Valley fever virus pseudotypes produced using the vaccinia T7 
polymerase/promoter expression system. MLV(RVFV) pseudotypes were 
produced in 293T cells using CMVi, CNCG and pTM1-GnGc in the presence of 
recombinant vaccinia virus as the source of T7 pol. Pseudotypes were harvested 
at 24 h and used to transduce BHK-21, CRFK and Vero cell lines. GFP expressing 
cells were counted manually by fluorescence microscopy at 48 h post 
transduction. The ratios represent the plasmid ratio of CMVi:CNCG:pTM1-GnGc 
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respectively. MLV(VSV) and MLV(ΔEnv) were produced concurrently as positive 
and negative control pseudotypes. 
 
 
5.2.2 Production of rhabdoviral pseudotypes bearing Rift Valley fever virus 
glycoproteins 
Cifuentes-Monoz et al. (2010) successfully produced retroviral pseudotypes to 
ANDV, a hantavirus from the Bunyaviridae family, which were effectively 
neutralised by convalescent sera from ANDV-infected patients. In contrast to our 
study on retroviral RVFV pseudotypes, Cifuentes-Monoz demonstrated detectable 
ANDV glycoproteins in the supernatant of transfected cells. Pseudotype 
production using retroviral systems was attempted for hantaan and puumala 
hantaviruses and also SFTSV without success, however pseudotypes of these 
viruses were successfully produced to reasonable titres when a VSV pseudotype 
system was employed (Higa et al., 2012, Hofmann et al., 2013). Another 
hantavirus, Seoul virus, and the phlebovirus SFTSV have also been successfully 
pseudotyped using this system (Ogino et al., 2003, Tani, 2014, Hofmann et al., 
2013). In 2014, Bukbuk et al. reported RVFV pseudotypes produced using the VSV 
pseudotype system, although no detail of the titres of such pseudotypes were 
discussed, they were successfully used to replace live virus in a RVFV pseudotype 
based neutralisation assay. 
The VSV pseudotype system utilises a recombinant VSV in which the glycoprotein 
has been deleted (rVSV-ΔG). Due to the mechanism of VSV budding, which does 
not require glycoprotein to be present, this recombinant VSV can therefore be 
used to produce pseudotypes using the glycoprotein of heterologous viruses 
(Whitt, 2010), this method was first reported in 1997 for pseudotyping Ebola 
virus (Takada et al., 1997). We therefore questioned whether rVSV-ΔG could be 
used to generate RVFV pseudotypes in this study. Various reporter genes have 
been incorporated into the rVSV-ΔG virus and viruses expressing GFP (rVSV-
ΔG*GFP), red fluorescent protein (RFP) (rVSV-ΔG*DsRed) and luciferase (rVSV-
ΔG*luc) for this study were kindly provided by Dr. Michael Whitt (University of 
Tennessee). To determine optimal pseudotype production prior to pseudotyping 
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RVFV, the VSV system was used initially to produce rabies virus pseudotypes. 
Briefly, 293T cells were transfected with a rabies virus glycoprotein expression 
vector and incubated for 4 h at 37°C. Transfection medium was then replaced 
with low serum concentration media and incubated for a further 24 h. 
Transfected cells were infected with rVSV-ΔG at MOI 1 and adsorbed for 2 h, 
after which cells were extensively washed with serum free media. Fresh medium 
was added to the wells and further incubated at 37°C. Supernatants were 
harvested 24 h post infection, filtered and frozen at -80°C until required. This 
protocol differed slightly to the protocol suggested by Whitt et al. (2010), as 
293T cells were used in place of BHK-21 cells, infection with rVSV-ΔG was 
carried out at a lower MOI than suggested and that rVSV-ΔG was removed after 2 
hours where cells were additionally extensively washed. These alterations to the 
protocol were necessary, as prior to such modifications ΔEnv pseudotypes 
expressed significant levels of the reporter genes upon transduction of target 
cells, suggesting non-specific pseudotype production or carry over of reporter 
expressing virus. Protocols reported by Tani et al. (2011) recommend the 
removal of virus and extensive washing of cells for successful pseudotype 
production, we found this modification, in addition to a reduction in the MOI of 
rVSV-ΔG, removed the majority of non-specific pseudotype production. After 
optimising the VSV pseudotype system for rabies virus (VSV(rabies)), we 
produced VSV-derived RVFV pseudotypes using both pTM1-GnGc expression 
plasmid (with the addition of vaccinia virus) and RVF-GnGc. With all rVSV-ΔG 
constructs, expressing GFP, RFP and luciferase, VSV(RVFV) pseudotypes were not 
produced to a high titre, additionally positive cells were observed in target cells 
transduced with negative control ΔEnv pseudotypes (Figure 5.11). The positive 
control VSV(VSV) pseudotypes produced in parallel were always produced to a 
very high titre (Figure 5.11 and 5.12). In contrast to the MLV(rabies), in which 
high titres are achieved, the rabies virus pseudotypes produced using the VSV 
pseudotype system demonstrated only modest titres (Figure 5.12). Due to the 
poor pseudotype titres obtained using the VSV pseudotype system for RVFV 
pseudotypes, in addition to the non-specificity demonstrated upon transduction 
of the ΔEnv pseudotypes, the VSV(RVFV) pseudotypes were determined not to be 
suitable for use in a pNT.     
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Figure 5.11 Reporter gene expression of Rift Valley fever virus 
pseudotypes produced using the rVSV-ΔG pseudotyping system. CRFK cells 
were transduced with pseudotypes bearing RVFV glycoproteins produced using 
rVSV-ΔG*DsRed and rVSV-ΔG*GFP. Cells were examined at 24 h post 
transduction. VSV and ΔEnv were produced in parallel and served as positive and 
negative control pseudotypes respectively. 
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Figure 5.12 Expression of GFP following transduction with rVSV-ΔG 
pseudotypes. Pseudotypes were produced by transfecting RVF-GnGc into 293T 
cells followed by infection with rVSV-ΔG*GFP at 4 h. The resulting VSV(RVFV) 
pseudotypes were harvested at 24 h post infection. The concentrations represent 
the amount of RVF-GnGc plasmid transfected initially into 293T cells. 293T and 
CRFK cells were transduced with neat pseudotype and GFP expression was 
analysed by flow cytometry at 24 h post transduction. VSV(VSV-G) and 
VSV(rabies) pseudotypes were produced in parallel as positive controls and 
VSV(ΔEnv) was produced in parallel as a negative control. 
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5.2.3 Optimisation and validation of a Rift Valley fever virus neutralisation 
assay using luciferase-expressing Rift Valley fever virus 
The low and inconsistent titres achieved when pseudotyping with RVFV 
glycoproteins suggested that an RVFV pNT would not be suitable for a reliable, 
high-throughput assay. We therefore designed an alternative neutralisation assay 
for the detection of RVF VNAb using a recombinant RVFV which incorporates a 
luciferase reporter gene. This recombinant virus, rMP12ΔNSs:hRen, was kindly 
provided by Dr. Ben Brennan (University of Glasgow). The virus was derived from 
the MP-12 strain of RVFV in which the NSs coding sequence was replaced with a 
humanised Renilla luciferase. Upon infection and virus replication, luciferase 
expression can be measured in the infected cells using a luminometer. Initially, 
to determine the infectivity of the recombinant virus and to determine the 
optimum incubation time, BHK-21 cells were infected with rMP12ΔNSs:hRen at 
an MOI of 1 and 5 and measured at 3, 6 and 24 h post-infection (hpi). Luciferase 
activity was detectable from 3 hpi with an approximate 22- and 117-fold 
increase in luciferase signal over background for cells infected with MOI of 1 and 
5 respectively. At 6 hpi this increased to an approximate 2300- and 10000-fold 
increase. Luciferase levels were similar for both MOI 1 and 5 at 24 hpi, with an 
approximate 8000-fold increase over background (Figure 5.13). Based on the 
results of this experiment, we determined that for our RVFV luciferase 
neutralisation test (RVFV-luc NT) an intermediate MOI of 2 would be used and 
the assay would be analysed at 6 hpi, providing a clear distinction between virus 
infection and background signal and allowing a result to be reported 12 times 
faster than the current gold standard PRNT.      
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Figure 5.13 Luciferase expression following rMP12ΔNSs:hRen infection of 
BHK-21 cells. BHK-21 cells were infected with rMP12ΔNSs:hRen at an MOI of 1 
and 5 while control cells were left uninfected to determine background 
luciferase signal. At the indicated time points, BHK-21 cells were lysed and 
luciferase signal measured in relative light units (rlu). Infections were performed 
in duplicate. 
 
 
Seven serum samples which had previously been tested by a RVFV IgM capture 
ELISA were tested on the RVFV-luc NT to evaluate whether the assay could 
detect antibodies to RVFV. Three samples had tested negative by ELISA (112,118 
and 214) and four had tested positive by ELISA (35, 86, 2489 and 2543). A 
doubling dilution series, ranging from 1:10 to 1:1280, of these seven samples was 
tested by the RVFV-luc NT in duplicate. The percentage neutralisation was 
calculated using the following formula: 
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Neutralisation (%) =    1 -   (mean sample rlu) – (mean uninfected cell rlu)     x100     
                mean rMP12ΔNSs:hRen infected cells rlu  
 
Neutralisation of rMP12ΔNSs:hRen was observed in all RVFV antibody positive 
sera (Figure 5.14), with 75% (n=3) of the ELISA positive samples demonstrating 
100% neutralisation in all dilutions up to 1:1280, with luciferase activity 
mimicking that of uninfected cells, suggesting complete neutralisation of 
rMP12ΔNSs:hRen by sera. There appeared to be non-specific neutralisation in 
ELISA negative samples at all dilutions, with levels of luciferase expression not 
reaching the level in rMP12ΔNSs:hRen infected cells in the absence of serum. To 
further evaluate the limit of detection of the assay, one ELISA positive (#86) and 
one ELISA negative (#118) sample were further diluted two-fold from 1:100 to 
1:420000000 (Figure 5.15). The luciferase signal plateaued at serum dilutions of 
around 1:200 and 1:12800 in the negative and positive samples respectively. In 
both samples, the maximum luciferase signal reached was two-fold lower than 
untreated infected cells, this may be due to non-specific inhibition of the 
rMP12ΔNSs:hRen by unknown factors in the serum. 
To compare the RVFV-luc NT to the gold standard PRNT, a doubling dilution 
series of a mouse monoclonal antibody (4D4) known to neutralise RVFV was 
tested on both assays. The PRNT gave a PRNT50 value of 1:128. For a relative 
comparison the luciferase expression of uninfected cells and luciferase 
expression at the maximum antibody dilution of 1:4096 were taken as 100% and 
0% values respectively. Using these values a 50% reduction in luciferase 
expression was obtained at the 1:1024 antibody dilution, demonstrating an 
almost 10-fold increase in sensitivity of the RVFV-luc NT compared to the PRNT 
(Figure 5.16).  
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Figure 5.14 Evaluation of the RVFV-luc neutralisation test using samples 
of known Rift Valley fever virus antibody status. Seven buffalo sera which 
had previously been tested by RVFV IgM ELISA were serially diluted two-fold from 
1:10 to 1:1280 and tested on the RVFV-luc NT, utilising rMP12ΔNSs:hRen at MOI 2 
with luciferase activity measured at 6 hpi. Green lines represent samples testing 
positive by ELISA and those in black tested negative by ELISA for RVFV IgM. The 
red dashed line represents a level of 98% neutralisation.  
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Figure 5.15 Extended dilution series of Rift Valley fever virus antibody 
positive and negative sera. The RVFV-luc NT was repeated on two of the 
samples previously tested in Figure 5.14, samples were further diluted from 1:50 
to 1:419430400. Sample 118 had previously tested negative for RVFV IgM 
antibodies and sample 86 had tested positive. The red dashed line represents a 
level of 98% neutralisation.  
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Figure 5.16 Comparison of a dilution series of a neutralising antibody to 
Rift Valley fever virus when measured by PRNT and RVFV-luc NT. A 
doubling dilution series of the mouse monoclonal RVFV neutralising antibody 
(4D4) was tested on both the PRNT and RVFV-luc NT. The PRNT was performed 
using the MP-12 strain of RVFV and plaque reduction was analysed at 72 hpi. 
Luciferase expression in the RVFV-luc NT was analysed at 6 hpi. The PRNT was 
performed by Dr. Felix Kreher and the RVFV-luc NT was performed by Dr. 
Stephen Welch.  
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Ideally the RVFV-luc NT would be performed using a single serum dilution to 
allow for high-throughput serum analysis, which is preferable for large scale 
serosurveillance. The data presented in Figure 5.14 suggest that using a single 
serum dilution of 1:100 and a cut-off of ≥98% neutralisation would successfully 
differentiate between RVF VNAb positive and negative sera. To validate the 
RVFV-luc NT using a serum dilution of 1:100 and a cut-off for neutralising 
activity of ≥98%, 53 serum samples of known RVFV antibody status were tested 
using the RVFV-luc NT. These samples comprised 19 lion serum samples 
previously tested by the gold standard PRNT, kindly provided by Prof. Craig 
Packer (University of Minnesota). Five of the samples were positive for RVF VNAb 
with PRNT50 titres of 160, two samples were considered inconclusive with a titre 
of 40, while 12 samples were negative with PRNT50 titres of ≤10. A further 34 
samples (21 African buffalo samples and 13 serum samples from Thomson’s 
gazelle) which had previously been tested by RVFV IgM ELISA, were also utilised 
in the validation panel. One Thomson’s gazelle sample and nine buffalo samples 
were positive for RVFV IgM, two buffalo samples were equivocal by ELISA and the 
remaining samples were negative. Samples were tested at a dilution of 1:100 in 
duplicate and a level of neutralisation was calculated using the aforementioned 
formula, a level of ≥98% was considered positive for the presence of RVF VNAb. 
We demonstrated a 100% correlation of results obtained using the RVFV-luc NT 
with the lion samples tested by PRNT, with all negative and positive samples 
being correctly interpreted, the two inconclusive samples were negative by 
RVFV-luc NT (Figure 5.17a). When comparing the results of the RVFV-luc NT to 
the RVFV IgM ELISA, 100% (21/21) of the negative samples were correctly 
interpreted and 91% (10/11) of the positive samples were correctly interpreted, 
one of the inconclusive samples tested positive and one negative by RVFV-luc NT 
(Figure 5.17b). Using these results (excluding inconclusive samples) the 
sensitivity and specificity of the RVFV-luc NT are 94% (95% CI 69.8-99.8%) and 
100% (95% CI 89.4-100%) respectively.   
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Figure 5.17 Validation of the RVFV-luc neutralisation test using 53 
samples of known RVFV antibody status. Fifty-three samples previously 
tested for antibodies to RVFV were tested by RVFV-luc NT, in duplicate using a 
single serum dilution of 1:100 and a cut-off of ≥98%. a) Nineteen lion serum 
samples were tested on the RVFV-luc NT which had previously been tested by 
RVFV PRNT, a neutralising titre of <40 was considered negative in the PRNT, a 
titre of 40 was inconclusive and >40 was considered positive. b) Thirty four 
samples were tested on the RVFV-luc NT which had previously been tested by 
RVFV IgM capture ELISA. The colours of the bars represent the RVFV antibody 
status at previous testing. The red dashed line represents the cut-off of 98% 
neutralisation. 
  
 
To determine the optimal percent neutralisation threshold for the RVFV-luc NT, 
a receiver operating characteristic (ROC) curve was performed using the results 
of the validation panel (n=49) (Figure 5.18). The RVFV-luc NT demonstrates 
excellent discrimination between RVF VNAb positive and negative samples, with 
an area under curve (AUC) of 0.97 (95% CI 0.90-1.03) and p<0.0001. The optimal 
percent neutralisation cut-off calculated by the ROC analysis was 93.9%, which 
would provide an assay sensitivity of 93.8% (95% CI 69.8-99.8%) and specificity of 
100% (95% CI 89.4-100%). However, Figure 5.14 demonstrates that sera negative 
for RVF VNAb, at dilutions of 1:160, demonstrate percent neutralisation of 
around this cut-off (92.8%, 94.0% and 94.6%), therefore we decided to retain the 
more stringent cut-off of ≥98% neutralisation as evidence of RVF VNAb. Although 
this more stringent cut-off may reduce the sensitivity of the assay slightly, it was 
deemed that the specificity of the assay was of greater significance as the aim 
of this project was to provide reliable serosurveillance data.  
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Figure 5.18 Receiver operator characteristic (ROC) analysis of RVFV-luc 
neutralisation test. ROC curve analysis of sensitivity and 100-specificity (%) 
data for the RVFV-luc NT based on 49 samples of known RVFV antibody status, 
which had previously been tested using the PRNT or RVFV IgM capture ELISA. 
AUC=0.966. 
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To investigate inter-assay variation in the RVFV-luc NT 16 samples were selected 
from five different species (lion n=2, gazelle n=5, buffalo n=4, cattle n=3, goat 
n=2) and tested on two different days, using different BHK-21 cells and different 
aliquots of rMP12ΔNSs:hRen. The results demonstrated a good agreement 
between both assays with 88% (14/16) of samples being classified as either RVF 
VNAb positive or negative on both tests (Figure 5.19). The results of two samples 
were discrepant between the tests. One buffalo sample tested negative on the 
first test but positive on repeat testing, one cattle sample tested negative on 
the first test and positive on repeat testing, however in both samples the 
negative result fell close to the cut-off value of ≥98% (97.11% and 94.63%). This 
data supports the use of the lower cut-off of >94% in the RVFV-luc NT, 
reinforcing the need for further validation of the assay, and the potential cut-
off, by comparing field samples tested by RVFV-luc NT and the gold standard 
PRNT. 
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Figure 5.19 Inter-assay variation in the RVFV-luc NT was investigated by 
testing samples on two different days. Sixteen samples from five different 
species were tested on the RVFV-luc NT on two different days using different 
aliquots of virus and a different batch of BHK-21 cells to assess the level of 
inter-assay variation. Red diamonds represent samples that tested RVF VNAb 
positive on both tests (n=6), blue diamonds represent samples testing RVF VNAb 
negative on both tests (n=8) and green diamonds represent samples testing RVF 
VNAb positive on one test and negative on repeat testing (n=2). 
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In the rabies virus pNT, we demonstrated that non-specific neutralisation in 
serum samples could cause false positive results. This problem was addressed by 
testing serum against an unrelated pseudotype to detect non-specific 
neutralisation, samples that demonstrated non-specific neutralisation were 
investigated further. There is no non-specific neutralisation control included in 
the RVFV-luc NT. To determine if non-specific neutralisation may be a factor in 
the RVFV-luc NT, we tested a random selection of serum samples on the RVFV-
luc NT and further tested them using an identical method but replacing the   
rMP12ΔNSs:hRen with rBUNΔNSs:hRen. The rBUNΔNSs:hRen virus is a 
recombinant bunyamwera virus expressing Renilla luciferase kindly provided by 
Dr. Xiaohong Shi (University of Glasgow). Bunyamwera virus is a member of the 
Orthobunyavirus genus of the Bunyaviridae family, which is present throughout 
the world (Tauro et al., 2009). To determine if non-specificity affected the 
classification of neutralising or non-neutralising serum, we tested 73 samples 
using both the RVFV-luc NT and the BUNV-luc NT, these samples comprised of 
samples from lions (n=10), buffalo (n=14), gazelle (n=11), cattle (n=14), sheep 
(n=10) and goats (n=14). Twenty-five of these samples tested positive for RVF 
VNAb (lions n=3, buffalo n=5, gazelle n=3, cattle n=6, sheep n=2 and goat n=6), 
the remaining 48 tested negative by RVFV-luc NT. Eleven samples neutralised 
rBUNΔNSs:hRen at a level of ≥98% (lions n=3, buffalo n=4, gazelle n=1, cattle 
n=1, sheep n=1 and goat n=1), the remaining samples were non-neutralising 
(Table 5.3). All of the buffalo samples testing positive on the BUNV-luc NT were 
also RVF VNAb positive, the remaining seven samples demonstrating 
neutralisation on the BUNV-luc NT were negative when tested by RVFV-luc NT. 
The proportion of bunyamwera VNAb positive samples amongst RVF VNAb 
positive and negative samples were 16% and 15% respectively, therefore non-
specific neutralisation did not appear to be an issue in these samples. Antibodies 
to the bunyamwera serogroup have been reported from a variety of both 
domestic and wildlife species (Issel et al., 1970, Campbell et al., 1989, Fagbami 
and Fabiyi, 1975, Sahu et al., 2002) and therefore the presence of antibodies to 
bunyamwera virus in sera tested in this study is not entirely unexpected.  
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 Positive Negative Total 
Positive 4 21 25 
Negative 7 41 48 
 Total 11 62 73 
 
Table 5.3 Rift Valley fever and bunyamwera virus neutralisation by serum 
samples. Seventy-three serum samples from five species were tested using the 
RVFV-luc NT and BUNV-luc NT for neutralising antibodies to RVFV and BUNV 
respectively. Tested sera comprised of lion (n=10), buffalo (n=14), gazelle 
(n=11), cattle (n=14), sheep (n=10) and goat (n=14) samples, tested at a single 
serum dilution of 1:100. A level of ≥98% was considered evidence of VNAb in 
these assays.     
 
 
5.3 Discussion  
The current gold standard serological assay for evidence of RVFV infection is the 
VNT, which is highly specific and is the World Organisation for Animal Health 
(OIE) prescribed test for international trade (OIE, 2012a). However, the PRNT is 
laborious, demands technical expertise, requires 5-7 days for completion and 
most significantly, as live virus is required, the PRNT must be performed under 
BSL-3 conditions. Due to the biosafety implications and the incubation time 
required for the VNT it has limited use for large scale serosurveillance. The 
ELISA is the most commonly utilised method of RVFV antibody detection for sero-
epidemiology (Mansfield et al., 2015) and commercial ELISAs based on the 
recombinant RVFV nucleoprotein are available. However, our laboratory and 
others (Faburay et al., 2013, Niklasson et al., 1984) have encountered a high 
degree of non-specific background when using RVFV ELISAs, which causes 
difficulty in the interpretation of results. Additionally, the ELISA is species-
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specific and requires revalidation when sera from different species are tested. 
Currently the majority of commercial ELISAs are validated for humans or for 
domestic and wild ruminants only (Paweska et al., 2005), however a multi-
species ELISA has been developed more recently. The reservoir species of RVFV 
remain unknown, with potential reservoir species ranging from rats to bats 
(Olive et al., 2012), hence pan-species serological assays for RVFV surveillance 
are required.  Studies have also demonstrated cross-reactivity of the 
nucleoproteins of members of the Phlebovirus genus (Wu et al., 2014, Xu et al., 
2007, Tesh et al., 1982, Szymczak et al., 2015), which renders these commercial 
ELISAs inadequate for serosurveillance in areas where other phleboviruses 
circulate, or indeed where as yet unknown phleboviruses may be circulating. The 
VNT is considered the most specific serological assay for RVFV (Beechler et al., 
2015), as there is little or no cross-reactivity of phleboviral VNAbs (Pepin et al., 
2010), in addition the assay is not affected by the species being tested. Previous 
studies comparing RVFV serology using both ELISA and VNT have demonstrated 
high proportions of discrepant results, with the ELISA reporting high numbers of 
positives which cannot be confirmed by VNT (Evans et al., 2008, Gray et al., 
2015), one study reported seroprevalence of RVFV in sheep and goats in Kenya as 
17% when tested by ELISA but only 4% when the same samples were tested by 
VNT (Kariithi et al., 2010). Therefore, highly specific RVFV sero-diagnostic assays 
are required for generating reliable epidemiological evidence of RVFV circulation 
and maintenance, such assays require the specificity of the VNT but the ease, 
high-throughput and low biosafety requirements associated with an ELISA.  
In this study initial attempts at developing such an assay focussed on the 
development of a pNT, following on from the success of the rabies virus pNT 
developed in Chapter 3. However, in this study MLV(RVFV) pseudotypes were 
produced at low titres, and although successfully neutralised by RVFV specific 
VNAb, these low and inconsistent titres made the RVFV pNT unfeasible for high-
throughput serological screening. Successful incorporation of viral glycoproteins 
into pseudotype particles is dependent on the intrinsic cell localisation of the 
glycoprotein (Whitt, 2010, Sandrin and Cosset, 2006). Little or no glycoprotein 
expression has been observed on the plasma membrane of cells infected with 
viruses of the Bunyaviridae family (Pettersson and Melin, 1996). The 
glycoproteins of RVFV accumulate in the Golgi apparatus due to a Golgi 
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retention motif situated in the cytoplasmic tail of Gn (Gerrard and Nichol, 2002) 
and as with all bunyaviruses RVFV buds from the Golgi (Andersson et al., 1997). 
It can be assumed that during transfection GnGc proteins are also expressed on 
the Golgi membrane, for successful pseudotype production glycoprotein 
expression is required at the plasma membrane where retroviral and rhabdoviral 
pseudotypes bud. The small number of RVFV pseudotypes produced in our 
experiments could be due to a limited number of pseudotype particles which 
assemble and bud from endosomal vesicles, which have previously been reported 
(Sandrin and Cosset, 2006, Tani, 2014). In our study, attempts to improve 
glycoprotein expression using a T7 polymerase/promoter system did not 
sufficiently improve RVFV pseudotype titres. Filone et al. (2006) achieved 
significantly high cell surface expression of RVFV glycoproteins when the M 
segment of RVFV was cloned into a Venezuelan equine encephalitis virus vector, 
which was further utilised to develop a cell-cell fusion assay. If future attempts 
were made to pseudotype RVFV, such alphavirus replicon particles may be 
considered to achieve sufficient plasma membrane expression of RVFV 
glycoproteins and in turn allow for high titre RVFV pseudotypes to be produced. 
Previous studies have also reported glycoproteins previously unsuccessfully 
incorporated into pseudotypes being successfully incorporated when the 
cytoplasmic tail of the glycoprotein was deleted or replaced with the 
cytoplasmic tail of another virus. Sandrin et al. (2006) reported unsuccessful 
pseudotypes produced when the wild type glycoprotein of the cat endogenous 
retrovirus RD114 was transfected with retroviral vectors, however pseudotypes 
were successfully produced when the cytoplasmic tail of RD114 was replaced 
with the cytoplasmic tail of MLV. Further studies have also reported successful 
incorporation of viral glycoproteins when chimeric MLV cytoplasmic tails were 
produced (Lindemann et al., 1997, Christodoulopoulos and Cannon, 2001) and 
other studies have used similar methodologies using chimeric VSV cytoplasmic 
tails (Carpentier et al., 2012). Additionally, measles lentiviral pseudotypes have 
been described in which wild type measles glycoproteins F and H were only 
successfully incorporated into pseudotype particles when their cytoplasmic tails 
were truncated (Frecha et al., 2008). As the retention motif of the RVFV 
glycoproteins is in the cytoplasmic tail, such strategies could also be attempted 
to increase RVFV glycoprotein expression at the plasma membrane and hence 
increase RVFV pseudotype titres. 
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Many viruses have been pseudotyped using the VSV pseudotyping system, 
including influenza C, Ebola, measles, hepatitis C virus and hantaviruses (Hanika 
et al., 2005, Takada et al., 1997, Tatsuo et al., 2000, Tamura et al., 2005, Ogino 
et al., 2003), these include hantaviruses that could not be pseudotyped using 
retroviral vectors (Higa et al., 2012). To our knowledge the only phleboviruses 
that have been successfully pseudotyped are SFTSV and RVFV, in both instances 
pseudotypes were produced using the VSV pseudotype system. However, these 
phlebovirus pseudotypes were produced at low titres, around 100-fold lower 
than the control pseudotypes produced using the glycoprotein of VSV (Tani, 
2014). We used the VSV pseudotype system to produce VSV(RVFV) pseudotypes 
and although reporter expression was noted on transduction of target cells, 
negative control pseudotypes lacking glycoprotein also produced positive cells 
upon transduction. VSV has been shown to bud at a low level in the absence of 
any glycoprotein (Robison and Whitt, 2000) and non-specific cellular uptake of 
envelope deficient retroviral pseudotypes has been reported previously (Voelkel 
et al., 2012), a combination of these two events could result in non-specific 
reporter expression seen upon transduction of VSV(ΔEnv) pseudotypes. However, 
we noted increased expression of reporter genes upon transduction when cells 
were not extensively washed after removal of rVSV-ΔG, suggesting reporter 
expression could be due to residual carry over of the rVSV-ΔG. Previous studies 
reporting use of the VSV pseudotyping system have incubated transfections with 
polyclonal anti-VSV serum to neutralise residual rVSV-ΔG, hence such non-
specific carry over seems to have been a factor in other studies (Hofmann et al., 
2013, Hanika et al., 2005). When pseudotypes are produced to high titres such 
non-specific background may be negligible, however with such low VSV(RVFV) 
pseudotype titres achieved, and background expression levels not significantly 
different, such a background is unacceptable. Pseudotypes are a powerful tool 
for studying cell entry, gene transfer, vaccine candidates and for measuring 
neutralising antibodies, and although many viruses have been successfully 
pseudotyped some viruses may require further modifications before pseudotypes 
can be produced to a useable titre.               
With the RVFV pNT not a viable option for screening for VNAb, we investigated 
alternative methods for RVF VNAb detection. The RVFV-luc NT developed in this 
Chapter is a novel assay for detecting RVF VNAb, which allows for high-
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throughput, rapid and sensitive screening of serum regardless of host species. In 
comparison to the PRNT which can take up to 7 days to perform, and indeed the 
pNT which requires 48 h incubation, the RVFV-luc NT is incubated for only 6 h, 
resulting in a huge reduction in turnaround time. An additional improvement of 
this assay over the PRNT is that results are reported in absolute number and 
therefore it does not rely on the subjective nature inherent in interpreting viral 
plaque formation, hence inter-assay variability is greatly reduced. Comparison of 
50% neutralisation values of a monoclonal neutralising antibody measured on 
both the PRNT and RVFV-luc NT demonstrated increased sensitivity of the RVFV-
luc NT assay over PRNT, however this result should be additionally confirmed 
using a panel of RVF VNAb positive sera. The RVFV-luc NT also lends itself to full 
automation, as with appropriate robotic and liquid handling systems the entire 
process could be automated once the cells have been prepared, offering huge 
advantages when large scale serosurveys are required. In this study the RVFV-luc 
NT was performed at BSL-3 as the MP-12 strain of RVFV is a live attenuated 
vaccine strain, however in the United States only BSL-2 containment is required 
for virus manipulation (CDC, 2009). Considering the recombinant virus used in 
the RVFV-luc NT is an attenuated strain, and the nonstructural (NSs) gene has 
been deleted, BSL-3 requirements for this strain could potentially be 
downgraded in the United Kingdom, in which case the RVFV-luc NT will be 
further improved by lowering the biosafety requirements of the assay. We have 
demonstrated serum cytotoxicity in the rabies virus pNT, which may cause false 
positive results. As the RVFV-luc NT is analysed using a luminometer, cell 
cytotoxicity cannot be ascertained through microscopy as it would be in a 
conventional VNT or pNT. However, Garcia et al. (2014) have described a high-
throughput luciferase assay in which a metabolic viability dye can be 
incorporated into the assay to attain an assessment of cell cytotoxicity using the 
luminometer. Such methodology should be considered to improve the reliability 
of the RVFV-luc NT, if this assay were to be further developed, ensuring cell 
viability in the assay would be an important improvement.      
 A limitation of this study was the small number of serum samples used for 
validation, 53 previously analysed samples were tested on the RVFV-luc NT, of 
which only 19 were tested by the gold standard PRNT. Ideally for a more reliable 
calculation of sensitivity and specificity, a larger sample size should be tested by 
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the gold standard for comparison with RVFV-luc NT, unfortunately due to time 
constraints this was not possible during this project. To establish a high-
throughput assay a single serum dilution was used rather than titration to 
endpoint. However, ideally for further validation of the assay serum samples 
should be further titrated to give a quantification of RVF VNAb in the sample. 
Again due to time constraints in the study this was not done. To improve the 
assay, during serosurveillance studies serum samples testing positive on the 
RVFV-luc NT should be further titrated to allow an end point titre to be 
calculated. With this approach the stringent cut-off of 98% neutralisation 
selected in this study could be lowered, as high sensitivity is preferable to high 
specificity in a screening assay, as false positives will be detected upon full 
serum titration.  
Understanding the dynamics of RVFV during both epidemics and inter-epidemic 
periods relies on robust serosurveillance data from a wide range of host species. 
The aim of this research was to develop a high-throughput, reliable VNT for use 
with multiple species, allowing collection of robust serosurveillance data and in 
turn improving the understanding of RVFV transmission, reservoir species and 
host susceptibilities. The RVFV-luc NT is employed in Chapter 6 to investigate 
some of these questions.           
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 Chapter 6. A sero-epidemiological 
study of Rift Valley fever virus in 
Tanzania  
 
6.1 Introduction 
Rift Valley fever virus (RVFV) is an arbovirus spread by mosquito vectors which 
can cause severe disease in both humans and animals. The virus is considered 
endemic in sub-Saharan Africa (Mansfield et al., 2015), and prior to the year 
2000 had not been detected outside the African continent, but has since spread 
to the Arabian Peninsula (Balkhy and Memish, 2003) and the Comoros 
Archipelago (Sissoko et al., 2009). Outbreaks of RVFV occur after periods of 
heavy rainfall and flooding, which provide optimum breeding conditions for 
mosquito vectors. Transovarian transmission of RVFV has been observed in 
mosquitoes (Linthicum et al., 1985) and it is hypothesised that infected, 
diapause eggs may survive in shallow wetland areas during inter-epidemic 
periods (IEP). After extensive flooding large numbers of these infected eggs 
hatch and an ensuing RVFV epidemic occurs, resulting in extensive transmission 
to animals and subsequent amplification of the virus.  
Rift Valley fever is mainly considered a disease of domestic ruminants and 
humans. However, many other animals have exhibited symptomatic disease 
associated with RVFV infection, including camels (El Mamy et al., 2011), African 
buffalo and waterbuck (Beechler et al., 2015), while many more apparently 
healthy animals from diverse species have been found to be seropositive for 
RVFV-specific antibodies. Antibodies to RVFV have been reported in many wild 
animals including African buffalo (LaBeaud et al., 2011), impala (Capobianco 
Dondona et al., 2016) elephants (Evans et al., 2008), giraffes (Bird et al., 2008), 
black rhino (Lwande et al., 2015) and in one study RVFV antibodies were 
detected in lions (House et al., 1996). It is widely hypothesised that RVFV does 
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not circulate during IEP and transmission occurs only during outbreaks, however 
antibodies to RVFV have been detected both in animals, and in humans, who 
have only lived through IEP (Sumaye et al., 2013, LaBeaud et al., 2008, Gray et 
al., 2015). Much remains to be understood regarding the mechanisms of inter-
epidemic persistence and circulation in mammalian host species.    
The gold standard serological assay for detecting antibodies to RVFV is the virus 
neutralisation test (VNT), however this test is both time consuming, technically 
demanding and requires high containment facilities, and as a result, can be 
performed in  very few laboratories in RVFV endemic countries in Africa. ELISAs 
are widely utilised for sero-epidemiological studies of RVFV, however results of 
ELISAs have been shown to correlate poorly with results from the VNT (Gray et 
al., 2015, Evans et al., 2008, Kariithi et al., 2010, Boussini et al., 2014). Robust 
serological evidence is imperative to understanding the complex, multi-host 
ecology of RVFV. In Chapter 5 we described a neutralisation assay in which 
wildtype virus is replaced with a recombinant RVFV expressing luciferase. This 
assay (RVFV-luc NT) allows for high-throughput testing using a single serum 
dilution of 1:100 and unlike many RVFV ELISAs, allows testing of serum from any 
species. We established a cut-off value of ≥98% effective neutralisation as 
evidence of RVF virus neutralising antibodies (VNAb) and this cut-off was utilised 
in these studies. In this Chapter we describe the use of the RVFV-luc NT to 
investigate the presence of VNAb to RVFV in the unique archive of wildlife and 
livestock sera, collected over the past 20 years, from the Serengeti ecosystem. 
Using linked epidemiological data we aim to provide preliminary data to enable 
us to further understand the epidemiology of RVFV in Tanzania. 
The study area comprises the Serengeti National Park (SNP), Ngorongoro 
Conservation Area (NCA) and the surrounding areas in Northern Tanzania (Figure 
6.1). The SNP encompasses diverse wildlife communities and is a protected area 
which is bordered to the North by the Maasai Mara National Reserve, Kenya. The 
NCA is a wildlife protected area, however also functions as a multiple land use 
area, with wildlife, livestock and humans co-existing. There is a large pastoral 
Maasai population which live and herd cattle in the NCA. The area to the North 
West of the SNP is the Serengeti district which is inhabited by agro-pastoralist 
communities. To the East of the SNP and North of the NCA is Loliondo district 
which is inhabited by pastoralist communities. There are no physical boundaries 
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separating wildlife protected areas and human settlements (Lembo et al., 2008), 
hence wildlife and livestock are potentially in close contact.   
Rift Valley fever virus was first documented in Tanzania in 1930 and since then 
periodic outbreaks of the disease have occurred in the country, major epidemics 
were reported in 1947, 1957, 1977/1978, 1997/1998 and 2006/2007. The largest 
RVFV outbreak in Tanzania was the most recent outbreak which affected 175 
villages in North East and Central Tanzania in 2006/2007 (Sindato et al., 2014). A 
total of 144 human deaths were reported from this outbreak (Mohamed et al., 
2010) and there were 32,000 reported cases in animals (Nanyingi et al., 2015). In 
addition to human fatalities, RVFV outbreaks also have significant socio-
economic implications, to the extent that the 2006/2007 RVFV outbreak in 
Tanzania was declared a national disaster (Fyumagwa et al., 2011).    
In this Chapter we perform three sero-epidemiological studies of RVFV in 
Northern Tanzania. The first study explores RVFV seroprevalence in lions living in 
the SNP; the second study investigates two wild ruminant species (African 
buffalo and gazelle) for evidence of RVF VNAb; and the third study is a 
longitudinal serosurvey of livestock from the Serengeti and Loliondo districts. 
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Figure 6.1 Map of Northern Tanzania demonstrating the locations of the 
Serengeti National Park and Ngorongoro Conservation Area. Map of North 
East Tanzania, thick black lines demonstrate the boundaries of the SNP and NCA 
(boundaries were reproduced from Somers and Hayward (2012)). Maps were 
produced in Google My Maps (Google, 2016). 
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6.2 Results  
6.2.1 Rift Valley fever virus neutralising antibodies in lions from the Serengeti 
National Park 
We had access to lion samples which had been opportunistically collected as 
part of management or research interventions in the SNP between 2008 and 
2011. Sera had been collected from lions within, or close to the border of the 
SNP (Figure 6.2). These sera were considered an interesting sample set to test 
for RVF VNAb, as a previous serological survey had demonstrated antibodies in 
African lions (House et al., 1996). To investigate whether these lions had been 
exposed to RVFV, 36 samples were tested on the RVFV-luc NT.  
The number of samples collected per year was fairly evenly distributed, however 
sampling was highly skewed towards female lions (88%) (Table 6.1). Age data 
recorded for the lions was approximate, estimated on the basis of nose 
colouration (Whitman et al., 2007), and was typically recorded as adult (3+ y), 
young adult (18 m – 3 y) or young (<18 m). Thirty-three of the lions tested were 
classified as adults, two as young adults and one as young.  
Twelve lion samples tested positive for RVF VNAb, with positive samples 
observed in all years included in the study (Figure 6.3). The overall 
seroprevalence in these lions was 33% (95% CI 19-50%). Eleven of the positive 
samples were from adult lions, and one positive result was obtained from the 
only ‘young’ lion among the sampled individuals. The sample from the young lion 
was collected in November 2010, 3 years following the end of the 2006/2007 
RVFV outbreak, this lion would therefore have lived only through IEP. The results 
of our study support previous evidence of RVFV exposure in African lions and 
additionally provides evidence of inter-epidemic exposure and seroconversion to 
RVFV in lions in the Serengeti ecosystem. 
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Figure 6.2 Map of the Serengeti National Park displaying locations of lions 
tested for Rift Valley fever virus neutralising antibodies. Map of the SNP in 
Northern Tanzania demonstrating the locations of lion sampling. Green circles 
represent locations of lions which tested negative for RVF VNAb, red circles 
represent locations of lions which tested positive for RVF VNAb. A small amount 
of random displacement in map locations has been added to allow visualisation 
of overlapping data points. Location data was available for only 33 lions tested 
in this study.  
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Year M F NK Total 
2008 -  6 [1] - 6 (17%) 
2009 - 7 [3] - 7 (43%) 
2010 4 [1] 6 [3] - 10 (40%) 
2011 - 9 [3] 1 [1] 10 (40%) 
NK - 1 [0] 2 [0] 3 (0%) 
Total 4 (25%) 29 (34%) 3 (33%) 36 (33%) 
 
Table 6.1 Sample distribution of lion samples tested for Rift Valley fever 
virus neutralising antibodies.  Lion samples from the Serengeti National Park 
in Tanzania, collected between 2008 and 2011, were tested for VNAb using the 
RVFV-luc NT. Numbers in square brackets represent the number of lions testing 
positive for RVF VNAb. Numbers in brackets represent the percentage of animals 
testing positive for VNAb. NK = not known.  
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Figure 6.3 Levels of neutralisation of recombinant Rift Valley fever virus 
by lion sera. Thirty-six lion sera were tested for the presence of RVF VNAb using 
the RVFV-luc NT. The red dotted line represents a level of 98% neutralisation. 
Numbers above the bars represent the percent neutralisation in VNAb positive 
samples. 
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6.2.2 Rift Valley fever virus neutralising antibodies in African buffalo and 
gazelle in the Serengeti National Park and Ngorongoro Conservation Area 
In this study 173 serum samples from African buffalo (n=99) and gazelle (n=74) 
from within the SNP or from NCA were tested for RVF VNAb using the RVFV-luc 
NT. Samples had been collected during wildlife disease surveillance, research 
and conservation management and were available from an archived serum bank. 
This study included 34 samples (21 African buffalo and 13 gazelle) that had 
previously been tested during validation of the RVFV-luc NT in Chapter 5.  
Gazelle samples comprised samples from both Thomson’s (n=63) and Grant’s 
gazelle (n=11) collected between 1993 and 2012. Four of the 74 samples tested 
positive for RVF VNAb, providing an overall seroprevalence in gazelle of 5% (95% 
CI 2-13%). All seropositive samples derived from animals sampled in the NCA in 
2004 and included both Thomson’s and Grant’s gazelles (Table 6.2), however no 
samples were available for testing from gazelles in the SNP at this time point. 
Overall, seroprevalence was significantly higher in gazelles in the NCA, 13% (95% 
CI 4-29%) compared to those in the SNP 0% (95% CI 0-10%) (X2=4.8, n=68, df=1, 
p=0.029). No age data were available for the seropositive Thomson’s gazelle, 
however of the seropositive Grant’s gazelles, two were classified as young and 
the remaining animal was classified as a sub-adult in 2004, hence all three 
animals would have lived only through IEP.   
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 Ecosystem  
 Serengeti Ngorongoro Unknown  
Year Thomson Grant Thomson Grant Thomson Grant Total 
1993 - - - - 6 [0] - 6 [0] 
1994 3 [0] - - - - - 3 [0] 
2004 - - 7 [1] 6 [3] - - 13 [4] 
2006 3 [0] - - - - - 3 [0] 
2007 1 [0] 5 [0] - - - - 6 [0] 
2010 2 [0] - - - - - 2 [0] 
2012 22 [0] - 19 [0] - - - 41 [0] 
Total 31 (0%) 5 (0%) 26 (4%) 6 (50%) 6 (0%) 0 74 (5%) 
 
Table 6.2 Distribution of Thomson’s and Grant’s gazelle samples tested for 
Rift Valley fever virus neutralising antibodies.  Thomson’s and Grant’s 
gazelle samples from the SNP and NCA, collected between 1993 and 2012, were 
tested for VNAb using the RVFV-luc NT. The numbers in square brackets 
represent the number of gazelle testing positive for VNAb. The numbers in 
brackets represent the percentage of animals testing positive for RVF VNAb. 
 
 
Ninety-nine African buffalo samples, collected between 2007 and 2012, from 
animals in the SNP (n=49) and NCA (n=50) were tested for RVF VNAb. Thirty-two 
of the 99 samples were positive for VNAb, providing an overall seroprevalence of 
32% (95% CI 23-43%) (Table 6.3). The seroprevalence in African buffalo from the 
NCA was significantly greater (46%, 95% CI 32-61%) than for buffalo from the SNP 
(18%, 95% CI 9-32%), (X2=8.6, n=99, df=1, p=0.029). 
Age data, determined from tooth eruption and horn growth and size (Sinclair, 
1977) were available for 74% (n=73) of buffalo tested in this study. Using this 
data we calculated the RVFV age seroprevalence in these buffalo. Due to small 
sample sizes in each age class, data had to be combined for analysis (Table 6.4). 
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Seropositivity was significantly associated with age (X2=11.9, n=73, df=5, 
p=0.036), with seroprevalence generally increasing with increasing age.  The 
seroprevalence of animals which had lived through the 2006/2007 outbreak was 
39% (95% CI 25-54%) and for those born after the outbreak, seroprevalence was 
8% (95% CI 1-27%). Samples from two young buffaloes (3 and 4 years old) 
collected in 2012 were seropositive, providing evidence of infection during the 
IEP. As buffalo in this study were wild, age data is only an approximation, 
however the accuracy of tooth eruption in young buffalo (<5 years of age) is 
reported to be +/- 0.5 years (Grimsdell, 1973) and therefore we are confident 
that VNAb in these two African buffalo demonstrates evidence of inter-epidemic 
transmission of RVFV.  
 
 
 
Ecosystem  
Year Serengeti Ngorongoro Total 
2007 13 [6] - 13 (46%) 
2010 8 [0] - 8 (0%) 
2011 15 [3] 20 [13] 16 (46%) 
2012 13 [0] 30 [10] 43 (23%) 
Total 49 (18%) 50 (46%) 99 (32%) 
 
Table 6.3 Distribution of African buffalo samples tested for Rift Valley 
fever virus neutralising antibodies.  African buffalo samples from the SNP and 
NCA, collected between 2007 and 2012, were tested for VNAb using the RVFV-luc 
NT. The numbers in square brackets represent the number of animals testing 
positive for VNAb, the numbers in brackets represent the percentage of animals 
testing positive for RVF VNAb.  
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Age Number positive/tested Seroprevalence 
<3 y 0/8 0% 
3-4 y 4/22 18% 
5-6 y 3/14 21% 
7-8 y 1/4 25% 
9-10 y 6/10 60% 
>10 y 7/15 47% 
Total 21/73 29% 
 
Table 6.4 Age seroprevalence of Rift Valley fever virus in African buffalo.  
Seroprevalence of Rift Valley fever virus in African buffalo when classified by 
age (n=73).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6. A sero-epidemiological study of Rift Valley fever virus in Tanzania                       213 
 
      16
1
 
To compare the serology results obtained using the RVFV-luc NT, the buffalo 
samples tested in this study were also tested by RVFV recN indirect IgG ELISA 
(Paweska et al., 2007). Ninety-eight of the African buffalo samples tested by the 
RVFV-luc NT were also tested by ELISA. One sample was not tested due to an 
inadequate volume of serum available. The results of the RVFV-luc NT and the 
ELISA were consistent for the majority of samples (85%) (Table 6.5). Cohen’s 
kappa was employed which reported a good agreement between both assays, 
ĸ=0.64 (95% CI 0.48-0.81). 
 
  RVF indirect IgG ELISA 
R
V
F
V
-l
u
c
 N
T
  Positive Negative 
Positive 23 8 
Negative 7 60 
 
Table 6.5 Rift Valley fever virus serology results of African buffalo when 
tested by RVFV-luc NT and ELISA. Ninety-eight African buffalo samples were 
tested for RVFV antibodies by the RVFV-luc NT and the RVFV recN indirect IgG 
ELISA and categorised as positive or negative. Cut-off values for seropositivity 
for the RVFV-luc NT was ≥98% and for the RVFV recN IgG indirect ELISA it was 
≥31.0. RVFV recN indirect IgG ELISA was kindly performed by Dr. Ayman Samman 
(University of Glasgow).      
 
 
6.2.3 Rift Valley fever virus neutralising antibodies in domestic ruminants in 
Northern Tanzania  
In 2009 a longitudinal study of cattle, sheep and goats from villages surrounding 
the SNP and NCA was performed to determine the seroprevalence of RVFV 
antibodies in these species. The project was intended to provide baseline 
seroprevalence data to inform models used to predict RVFV outbreaks based on 
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climate and rainfall data. A selection of samples were initially tested for RVFV 
antibodies using commercial ELISAs, however the authors of the study 
experienced poor repeatability using such assays, therefore this sample set was 
never fully tested. With the development of the RVFV-luc NT, we were able to 
test these samples for RVF VNAb. 
Three sets of samples were collected at four month intervals, with initial 
samples (time point 1) collected between October and December 2009, the 
second samples (time point 2) were collected between February and March 2010 
and final samples (time point 3) were collected in June and July 2010. A total of 
1348 animals were recruited into the study, this cohort comprised of 697 cattle, 
444 goat and 207 sheep (Table 6.6). Livestock sampling was conducted in two 
areas; the Serengeti district to the west of the SNP, and Loliondo district to the 
East of the SNP and to the north of the NCA (Figure 6.4). Livestock samples were 
collected from eight villages in each area with three herds being sampled in 
each village. The majority of herds were of mixed species although a handful of 
these herds were comprised solely of cattle or goats. A total of 646 and 702 
animals were recruited from the Serengeti and Loliondo districts respectively.   
Due to time constraints we were unable to test samples from all three time 
points, therefore we chose to test samples from time points 1 and 3 only, 
allowing for the most time to have passed between sampling.  
 
Chapter 6. A sero-epidemiological study of Rift Valley fever virus in Tanzania                       215 
 
      16
1
 
 
Figure 6.4 Map of villages in the Serengeti and Loliondo districts where 
livestock were recruited for a Rift Valley fever virus serosurveillance 
study. Map of the areas surrounding the SNP and NCA, demonstrating locations 
of villages included in the study. Pie charts represent the proportions of animals 
testing RVF VNAb positive (red) and negative (green) in each village at tp 1. Size 
of the circles is proportional to the number of samples tested in each village.  
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District Village Species 
Number of 
animals 
Total animals 
per village 
Serengeti 
 
Bonchugu 
Cattle 57 
87 Sheep 10 
Goat 20 
Bukore 
Cattle 35 
83 Sheep 21 
Goat 27 
Mariwanda 
Cattle 54 
76 Sheep 0 
Goat 22 
Miseke 
Cattle 36 
56 Sheep 0 
Goat 20 
Nata 
Cattle 67 
101 Sheep 4 
Goat 30 
Nyamburi 
Cattle 41 
65 Sheep 6 
Goat 18 
Robanda 
Cattle 47 
98 Sheep 20 
Goat 31 
Singisi 
Cattle 29 
80 Sheep 19 
Goat 32 
Loliondo 
 
Engaresero 
Cattle 44 
90 Sheep 15 
Goat 31 
Enguserusambu 
Cattle 45 
90 Sheep 19 
Goat 26 
Kisangiro 
Cattle 43 
90 Sheep 9 
Goat 38 
Maaloni 
Cattle 48 
93 Sheep 17 
Goat 28 
Malambo 
Cattle 38 
90 Sheep 20 
Goat 32 
Masusu 
Cattle 45 
90 Sheep 15 
Goat 30 
Piyaya Cattle 29 75 
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Sheep 15 
Goat 31 
Wasso 
Cattle 39 
84 Sheep 17 
Goat 28 
Total 
   
1348 
 
Table 6.6 Livestock enrolled in the Rift Valley fever virus serosurveillance 
study. Cattle, sheep and goats from 16 villages from either the Serengeti (n=8) 
or Loliondo districts (n=8) of Tanzania were enrolled in a RVFV serosurveillance 
study in 2009. 
 
 
Samples collected at the first time point (n=1302) were tested for VNAb using 
the RVFV-luc NT. A total of 207 animals demonstrated VNAb, providing an overall 
seroprevalence of 16% (95% CI 13-19%) (Table 6.7). Thirty-seven of the 44 study 
herds (84%) included at least one animal with RVF VNAb, three of the 
seronegative herds were from villages within the Serengeti district and 4 were 
from villages in Loliondo district. Individual village seroprevalence for villages in 
the Serengeti area ranged from 12% to 20% and for villages in Loliondo this 
ranged from 2% to 35%. Villages Enguserusambu and Wasso, which are close to 
the Kenyan border, had the lowest seroprevalence with only 2 seropositive 
animals in each village (Figure 6.4).  
There was no significant difference in seroprevalence between species, with 16% 
of cattle (95% CI 13-19%), 14% of sheep (95% CI 9-19%) and 18% of goats (95% CI 
14-22%) seropositive (X2=1.4, n=1302, df=2, p=0.49). Cattle and goats had the 
highest seroprevalence in villages in the Serengeti region whereas sheep and 
goats had the highest seroprevalence in Loliondo (Table 6.7). However this may 
be influenced by the age distribution of livestock in each area, as there were a 
larger proportion of older cattle in villages from the Serengeti region than in 
Loliondo and higher numbers of sheep and goats aged over 5 years in Loliondo 
than in the Serengeti villages (Table 6.7). 
The 2006/2007 RVFV outbreak in Tanzania occurred over two years prior to 
commencement of this study, therefore livestock in this study classified as less 
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than one year of age would have lived through IEP only. Livestock of one year or 
younger comprised 25% of the total number of seropositive animals in the study, 
strongly suggesting RVFV is present during IEP in both the Serengeti and Loliondo 
regions. The seroprevalence of animals that had lived through the 2006/2007 
outbreak (n=600) was 17% (95% CI 14-20%) and for those born after the end of 
the outbreak (n=700) the seroprevalence was 15% (95% CI 13-18%). 
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District Species Age Total 
 
 
<6 months 6-12 months 1-5 years >5 years Unknown 
 
Serengeti 
Cattle 34 (12%) 56 (7%) 152 (19%) 110 (22%) 1 (0%) 353 (17%) 
Sheep 3 (0%) 29 (10%) 43 (7%) 2 (0%) 0 (0%) 77 (8%) 
Goat 35 (11%) 57 (18%) 80 (20%) 11 (9%) 1 (0%) 184 (17%) 
Total 72 (11%) 142 (12%) 275 (17%) 123 (20%) 2 (0%) 614 (16%) 
Loliondo 
Cattle 5 (20%) 94 (11%) 157 (15%) 68 (15%) 0 324 (14%) 
Sheep 3 (0%) 24 (17%) 77 (18%) 21 (19%) 0 125 (18%) 
Goat 1 (0%) 45 (24%) 145 (16%) 48 (21%) 0 239 (18%) 
Total 9 (11%) 163 (15%) 379 (16%) 137 (18%) 0 688 (16%) 
 
Table 6.7 Prevalence of Rift Valley fever virus neutralising antibodies in livestock in Tanzania.  Age, species and location data of 
1302 livestock samples tested for RVF VNAb, collected in 2009 from either the Serengeti or Loliondo districts of Tanzania. 
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A generalised mixed-effects model was used to investigate whether species, age 
and sex were associated with seropositivity to RVFV. Seropositivity at time point 
one was used as the response variable and was assessed as a binary value. 
Species, sex and age were considered as fixed effect explanatory variables. 
Individuals sampled from the same location did not represent statistically 
independent data points, therefore to reflect this, the district, village and herd 
of sampled individuals were accounted for using a nested random effect. Models 
including interactions between fixed effects did not converge and therefore 
could not be properly assessed. All animals with complete information for all 
variables were included in the model (n=1300).  
Using a backward elimination procedure, nested models were compared using 
likelihood ratio tests to determine which of the fixed effects should be included 
in the final model (Table 6.8). Model selection indicated that seropositivity to 
RVFV was significantly lower in males compared to females (p=0.023). 13% (95% 
CI 9-16%) of male animals demonstrated VNAb compared to 17% (95% CI 15-20%) 
of females. Previous studies of RVFV seroprevalence in domestic livestock have 
also demonstrated higher seroprevalence rates in females than males (Sumaye et 
al., 2013, Ringot et al., 2004). 
Individual generalised linear models were used to further elucidate the 
relationship between seropositivity and sampling location. No difference in 
seropositivity rates were observed between the Serengeti and Loliondo districts 
(p=0.96), however at the village and herd level there were highly significant 
associations between seropositive animals and the village (p<10-10) or herd (p<10-
12) they were sampled from.  
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Model AIC Log Likelihood Degrees of 
freedom 
p-value 
D/V/H + S + Sx + A 1104.0 -544.0 8 0.773 
D/V/H + Sx + A 1100.5 -544.2 6 0.139 
D/V/H + Sx 1100.7 -545.3 5 0.023 
D/V/H 1103.8 -547.9 4 1.08 x10-9 
Intercept  model 1142.5 -570.2 1 - 
  
Table 6.8 Values associated with model selection used to derive the 
model of seropositivity to Rift Valley fever virus. Model formulae 
demonstrate variables included in the model (D=district, V=village, H=herd, 
S=species, Sx=sex, and A=age). Italics are used to indicate random effects while 
other terms were fixed effects, forward slashes indicate a nested model 
structure. For each model, AIC, log likelihood and degrees of freedom used in 
the model are shown. p-values are shown for the emboldened and underlined 
term in each model. These were derived from likelihood ratio tests between the 
model shown inline and the nested model below.  
 
 
At time point 3 a total of 773 samples were collected from animals originally 
enrolled in the study, the reasons given by farmers for the remaining animals 
being unavailable for sampling included the animal dying, being moved away, 
slaughtered, returned to its owner or being sold. A total of 617 of the 773 
samples were available for RVF VNAb testing in our study, representing 12 of the 
original 16 villages included in the study. A small number of samples (n=34) 
collected at time point 3 were from animals which were not tested for RVF VNAb 
at time point 1 (Table 6.9).  
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Tested at time point 3 
(June-July 2010) 
 
  Yes No Total 
T
e
st
e
d
 a
t 
ti
m
e
 p
o
in
t 
1
 (
O
c
t-
D
e
c
 2
0
0
9
) 
Yes 583 719 1302 
No 34 0 34 
 Total 617 719 1336 
 
Table 6.9 Samples tested for Rift Valley fever virus neutralising antibodies 
at time points one and three. The number of samples tested from each time 
point in this study. A total of 1919 samples, from 1336 animals, were tested in 
this study. These numbers represent only samples used in this study and do not 
represent the number of samples collected in the original study.  
 
 
At time point 3 the seroprevalence was 11% (95% CI 7-15%) in the Serengeti 
district and 15% (95% CI 11-19%) in Loliondo district. In the 6-8 months since 
initial testing, 26/457 individuals (6%, 95% CI 4-8%) showed evidence of 
seroconversion to RVFV. Animals that seroconverted (cattle n=14, goat n=7, 
sheep n=5) during the study period came from 8 of the 12 villages tested at time 
point 3. The individual village level seroprevalence for both time points is 
presented in Figure 6.5, and there are contrasting seroprevalence rates of RVF 
VNAb in some villages at the first and final time points.  
We further examined these longitudinal data to investigate the RVFV antibody 
status of individual animals at both time points (Table 6.10a). Of the 583 
animals tested at both time points, the majority of animals that tested negative 
at time point 1 were also negative at time point 3. Of the 126 animals which 
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were seropositive at time point 1 only 39% remained VNAb positive at time point 
3. Animals that were VNAb positive at time point 1 and then became 
seronegative were termed ‘seroreverters’. We compared the characteristics of 
the animals depending on their RVF VNAb status throughout the study, analysing 
age, species, sex and whether the samples came from the Serengeti and 
Loliondo districts (Table 6.11).  
To statistically investigate predictors of seroconversion and seroreversion, 
generalised mixed-effects models were utilised.  A model was used to determine 
whether species, sex, or age could be used as predictors of seroconversion or 
seroreversion during the study period. Seroconversion and seroreversion were 
considered binary response variables that were modelled with a binomial error 
structure. As in the seropositivity model (Table 6.8), sampling location was 
accounted for using a nested random effect. Neither species, sex nor age was 
found to correlate significantly with seroconversion or seroreversion. Separate 
generalised linear models were used to further elucidate the relationship 
between antibody status and sampling location. In both seroconversion and 
seroreversion models, village (p<0.0001) and herd (p<0.005) were statistically 
associated with serostatus, however district was not. 
The ROC analysis in Chapter 5 suggested a cut-off value of 94% for the RVFV-luc 
NT, however we opted for a more stringent cut-off of ≥98% to ensure optimum 
specificity of the assay, perhaps at the expense of sensitivity (sensitivity=94% 
and specificity=100%). To investigate whether the same serological patterns 
were observed using the lower cut-off of ≥94%, we compared the RVF VNAb 
status of samples tested at both time points using both test cut-offs (Table 
6.10), and similar levels of seroreversion were demonstrated. 
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Figure 6.5 Village level seroprevalence of Rift Valley fever virus 
neutralising antibodies at time point one and time point 3. Livestock from 
villages in the Serengeti and Loliondo districts were tested for RVF VNAb and 
seroprevalence rates were calculated for time point 1 (Oct-Dec 2009) (n=1302) 
and time point 3 (June-July 2010) (n=617). *represents villages that were not 
tested at time point 3. The numbers above June-July 2010 seroprevalence bars 
indicate the number of animals in that village which seroconverted to RVFV 
between time points one and three. Error bars represent 95% confidence 
intervals. a) Includes all animals tested at each time point (n=1919) b) includes 
only animals tested at both time points (n=583). 
 
 
 
a)  ≥98% cut-off  b)  ≥94% cut-off 
  Time point 3    Time point 3 
  NEG POS    NEG POS 
T
im
e
 p
o
in
t 
1
 
NEG 431 (94%)  26 (6%)   
T
im
e
 p
o
in
t 
1
 
NEG 335 (85%) 57(15%) 
POS 77 (61%) 49 (39%)  POS 104 (54%) 87 (46%) 
 
Table 6.10 Comparison of Rift Valley fever virus antibody status of 
livestock tested at both time points using two assay cut-off values. 
Longitudinal data (n=583) was analysed using two cut-off values for the RVFV-luc 
NT test a) ≥98% and b) ≥94%. 
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  Sero-
reverters 
Consistent 
seropositives 
Consistent 
seronegatives 
Sero-
converters 
A
g
e
 
<1 y 16% 6% 16% 15% 
1-5 y 61% 65% 73% 81% 
5+y 23% 29% 11% 4% 
S
p
e
c
ie
s 
Cattle 57% 51% 61% 54% 
Sheep 16% 9% 29% 19% 
Goat 27% 40% 10% 27% 
S
e
x
 Female 79% 86% 71% 77% 
Male 21% 14% 29% 23% 
D
is
tr
ic
t Serengeti 40% 43% 48% 42% 
Loliondo 60% 57% 52% 58% 
 
Table 6.11 Characteristics of animals classified by Rift Valley fever 
antibody status at time point 3. Animals which tested RVF VNAb positive at 
time point 1 and became RVF VNAb negative at time point 3 were termed 
‘seroreverters’ (n=77), those which remained VNAb positive at time point 3 were 
termed ‘consistent seropositives’ (n=49). Animals which seroconverted between 
the two time points were termed ‘seroconverters’ (n=26) and those which 
remained seronegative throughout the study were termed ‘consistent 
seronegatives’ (n=431). The age, sex, species and district of animals in both 
groups were compared.   
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6.3 Discussion  
Rift Valley fever virus has devastating effects on the economy, human health 
and animal health and production during outbreaks. Active surveillance is 
required during IEP to improve predictions, and the early detection, of RVFV 
outbreaks. Currently the majority of RVFV surveillance in Tanzania is passive, 
relying on communities who have little contact with veterinarians reporting 
potential RVFV cases. Additionally, the symptoms of RVFV are similar to other 
diseases such as peste des petits ruminants virus and brucellosis, and outwith 
RVFV epidemics the virus is not always considered by farmers as a cause of 
disease (Wensman et al., 2015). Robust serological assays are required to allow 
for active serosurveillance. The RVFV neutralisation test developed in Chapter 5 
allows for high-throughput detection of RVF VNAb from sera, of any species, with 
results available in less than 8 hours.  
These studies clearly demonstrate the value of applying the RVFV-luc NT to the 
investigation of the multi-host epidemiology of RVFV in a complex, natural 
ecosystem. Although inter-epidemic circulation of RVFV has been documented 
previously in Southern Tanzania (Sumaye et al., 2013, Sumaye et al., 2015) and 
elsewhere in East Africa (Evans et al., 2008), these studies add to our 
understanding of spatial and temporal patterns of RVFV circulation. The key 
findings of these epidemiological studies include 1) evidence of infection in a 
wide range of mammalian host species, including several wildlife (lions, buffalo 
and gazelles) and livestock species (cattle, sheep and goats); 2) robust support 
for the existence of inter-epidemic circulation of RVFV; 3) evidence of high rates 
of seroreversion in livestock, suggesting a rapid decline in VNAb titres in villages 
with no or low levels of recent infection.  
In this study we demonstrated a high RVFV seroprevalence in lions, a species 
that has been scarcely mentioned in the RVFV literature. The only published 
account of RVF VNAb in lions documented seropositivity in 56% (9/16) of lions 
from Ngorongoro and 10% (3/31) of lions from the Kruger National Park, South 
Africa (House et al., 1996). In their study, samples from lions, African wild dogs 
and cheetahs were tested for RVF VNAb with only lions demonstrating 
seropositivity. Additionally, a large unpublished study on RVFV serosurveillance 
in lions from the SNP, performed by Prof. Craig Packer (University of Minnesota), 
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also documented RVF VNAb in lions. In his study 240 lion serum samples, 
collected between 1984 and 1999, were tested for RVF VNAb using the VNT. 
Samples collected between 1984 and 1997 all had titres of ≤40, whereas 40% of 
lions sampled in 1998 and 1999 were seropositive (Packer, 2016, unpublished 
data), possibly suggesting infection in lions after the RVFV outbreak in Tanzania 
in 1997/1998. Clinical disease has not been reported in lions, either due to RVFV 
causing only subclinical infections or as it is not considered a cause of disease in 
this species. There have been many reports of lions being infected with 
pathogens not primarily associated with wild felids, such as canine distemper 
virus, rabies and bovine tuberculosis (Roelke-Parker et al., 1996, Berentsen et 
al., 2013, Renwick et al., 2007), hence RVFV infection in lions would not come 
as a complete surprise. Lions may become infected with RVFV either directly via 
the bite of an infected mosquito, or by ingestion of infected prey, such as 
gazelle and buffalo; species which demonstrated evidence of infection in our 
study.  
Our finding of seropositivity in buffalo is consistent with previous studies 
demonstrating high prevalence of antibodies to RVFV in African buffalo from 
Kenya (Evans et al., 2008), South Africa (LaBeaud et al., 2011, Beechler et al., 
2015), Botswana (Jori et al., 2015) and Tanzania (Sindato et al., 2013). Reports 
of antibodies to RVFV in gazelle have also been previously reported (Britch et 
al., 2013, Evans et al., 2008), however this study is, to our knowledge, the first 
to report seropositivity in Grant’s gazelle. With 75% of seropositive individuals 
this species, further investigation into the role of Grant’s gazelle in the 
epidemiology of RVFV is clearly warranted.  Clinical symptoms of RVFV infection 
have been observed in both buffalo and gazelle (Beechler et al., 2015, ProMED-
mail, 2013) and additional research is required to further elucidate the role of 
these wildlife species in RVFV maintenance.  
In this study we detected RVF VNAb in 16% of domestic livestock tested. 
Seroprevalence studies from other regions of Tanzania have demonstrated RVFV 
seroprevalence of 40% in livestock during outbreaks (Chengula et al., 2014) and 
8-11% seropositivity outwith outbreaks (Wensman et al., 2015, Sumaye et al., 
2013). Additionally, RVFV antibodies have been demonstrated in livestock from 
regions of the country that have never experienced RVFV outbreaks (Kifaro et 
al., 2014).  
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In both gazelle and buffalo the number of RVF VNAb positive animals was higher 
in wild ruminants from NCA compared to those from the SNP. The NCA and 
Loliondo district are considered high risk areas for RVFV, with outbreaks 
recorded historically in this area during many of the previous epidemics (Sindato 
et al., 2014). However the precise risk factors are still uncertain and it is 
unknown whether the same risk factors that predispose to an epidemic during 
periods of high rainfall are the same as those that predispose to infection during 
IEP. An interesting observation from this study was that, unlike wild ruminants, 
the seroprevalence of livestock was similar in both the Serengeti and Loliondo 
districts and further analysis will be required to identify risk factors in the 
different regions.  
Numerous gaps still remain in understanding the epidemiology of RVFV during 
IEP. The leading hypothesis suggests RVFV does not circulate between outbreaks, 
but is instead maintained in mosquito eggs. However, there is now a growing 
body of evidence suggesting RVFV is indeed circulating and being maintained in 
mammalian hosts between outbreaks. In this Chapter we observe VNAb in 
animals, of all species tested, which have lived only through IEP. The 
longitudinal data also reveals geographically widespread infection during IEP 
which has seldom been documented in previous serosurveys as these have 
tended to concentrate on single areas. A limitation of the studies presented in 
this Chapter, and the use of VNTs in general, is that we cannot comment on the 
recency of infection, which can only be inferred by use of IgM ELISA, or directly 
via virus detection. However, as we have accurate age data for the majority of 
animals in our studies, we can be confident that the data presented here 
represents evidence of inter-epidemic transmission of RVFV in Northern 
Tanzania.  
Previous studies have also reported RVFV antibodies in animals which have lived 
only through IEP, these include both livestock (Sumaye et al., 2013, Lichoti et 
al., 2014, Rostal et al., 2010, Wensman et al., 2015) and African buffalo 
(Beechler et al., 2015), and further studies have observed the same in humans 
(LaBeaud et al., 2008, Sumaye et al., 2015, Gray et al., 2015). The results 
presented in this Chapter provide strong evidence for widespread, low-level 
circulation of RVFV in a multi-host ecosystem during IEP. 
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In the longitudinal study of livestock we observed a high proportion of RVF VNAb 
positive animals whom were antibody negative when re-tested 6-8 months later. 
These results were unexpected, as in the literature many describe RVF VNAb as 
being lifelong (Lwande et al., 2015, Jori et al., 2015, Pepin et al., 2010, 
Paweska et al., 2005). However, Niklasson et al. (1984) demonstrated a peak in 
RVF VNAb around 6 weeks post infection which dropped significantly to around a 
titre of 1:40 at 26 weeks post infection, furthermore very little data is available 
on the duration of RVF VNAb in natural infection. It is unknown whether animals 
that were previously VNAb positive, but now have undetectable antibody titres 
would still be provided protection from infection. 
A small proportion of animals that were less than one year of age at time point 1 
may have demonstrated seroreversion during the study period due to the loss of 
maternal RVFV antibodies, as maternal antibodies wane at around 7 months of 
age (Sumaye et al., 2013). However, this would only explain a very small 
proportion of seroreversions observed in our study. We also considered that the 
stringent cut-off of ≥98% on the RVFV-luc NT could have artificially elevated the 
number of seroreverters observed in this study, due to lowering the assay 
sensitivity. However, we reanalysed the results of all paired samples tested 
using the lower threshold of 94% and observed similar serological patterns (Table 
6.10).  
We hypothesise that the high proportion of animals demonstrating seroreversion 
may be due to waning of antibody after natural infection. As the date of 
exposure in these animals is unknown however such a hypothesis is difficult to 
evaluate. A high proportion of seroreverters were observed in villages in which 
no seroconversions were detected during the study period. Additionally, 
statistical models revealed no correlation between species, sex or age in relation 
to seroreversion, however significant correlations between village and herd were 
demonstrated. These results may suggest maintaining detectable antibody levels 
may rely on constant priming of the immune system with repeated viral 
exposures.   
Fafetine et al. (2013) performed longitudinal studies in sheep and goats in 
Mozambique and demonstrated 2/9 animals which were RVFV IgG positive at the 
beginning of the study were seronegative after 3-4 months. A longitudinal study 
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of African buffalo in South Africa also documented seroreversion in five buffalo 
over a six year study period (LaBeaud et al., 2011). In both of these studies the 
numbers of animals investigated was small. Our longitudinal study provides 
preliminary evidence of antibody waning in a cohort of over 500 naturally 
infected animals, which is the most comprehensive study to date. Further 
research is required to investigate the rate at which antibodies to RVFV wane 
over time. Analysing the middle time point (time point 2) from the original 
study, in addition to quantifying antibody titres would be essential to provide 
further evidence on the apparent waning of antibody observed in these animals, 
and this should be the initial experiment performed in any further research on 
this cohort. It is likely that herd immunity would significantly impact on the 
likelihood of an outbreak occurring and we may find that part of the complex 
ecology that allows explosive outbreaks to occur, includes the depletion of RVFV 
herd immunity.  
Many of the seroprevalence studies in the literature utilise commercially 
available ELISAs to detect antibodies to RVFV, such ELISAs have been shown to 
cross-react with other phleboviruses and have a high background which may 
cause false positive results. Owing to such high rates of false positives, some 
studies have used ELISAs to screen large numbers of animals for RVFV IgG and 
then confirm these using the VNT. Although ring trials have reported greater 
than 90% agreement between ELISAs and VNT, it appears to be much lower 
under field conditions, with correlations of 52% being reported in humans (Gray 
et al., 2015), 61% in buffalo (Evans et al., 2008) and 24-55% in domestic livestock 
(Kariithi et al., 2010, Boussini et al., 2014). In this study we tested African 
buffalo sera on both the RVFV-luc NT and a commercial indirect IgG ELISA and 
demonstrated a good correlation between the assays, however 15% of the results 
were discordant. Four of the 15 discordant samples had previously been tested 
by RVFV IgM capture ELISA, on IgM testing two samples were in agreement with 
results obtained from the RVFV-luc NT, one was in agreement with the RVFV IgG 
ELISA, and one was equivocal so could not be compared.  
Such results demonstrate the variability in RVFV serology data reported 
depending on the test used, further supporting the essential requirement for 
robust and repeatable serological assays for surveillance. This further reinforces 
the use of the more stringent cut-off of ≥98% in the RVFV-luc NT, to retain the 
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highest levels of specificity. It should however be noted that antibodies detected 
in the RVFV-luc NT are antibodies capable of neutralising virus, these VNAb are 
produced predominantly against epitopes on the viral glycoproteins, in contrast 
to antibodies detected in the commercial ELISAs which are raised to the viral 
nucleoprotein. Although natural exposure to RVFV should elicit antibodies to 
both viral glycoproteins and the nucleoprotein, the antibody titre and duration 
of these antibodies may vary.  
Although we reported a sensitivity and specificity of 94% and 100% respectively 
for the RVFV-luc NT in Chapter 5, this data was based on a small validation panel 
(n=49) and the results of these serosurveys should be interpreted with this in 
mind. The test ideally requires validation using a larger collection of sera 
previously tested using the VNT, and further validation of the RVFV-luc NT is 
currently ongoing. Additionally, it would be preferable to screen sera on the 
RVFV-luc NT using a single serum dilution of 1:100 (as performed in these 
studies) and then further titrate out sera which test positive, to provide a 
quantitative VNAb titre. Given more time we would have applied this protocol to 
all positive samples in these serosurveys, to provide further confidence in the 
results presented herein.  
The results of these sero-epidemiological studies establish the need for 
continued surveillance of RVFV in both domestic and wildlife species. 
Understanding the dynamics of RVFV, including IEP infection patterns, is 
critically important to identify potential approaches to disease control strategies 
in Tanzania. Integrating RVFV serology into already established disease 
monitoring programmes in and around the SNP would greatly improve the 
understanding of the disease dynamics in such a complex ecosystem. Based on 
the results presented herein, which support epidemiological data obtained using 
classical antibody detection methods, the RVFV-luc NT appears to be a reliable 
high-throughput alternative to the VNT.  
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 Chapter 7. Discussion  
 
7.1 Alternative neutralisation tests 
Understanding viral disease ecology, especially for viruses in which multiple host 
species exist, relies heavily on serology. In this thesis I developed two assays, 
the rabies virus pseudotype neutralisation test (pNT) and the Rift Valley fever 
virus luciferase neutralisation test (RVFV-luc NT), for the detection of virus 
neutralising antibody (VNAb) to these two important zoonotic viruses.  
Virus neutralisation tests (VNTs) are considered the most specific assays for 
detecting VNAb to rabies and Rift Valley fever virus (RVFV), with these tests 
being the World Organisation for Animal Health (OIE) prescribed tests for 
international trade. However, these VNTs use live virus to detect neutralisation, 
requiring them to be performed at high containment and presenting potential 
infection risks for laboratory staff. Both rabies and RVFV are endemic in Africa, 
where very few laboratories have the containment facilities necessary to 
perform such assays. Therefore, serosurveillance of these viruses are not readily 
performed in countries with the greatest need, alternatively in these countries 
serosurveys are performed using assays with poorer specificities.  
In addition to the high containment facilities required, these assays are labour 
intensive, have long incubation periods, require a level of post-assay processing 
and are costly. In this project, I aimed to develop novel neutralisation assays 
which would improve on the current gold standard assays for rabies and RVFV, 
whist retaining high specificities. Such improvements included negating the 
requirement for high containment, reducing or removing post-assay processing, 
decreasing the incubation time of the assay, allowing for high-throughput testing 
to be performed and providing economical assays for use in resource limited 
settings. Table 7.1 summaries the improvements achieved with the development 
of the rabies virus pNT and the RVFV-luc NT described in earlier chapters.     
     
  
2
3
5
 
  Rabies virus Rift Valley fever virus 
  FAVN/RFFIT Rabies virus pNT PRNT RVFV-luc NT 
Time to perform 24-72 h 48 h 3-7 days 8 h 
Cost High Low Medium High 
Post-assay processing 
required  
Yes No Yes Yes 
Containment level required BSL-3+ BSL-2 BSL-3 
BSL-3 (with potential 
for BSL-2) 
Subjectivity in 
interpretation  
Yes Yes Yes No 
High-throughput No 
No (with potential for 
high-throughput) 
No Yes 
Control for non-specificity 
included  
No Yes No 
No (with potential for 
control) 
Chapter 7. Discussion                                                                                                            236 
 
      23
5
 
Table 7.1 Comparison of conventional virus neutralisation tests with the 
alternative assays developed in this study. Comparison of the main attributes 
of the conventional neutralisation tests used for rabies and RVFV with the rabies 
virus pseudotype neutralisation test (pNT) and the luciferase expressing RVFV 
neutralisation test (RVFV-luc NT). RFFIT=rapid fluorescent focus inhibition test, 
FAVN=fluorescent antibody virus neutralisation test, PRNT=plaque reduction 
neutralisation test, BSL=biosafety level. 
 
  
The rabies virus pNT is low cost, can be performed at biosafety level (BSL) 2, 
requires no post-assay processing and includes a control for non-specificity. Such 
assays would be particularly beneficial in resource limited settings as only a 
fluorescence microscope is required. However, if fluorescence microscopy is 
unavailable the GFP reporter could easily be replaced with a lacZ gene, which 
further decreases the cost of the assay and requires no specialist equipment. An 
inability to identify a suspension cell line which was permissive to MLV(rabies) 
pseudotypes prevented analysis by flow cytometry from being further pursued. 
The rabies pNT is however amenable to high-throughput testing which has been 
successfully demonstrated for a Nipah virus pseudotype based neutralisation test 
(Kaku et al., 2012). Furthermore, Mather et al. (2014) have demonstrated that 
rabies virus pseudotypes can be lyophilised and subsequently used in a pNT, 
establishing the viability of a freeze-dried pseudotype-based kit to be 
distributed to resource limited settings.   
After the success of the rabies virus pNT, similar methods were employed to 
produce a neutralisation test to detect RVF VNAb, however RVFV pseudotypes 
were not produced to a titre that was high enough to permit their use in a pNT. 
The inability to produce high titre RVFV pseudotypes may be a result of the 
intrinsic cellular localisation of RVFV glycoproteins, which are expressed 
predominantly at the Golgi apparatus. The location of glycoproteins in the 
producer cells prior to pseudotype budding is known to affect successful 
incorporation of glycoproteins into pseudotype particles (Sandrin and Cosset, 
2006, Whitt, 2010).  In this study we did not quantitatively investigate the levels 
of RVFV glycoprotein expression on the cell surface, however further efforts to 
Chapter 7. Discussion                                                                                                            237 
 
      23
5
 
improve plasma membrane expression levels should be investigated if attempts 
to pseudotype RVFV are pursued further. Examples of such improvements 
presented in the literature were discussed in Chapter 5.  
As an alternative to the RVFV pNT, we developed a novel neutralisation assay 
utilising a recombinant luciferase expressing RVFV in place of wild type virus. 
The use of a single serum platform allowed for high-throughput testing to be 
performed using this assay. Additionally, this test required just 6 h incubation 
providing a considerable improvement over the plaque reduction neutralisation 
test (PRNT), in which up to 7 days are required to visualise viral plaques. The 
assay therefore provides a rapid, high-throughput alternative to the PRNT, 
however the use of a commercial luciferase substrate makes the assay costly in 
comparison, which would likely render its use prohibitive in resource limited 
settings. The RVFV-luc NT utilises the MP-12 strain of RVFV, which requires only 
BSL-2 containment in the United States (CDC, 2009), however the use of this 
strain still requires BSL-3 containment in the United Kingdom, restricting its use 
in the majority of laboratories. However, as the virus utilised in the RVFV-luc NT 
is a highly-attenuated strain in which the non-structural protein gene has been 
deleted, BSL-3 requirements for this virus may potentially be downgraded in the 
United Kingdom. 
The data presented in the RVFV sero-epidemiological studies suggest that the 
RVFV-luc NT is a robust, high-throughput alternative to the PRNT. However, 
validation of the assay was performed on a small panel of previously tested sera. 
For a more accurate assessment of assay sensitivity and specificity, and to 
determine the most appropriate assay cut-off, a larger validation panel of sera 
previously tested by PRNT is required. Due to time constraints in this study it 
was not possible to perform a more comprehensive validation and consequently 
a stringent cut-off of ≥98% was chosen as a high specificity was considered to be 
of most importance in our serosurveys. 
To further improve the RVFV-luc NT, serum samples testing positive at a dilution 
of 1:100 should be further titrated to allow a quantitative titre to be obtained. 
In utilising such an approach the stringent cut-off could be lowered, as high 
sensitivity is preferable to high specificity in a screening assay, as false positives 
will be detected upon full serum titration. This assay holds huge potential for 
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large scale RVFV serosurveillance, however to ensure the most confidence in the 
serological data generated, further validation of the assay is necessary.   
 
7.2 Non-specificity in neutralisation tests   
The results described in this thesis are based upon testing of over 3000 sera, 
from a wide variety of domestic and wildlife species, for evidence of VNAb. 
Throughout this study we experienced serum which proved cytotoxic, 
demonstrated non-specific inhibition of virus infection and replication or 
obscured the cell monolayer. Such effects of serum have been noted in previous 
studies, concerning many serological tests, not only VNTs (Ananthanarayan and 
Paniker, 1960, Tauraso et al., 1971, Mani and Madhusudana, 2013, Bedeković et 
al., 2013, Shiraishi et al., 2014a). 
When examining the cell monolayer visually for the presence of GFP in the 
rabies virus pNT, we observed examples of non-specific neutralisation and 
cytotoxicity, as described in Chapter 4. The integrity of the cell monolayer is 
critical for the interpretation of the VNT, as viruses, or pseudotypes, can only 
replicate/express efficiently in healthy cells. Hence, in the pNT if pseudotypes 
cannot transduce the cell line, and no GFP expression occurs, this could be 
mistakenly attributed to the presence of VNAb. To reduce the risk of such false 
positives occurring the cell monolayer is observed under the light microscope for 
evidence of cytotoxicity, however non-specific inhibitors present in serum can 
also inhibit pseudotype entry causing false positives even in the presence of a 
healthy cell monolayer.  
Inclusion of the MLV(VSV) pseudotype control with each sample tested ensured 
that neutralisation demonstrated in the assay was due to antibody-specific 
neutralisation as opposed to non-specific neutralisation or inhibition. The 
inclusion of the MLV(VSV) control in the lyssavirus pNT was considered to be of 
critical importance and consequently this assay may have superior specificity 
than conventional VNTs. Previous studies utilising pNTs have described multiplex 
assays in which VNAb to one or more viruses can be detected in a single assay 
(Wright et al., 2010, Molesti et al., 2014). Such approaches could be used to 
integrate the MLV(VSV) control into a multiplex assay allowing non-specific 
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neutralisation to be detecting in the same well as rabies VNAb, decreasing both 
assay set up times and volumes of serum required. Zhou et al. (2011) have 
utilised a similar method to develop a dual entry pseudotype assay to detect 
viral entry inhibitors for SARS coronavirus (SARS-CoV) which utilises both SARS-
CoV and MLV pseudotyped HIV particles. The MLV pseudotype acts as a control to 
detect compounds that cause non-specific inhibition.   
There is currently no control for non-specific neutralisation in the RVFV-luc NT. 
Additionally, as the assay is analysed using a luminometer, cell monolayers are 
seeded in opaque, white plastic 96-well plates and therefore also cannot be 
examined manual for cytotoxicity. In the RVFV serosurveys presented in this 
chapter, serum was screened at a dilution of 1:100, hence reducing the potential 
contribution from any non-specific inhibitors present in sera at low dilutions. 
However, we cannot guarantee that a minority of these positive samples may 
have been the result of cytotoxicity or high levels of non-specific neutralising 
factors in the sera. As discussed in Chapter 5, previous studies have been 
described in which a metabolic viability dye is incorporated into luciferase 
expression assays to assess cell viability. To further improve the RVFV-luc NT, 
such dyes, or indeed multiplexing an unrelated virus expressing firefly luciferase 
for example, could be employed as indicators of non-specificity. However, 
vesicular stomatitis virus (VSV) may not be the ideal candidate for use as a 
control virus as VSV affects livestock and related vesiculoviruses have been 
identified in Africa (Fontenille et al., 1994, Traoré-Lamizana et al., 2001).  
Multiplexing both the RVFV-luc NT and the rabies virus pNT, not only with 
controls for non-specificity, but also with other relevant viruses, would allow for 
serosurveillance of multiple viruses using one serum dilution. Such assays would 
be especially valuable for wildlife testing, where often only small volumes of 
sera are available. Examples of multiplex assays which would have been relevant 
in these sample sets include the multiplex analysis of VNAb to rabies and canine 
distemper virus in Serengeti lions and the detection of VNAb to Rift Valley fever, 
peste des petits ruminants and foot-and-mouth disease virus in the livestock 
samples from Northern Tanzania.   
Virus neutralisation tests are considered the most specific assays for detecting 
viral induced antibodies and both assays developed in this project appear to be 
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as specific as their conventional counterparts. However, as demonstrated with 
the phylogroup one lyssaviruses even VNTs with the highest specificity, by their 
very nature cannot differentiate between viruses in which the glycoprotein 
sequences are highly similar. When interpreting VNTs, one must be aware of 
antigenically similar viruses circulating in the study area and additionally we 
must also consider the as yet uncharacterised viruses circulating globally.    
      
7.3 Rabies virus serology  
In this thesis I demonstrate rabies VNAb in lions and domestic dogs that had not 
previously been vaccinated against rabies virus. Rabies VNAb present due to 
natural infection in both animals and humans has been demonstrated in previous 
serological studies (Table 1.2). However, there is very little in the literature 
regarding the relevance of such observations, or on the clinical course of such 
abortive infections. Although evidence of rabies VNAb in healthy humans, 
domestic animals and wildlife has been demonstrated in many studies, the fate 
of the majority of these seropositive individuals remains unknown. In this thesis I 
present evidence of rabies VNAb in free-roaming dogs that were followed for 14 
months and remained healthy throughout the study period.  
Although the lions tested in our study were not followed over time, we are 
confident that none of the lions succumbed to rabies virus, as there are intense 
disease monitoring efforts in the Serengeti National Park (SNP), particularly in 
lions, many of which have been followed from birth by the Tanzania Wildlife 
Research Institute. Additionally, there have been no documented cases of rabies 
in lions in the SNP (Prof. Sarah Cleaveland, 2016, personal communication). 
Previous studies of other carnivore species in the SNP have also demonstrated 
rabies VNAb in animals in the absence of clinical disease (East et al., 2001). The 
route of rabies infection in lions is unknown. There have been documented cases 
of lions receiving bites from suspected rabid dogs, (Prof. Sarah Cleaveland, 
2016, personal communication), however hunting infected prey, as suggested by 
Berry et al. (1993), would seem a more regular route of viral exposure. During 
hunting, the lions face comes into close contact with the prey’s head, by means 
of the lion suffocating or strangling its prey, and fatal rabies infection via oral 
and intranasal transmissions has been demonstrated in experimental infection 
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(Charlton and Casey, 1979). Rabies infection via ingestion of infected material 
has also been documented experimentally in carnivores (Bell and Moore, 1971). 
However, in their study those animals which did not show signs of infection also 
did not demonstrate evidence of seroconversion. Delpietro et al. (1990) reported 
rabies induced deaths in three of 132 rodents after ingestion of rabies-infected 
tissues. Additionally, in their study 22 of the surviving animals demonstrated 
rabies VNAb in serum, strongly suggesting ingestion of infected prey could be 
associated with protection from lethal rabies infection.    
We are confident that the rabies VNAb titres reported in previous chapters are 
specific, both due to the high test cut-off and the inclusion of a non-specific 
neutralisation control in the rabies virus pNT. We are therefore confident that 
the results presented herein represent evidence of natural, abortive rabies 
infection in both lions and free-roaming dogs. Further epidemiological evidence 
supports these claims, as years in which lions were found to be rabies VNAb 
positive correlated with years in which wildlife cases of rabies were reported in 
and around the SNP. 
Samples in which serum dilutions of 1:40 or greater neutralise MLV(rabies) 
pseudotypes are considered positive for rabies VNAb in these serosurveys. This 
cut-off is far higher than the 1:5 dilution considered positive for rabies-specific 
VNAb suggested by the Advisory Committee on Immunisation Practices (ACIP) 
(ACIP, 1999). More recently a titre of 1:25 serum dilution has been suggested as 
evidence of exposure, as non-specific inhibition was not demonstrated at such 
dilutions (Jackson and Wunner, 2007). Our results support this suggestion as we 
observed many serum samples which neutralised both MLV(rabies) and MLV(VSV) 
at serum dilutions of 1:10 and 1:20. The selection of appropriate cut-off titres 
for neutralisation assays is critical for result interpretation, choosing a titre that 
is too low will inevitably cause false positive results and distort the 
interpretation of genuine serological data.    
A titre of 0.5 IU/ml is recognised globally as the accepted rabies VNAb titre 
considered adequate to provide protection in humans post vaccination (ACIP, 
1999). However, this threshold has since been extrapolated to other situations, 
and other species, in which such a titre may not apply (Moore and Hanlon, 
2010). There is no accepted threshold, either measured as a serum dilution or in 
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IU/ml, for evidence of natural exposure in humans or animals. A wide range of 
thresholds have been used in the literature, with threshold levels as low as 0.06 
IU/ml, to a much more conservative cut-off titre of 0.8 IU/ml (Ellison et al., 
2014, Reynes et al., 2004). The complexity of the issue of threshold selection 
can be demonstrated using an example from Moore and Hanlon (2010) who 
analysed rabies VNAb titres recorded in vaccinated raccoons using the RFFIT. 
Analysing results using a 0.1 IU/ml threshold provided a sensitivity of 86% and a 
specificity of 83%, whereas the sensitivity decreased to 74% when a cut-off of 
0.5 IU/ml was applied, however test specificity increased to 98% (Moore and 
Hanlon, 2010). Prior to determining a cut-off titre for use in a serosurvey, 
consideration must be given to the particular study group and the experimental 
questions being explored and a threshold that is ‘fit for purpose’ should be 
employed. 
For rabies VNAb titres to be expressed in IU/ml, the OIE reference standard 
serum is required, however we were unable to acquire enough of this serum for 
our assays. Instead we employed a cut-off titre of 40, which was considered 
adequate for the research questions being investigated. This threshold is slightly 
higher than the suggested 1:25 dilution, however by selecting a slightly higher 
threshold we are increasing the specificity of the assay and in turn, as suggested 
by Reynes et al. (2004), these samples should be considered highly indicative of 
rabies-specific VNAb.  
Evidence of potential rabies exposure in our longitudinal Kenyan dog cohort was 
demonstrated at the final sampling time point, at which high rabies VNAb titres 
were detected. A high proportion of dogs demonstrated an apparent anamnestic 
response to rabies virus, which was not observed at any other point throughout 
the 14-month study. Geographical clustering of these dogs provided further 
evidence of a common source of rabies exposure. No rabies cases were officially 
reported, or noted by the original authors of the study, at this time point or in 
the following months. Given that over half of the study dogs demonstrated 
detectable rabies VNAb at the beginning of the study, with no history of prior 
vaccination, and that evidence of rabies transmission during the study period 
was detected, it is possible that non-symptomatic rabies infection occurs more 
often than we realise in rabies endemic settings. Improved understanding of 
factors that differentiate fatal from non-fatal rabies exposures in nature will 
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enhance our understanding of the natural course of rabies infection and in turn 
contribute to the eradication of canine rabies.  
 
7.4 Rift Valley fever virus serology  
Many gaps still exist in our understanding of the complex ecology of RVFV. The 
virus infects a wide range of host species, infections in some of which appear to 
be asymptomatic. Additionally the periodic nature of RVFV outbreaks presents 
numerous questions regarding the maintenance of the virus during inter-
epidemic periods (IEP).  
In this thesis I present evidence of RVFV exposure in a range of wildlife and 
domestic livestock species. We present data regarding RVFV seroprevalence in 
lions in the SNP, further supporting the few previous studies available on RVFV 
infection in this species. Additionally, we present evidence of widespread 
infection in African buffalo in Northern Tanzania in addition to demonstrating 
RVF VNAb in gazelle from this region. We demonstrate novel serological 
evidence of RVFV infection in Grant’s gazelle, a species in which seroprevalence 
has not been previously documented in the literature. In both African buffalo 
and gazelle, the highest seroprevalence was observed in animals from the high 
risk region of Ngorongoro Conservation Area.        
The age data associated with the serum samples tested in these studies are 
detailed and robust. As a result it is possible to confidently assert, from the 
presence of RVF VNAb in animals that have only lived through IEP, that evidence 
of inter-epidemic transmission of RVFV has been identified. Low levels of inter-
epidemic RVFV seroconversions were detected in all species tested in this study, 
namely lions, buffalo, gazelle, cattle, sheep and goats.  
In Chapter 6, data generated from a large cohort of livestock enrolled in a 
longitudinal study is presented, which, to our knowledge, is the largest 
longitudinal study of RVFV seroprevalence performed to date. A number of 
interesting findings resulted from this study, one of which was the high 
proportion of animals under one year of age demonstrating RVF VNAb, 
representing high IEP transmission of RVFV in these herds. Additionally, there 
was a wide variety in the seroprevalence of RVFV in different villages, with 
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seroprevalence ranging from 2-35%. However in contrast to the data generated 
in wild ruminants, the highest rates were not documented universally from 
villages in the highest risk areas. 
Perhaps the most striking finding this study was the evidence of rapid waning of 
RVF VNAb in livestock. High levels of seroreversion in animals in the 6-8 month 
period of the study were observed. Levels of seroconversion and seroreversion 
were statistically associated with the village and herd to which the animals 
belonged, suggesting a geographical relationship in RVFV exposure. The data 
presented in this study suggest that high levels of seroreversion occur in villages 
where the least number of new RVFV infections occur, this pattern was 
particularly apparent in animals in the Loliondo district where the greatest 
differences in seroprevalence were observed. For example, a high proportion of 
seroreversions were observed in villages Nyamburi, Masusu and Kisangiro (50%, 
63% and 82% respectively) and in these villages no seroconversions were 
detected during the study period. In contrast, Engaresero, Maaloni and Robanda 
had lower rates of seroreversion (20%, 33% and 30% respectively) and each had 
3-5 animals within the village seroconverting during the study period.  
Very little data is available in the literature regarding the duration of RVF VNAb 
following natural infection. As the date of exposure in these animals is unknown, 
we cannot comment on the duration of VNAb after natural infection. However, 
we describe low-level circulation of RVFV in this cohort, and in wildlife, during 
IEP, suggesting that RVFV is present outwith reported outbreaks. The mode of 
transmission may be either via mosquitoes or directly from other infected 
animals, wild or domestic, and further investigations are required to answer 
some of these questions.  
Outbreaks of RVFV occur periodically, often after periods of prolonged rainfall, 
however the risks associated with outbreaks are incredibly complex. Métras et 
al. (2015) described the risk factors associated with RVFV outbreaks and 
commented that to successfully predict future RVFV outbreaks knowledge of 
previously vaccinated individuals is required. In their models, previously infected 
regions were considered immune to future outbreaks under the assumption that 
‘natural RVFV infection causes life-long immunity’ (Métras et al., 2015). The 
duration of protective antibodies elicited after natural infection requires further 
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study, to improve predictive models of RVFV outbreaks and inform contingency 
plans for response to RVFV infections. Further research has commenced in our 
institute to investigate the levels and duration of immunity acquired to natural 
infection in study cohorts in South Africa.              
We hypothesise that the inter-epidemic transmission of RVFV may contribute to 
retaining herd immunity and therefore may provide protection against explosive 
RVFV outbreaks. If further studies elucidate an association between herd 
immunity and the occurrence of RVFV outbreaks, livestock herds may be 
employed as sentinels to monitor RVFV circulation and determine when critical 
levels of immunity may diminish allowing devastating outbreaks to occur. 
 
In summary, in this thesis I have optimised neutralisation assays to two 
important zoonotic diseases, the understanding of which can be improved by 
increasing the availability, and reliability, of serological assays. Preliminary 
seroprevalence data generated using these assays, from a wide range of 
ecological settings, are presented in Chapters 4 and 6. The data presented 
support previous serological studies in which data were generated using 
conventional antibody detection methods, providing evidence that these novel 
assays can provide robust serological data to further improve our understanding 
of rabies and RVFV.    
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